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ABSTRACT 
Prostacyclin is important for various physiological responses including inhibiting of 
platelet aggregation, maintaining vascular homeostasis, and protection against 
neuronal cell death. The prostacyclin receptor (IP-receptor), which is classified as a G 
protein-coupled receptor (GPCR), is capable of coupling to multiple O-proteins in a 
variety of cell types. However, it is difficult to clarify whether multiple pathway 
activation from IP-receptors is due to IP-receptor subtypes or a single IP-receptor 
coupling to multiple G-proteins. Therefore, the aim of this study was to assess the ftill 
G-protein coupling capacity of IP-receptors in transient transfection systems and relate 
this to IP-receptor activity in other cell systems. 
My results confirmed the multiple coupling capacity of the IP-receptor using various 
prostacyclin analogues in CHO cells transiently transfected with mouse IP-receptor 
cDNA (mlP-CHO). Similar activation of adenylate cyclase (AC) and phospholipase C 
was observed on stimulating IP-receptors in the rat/mouse neuroblastoma/glioma 
hybrid (NG108-15) cell line. In contrast, IP-receptors in the human neuroblastoma 
(SK-N-SH) cell line only activated AC. SK-N-SH cells were poorly transfected with 
Gaq cDNA，therefore I was unable to demonstrate enhancement of IP-receptor 
coupling to Gq by transfection with G„q cDNA as observed in mlP-CHO cells. The use 
of protein kinase A and protein kinase C inhibitors suggested that mlP-receptor 
coupling to second messenger pathways was controlled by an auto-inhibitory feedback 
mechanism. Data from chimeric IP/DP-receptors further suggested that the C-terminal 
tail of the IP-receptor is not important for coupling to Gq, and that mutation of 
isoleucine-328 destroys the gain in affinity seen in the constitutively active mutant 
IP/DP-receptor. -
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1.1 G protein-coupled receptors 
1.1.1 Introduction 
The activity of every cell in the body is regulated by extracellular signals that are 
transmitted into the cell interior through different classes of plasma membrane 
receptors. Receptors use chemical communication in order to coordinate the function 
of all the different cells and ultimately to fine-tune the physiological response. Before 
the impact of molecular biology in receptor research, isolation of receptors was mainly 
based on the use of biochemical method to extract and purify the target protein from 
tissue. However, extraction of receptor proteins directly from tissue could not isolate 
and purify large amount of receptor protein for further study. As a result, the 
investigation of receptor proteins using molecular biology method provides better 
condition for receptor research. Once receptors proteins were isolated and purified, it 
was possible to identify the amino acid sequence and retrieve the corresponding 
mRNA sequence. This information could be used to produce oligonucleotide probes, 
which extract the full-length DNA sequence of receptor proteins, using conventional 
cDNA cloning methods. Once the cDNA sequence was purified, bacterial cell could 
provide a host system to express the receptor proteins in large scale. It is also possible 
to introduce foreign DNA into mammalian cells using transfection methods. After the 
transfection, mammalian cells, which expressed the receptor proteins, could be used to 
study the binding and pharmacological characteristics • of the receptor proteins. 
Currently, researchers are identifying domains of function within the overall structure 
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of receptors, for example, by site-directed mutagenesis of cloned receptor genes. Such 
experiments identify regions of the protein that are in contact with the hormone and 
other components of the signal transduction pathway. 
1.1.2 G protein-coupled receptors 
G protein-coupled receptors (GPCRs) are a family of structurally related membrane-
bound proteins that play a central role in the recognition and signal transduction of 
hormones and neurotransmitters e.g. prostacyclin receptor (Fig. 1). GPCRs form one of 
the largest protein families found in nature. Current estimates are that~l% (about 1000) 
of the genes present in a mammalian genome code for GPCRs (Wess, 1998). Agents 
that act directly on GPCRs, or in turn indirectly affect the cellular pathways regulated 
by GPCRs, are widely used in drug therapy (Ostrom et a/.，2000). Both small-molecule 
natural products and synthetically designed therapeutic agents exert their effect on 
GPCRs by acting either as agonists that mimic the function of the endogenous ligand 
for its receptor or as antagonists that block the effect of such ligands. The binding of an 
agonist to its receptor results in a change in the conformation of the receptor that leads 
to the activation of specifically associated heterotrimeric G-proteins. In turn, this 
activation initiates a cascade of signalling events within the cell. Alternatively, 
antagonist binding stabilizes an inactive conformation of the receptor and blocks 
agonist-induced conformational changes and signal transduction (Gether & Kobilka， 
1998). 
GPCRs share general structural motifs, including seven transmembrane 
helices connected by intra- and extracellular loops, an extracellular amino terminus and 
a cytoplasmic carboxyl terminus (Fig. 1). Based on amino acid sequence, ligand 
pharmacology, and receptor ftmction, there have been over 100 distinct members of 
this receptor superfamily identified to date (Wess, 1998). Conclusions drawn from a 
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large number of studies suggest that general themes apply to the molecular interactions 
between GPCRs and their ligands (Wess, 1998). For example, small ligands generally 
require the binding site within the hydrophobic core of the transmembrane domains. 
However, for larger peptides and proteins, binding site usually require the amino 
terminus and the hydrophilic loops at the extracellular surface (Rohrer & Kobilka， 
1998). Furthermore, post-translational modification of GPCRs i.e. N-glycosylation 
provides enough structural diversity among GPCRs to design selective agonists and 
antagonists for different receptor subtypes. 
After the cloning of several hundreds different GPCRs, studies have shown 
that the ligands that act through GPCRs and the physiological function mediated from 
� these GPCRs are remarkably diverse (Wess, 1998). In general, GPCR family can be 
subdivided into several groups. One way to group GPCRs is based on the ligand 
structure. Other important classification criteria are degree of amino acid similarity and 
G-protein coupling properties. Base on all this criteria, GPCRs can be divided into four 
groups including the rhodopsin-type family, secretin/glucagon family, metabotropic 
glutamate family and pheromones family (Wess, 1998). Base on this classification 
scheme, prostanoid receptor is classified as rhodospin-type family of GPCR. 
Although the GPCR family has been divided into several sub-groups, it is 
still not enough to clarify the diverse physiological response mediated through 
different GPCRs. After understanding the molecular mechanism for signal 
transduction at the intracellular level, it seems that the G-protein is essential within the 
signal transduction pathway and understanding the interaction between different 
GPCRs and G-proteins could provide more information about GPCR-mediated 
physiological responses. As a result, to understand the physiological actions of a given 
GPCR, it is essential to identify the specific G-proteins with which it is able to interact. 
G P C R S can often couple to one or more different types of G proteins and this issue will 
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be discussed in section 1.1.3. 
1.1.3 Heterotrimeric G-proteins 
G-proteins are members of a superfamily of GTPases that are fundamentally conserved 
from bacteria to mammals and play diverse roles in many aspects of cell fiinction. 
More than 20 different a-subunits (encoded by 17 distinct genes) have been identified 
and reviewed by Wess (1998). Six different G-protein P- and 12 distinct y-subunits 
have been described and reviewed by Clapham & Neer (1997). At least theoretically, 
the existence of different f>- and y-subunits allows for the formation of 72 different py 
complexes. The potential functional importance of such diversity is unclear at present， 
particularly because most f>y complexes appear to exhibit similar functional properties. 
G-proteins have a aPy trimeric structure in their resting stage. A 39- to 46-
kilodalton a subunit, a 37-kilodalton P-subunit, and 8-kilodalton y-subunit (Clapham 
& Neer, 1997). As noted earlier, several different forms of each protein are found, 
allowing for a great variety of different G-proteins. The y-subunit is prenylated; that is, 
it contains a covalently bound C!�isoprenoid moiety at the C-terminal cysteine, which 
helps anchor the proteins in the membrane and may facilitate protein-protein 
interactions (Cohen et al., 2000). The a-subunit is myristoylated, containing a myristic 
acid moiety in amide linkage with C-terminal glycine (Chen & Manning，2001) and 
this also helps to anchor the proteins in the plasma membrane. The guanine 
nucleotide-binding site and its associated GTPase activity are both located on the a -
subunit. The slow GTPase activity reconverts a-GTP to a-GDP, and the a-GDP 
complex dissociates from effector molecules and rejoins the py dimer (Fig. 2). 
The G-protein is the intermediary component in the signal transduction 
machinery. After binding of the ligand，the receptor catalyzes the exchange ofGTP for 
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GDP on the G-protein causing it to dissociate from the receptor-G protein complex to 
receptor, activated a-subunit and Py dimer. Both the activated a subunits bearing GTP 
and the py dimer can act upon one or more of a variety of effector molecules, which 
may result in changes in the intracellular levels of second messengers such as cAMP, 
inositol phosphates, calcium and arachidonic acid. This interaction eventually leads to 
the desired physiological response. Further discussion about the function of G-protein 
in GPCRs activation will be mentioned in section 1.1.5. 
1.1.4 Second messenger systems 
Signal from agonist stimulation will be transmitted through the G-protein and in turn 
activate the effector protein after the receptor is activated by agonists. Activation of 
effector molecules increases the production of second messengers such as cAMR 
cAMP was the earliest known second messenger discovered in the mid-1950s. 
However, several comparable second (or third) messengers are now known, including 
cyclic GMP，inositol triphosphate, and diacylglycerol. 
Calcium ions have also been considered a second messenger (Rasmussen et 
a/.，1976). In muscle cells i.e. cardiac muscle, the activation of adenylate cyclase (AC) 
results in an influx of extracellular calcium. cAMP is suggested to be important for 
mediating physiological response through changing the level of calcium concentration. 
Because cAMP regulates calcium influx, it may be more appropriate to call calcium a 
third messenger than a second messenger (Liu et al, 1992). 
Cytosolic calcium levels can be increased also by release of Ca^" from 
intracellular calcium stores. Access to these intracellular stores is controlled by another 
set of messengers, the phosphoinositide system. We now know that a specific lipid in 
the phosphoinositide family, namely, phosphatidylinositol-4,5-bisphosphate (PIP:)，is a 
membrane-associated storage form for two second messengers (Morris & Malbon, 
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1999). The cleavage of PIPj by phospholipase C (PLC) is the functional equivalent of 
the synthesis of cAMP by AC. One of the second messengers released from PIP: is 
called inositol 1,4,5-trisphosphate (IP3), which is important in stimulation of 
intracellular calcium release from the endoplasmic reticulum (Morris & Malbon，1999). 
The calcium release can enhance the activity of protein kinase C (PKC). The other 
second messenger, diacylglycerol, stimulates PKC activity by greatly increasing the 
affinity of the PKC for calcium ions (Lee & Severson，1994). PKC phosphorylates 
specific serine and threonine residues in target proteins, e.g. calmodulin, and further 
transmits the signal into interior part of cells. Since many metabolic processes are 
controlled by calcium fluxes and by phosphorylation of specific proteins, the 
phosphoinositide system has great versatility as a control mechanism. 
1.1.5 Mechanism of GPCR activation 
For GPCRs it is widely believed that the critical event in agonist action is the 
stabilization of the ternary complex of agonist / receptor/ G-protein (Lefkowitz et al,, 
1993), and the better this ternary complex is stabilized, the more efficacious is the 
agonist. The formation of this activated state must involve a series of interactions 
between the agonist and the amino acid side chains of the receptor (Strange, 1996). 
Notionally, we can divide this activation process up into different stages (Fig. 2). First 
the agonist interacts with the free receptor to form an agonist / receptor complex. This 
then interacts with the G-protein, leading to the formation of the ternary complex, the 
activated state. If the formation of this activated state determines the efficacy of 
signaling, then the difference in free energy between the agonist / receptor complex in 
the ground and activated states determines efficacy. Agonist binding to a receptor, 
eliciting conformational change that is transmitted to the G-protein, causes the a_ 
subunit to release GDP and to bind GTP, thus initiating the activation of the G-protein. 
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GTP binding alters the conformation of three 'switch' regions in the a-subunit that are 
its primary contact sites with the py-subunit, promoting subunit dissociation 
(Lambright et aL, 1996; Wall et al, 1995). 
In the resting state (Fig. 2), the G-proteins are in their guanosine diphosphate, 
(GDP)-bound form. A hormone response leading to stimulation of effector molecules 
causes a conformational change that stimulates the receptor to interact with a nearby 
molecule, G-protein. This in turn stimulates an exchange of bound GDP for GTP. The 
activated G-protein is converted to a protein that activates effector molecules, 
producing second messengers such as cAMP. 
After interaction with ligands, a receptor will go to the next step in its life 
cycle and interact with G protein within the cell membrane (Fig. 2). It is a critical step 
in a receptor life cycle as this step determines both signal transduction and receptor 
regulation. Continued activation of G-proteins depends on the presence of bound GTP. 
The agonist-stimulated response is therefore controlled by the presence of a slow 
GTPase activity on the G-protein. Thus, bound GTP is slowly cleaved to GDP and loss 
of ability to stimulate effector molecules simultaneously. 
When a G-protein dissociates into a-subunit and py-dimer, both can activate 
effector proteins (Fig. 2). The role of a-subunit and Py-dimer are probably to induce a 
conformational change that allostercially stimulates catalysis of the effector molecule. 
Inactivation requires a-subunit performing GTP hydrolysis as shown in Figure 2， 
shifting the equilibrium in favor of subunit reassociation, preventing further signaling. 
The resulting a-GDP then dissociates from the effector, and reunites with (3丫， 
completing the cycle. Attachment of the a-subunit to an effector molecule actually 
increases its GTPase activity. Since GTP hydrolysis is the step that terminates the 
ability of the a-subunit to produce its effect, regulation of its GTPase activity by the 
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effector proteins means that the activation of the effector tends to be self-limiting. 
Other regulatory process (such as those mediated by arrestin or phosducin) may be 
rate-limiting. 
In general, the signal transduction pathway is mediated through the a -
subunit of a G-protein. GPCRs can couple to one or more different types of G-protein. 
Activation of Gs causes stimulation of AC and regulation of calcium channels via G^s 
subunits (Liu et al., 1992). Activation of Gq causes stimulation of PLC via G^q 
subunits. In contrast, activation of Gi can influence multiple second messenger systems, 
including inhibition of AC, activation of cGMP phosphodiesterase and regulation of K+ 
and Ca2+ channels through either a - or Py-subunits (Obadiah et al, 1999; Hill & Peralta, 
2001). Because of the diversity of G-proteins and downstream effector molecules, the 
pattern of biochemical and electrophysiological responses of a particular cell to 
stimulation of a given GPCR is quite complex. As a result, the property of the observed 
responses critically depends on which G-protein is recognized by the receptor and 
which specific effector molecules are present in the studied cell or tissue. 
1.1.6 GPCR cross talk 
In order to fine-tune the level of stimulation or inhibition of a physiological response, it 
is suspected that cross talk exist between different signal transduction pathways. GPCR 
cross talk indicates the modulation of one particular signaling pathway by another 
parallel but separate pathway within the same cell. As a result, the existence of cross 
talk between two signal transduction pathways either mediated by the same or different 
G P C R S is important for regulating cellular physiology. Cross talk between G„s and 
coupled receptors have been observed in mammalian brain slices (Donaldson et al., 
1988). While G,q coupled receptor activation stimulates production of inositol 
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phosphates, it can also augment G„s coupled receptor stimulation of AC activity. The 
augmentation may, in some examples, be mediated by PKC activity, since phorbol 
esters potentiate neurotransmitter stimulated cAMP accumulation in brain slices 
(Karbon et aL, 1986). Also, PKC inhibitors block a,-adrenoceptor and phorbol ester 
mediated potentiation of Pj-adrenoceptor stimulated cAMP levels in rat pinealocytes 
(Ho et aL, 1988). In addition, some forms of AC are activated by PKC mediated 
phosphorylation (Kawabe et al, 1994). A role for Ca^^ cannot be excluded, since the 
removal of extracellular Ca^^ results in reduced histamine (Hi) receptor and a -
adrenoceptor mediated augmentation of adenosine receptor stimulated increases in AC 
activity (Donaldson et al, 1988). This effect may be mediated by ACl, the Ca:. 
calmodulin activated isoform of adenylate cyclase (Tang & Gilman，1991). 
Apart from modulation of AC activity by components of the PLC pathway, 
further study has suggested that the AC pathway might also modulate PLC activity. Liu 
& Simon，（1996) suggested that cAMP dependent protein kinase (PKA) specifically 
inhibits py-subimit activated PLC-p2 activity but not that of the a-subunit activated 
PLC-pi isoforms, and that the effect of PKA is not mimicked by PKC isozymes. This 
result suggested that Gs-coupled receptors activate AC, increasing intracellular cAMP 
and activating PKA, which then phosphorylates PLC-P2 and prevents its activation. On 
the other hand, receptors coupled to the G^i subfamily inhibit AC, lowering 
intracellular cAMP and PKA activity, thereby helping free Py-subunits to activate 
PLC-P2. Such a mechanism would account for the specificity and communication 
between the cAMP and the phosphatidylinositol signaling pathways. 
An alternate mechanism for stimulation of Ca^^ signaling by Gs-coupled 
receptors is activation of PLC-P by PKA. In several cell types, increasing cellular 
cAMP with forskolin (Chew, 1986; Dehaye et al, 1993; Xu et al, 1996) or membrane 
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permeable cAMP analogues (Chew, 1986) increased [Ca^^^ similar to stimulation of 
Gs-coupled receptors. In a recent study using submandibular gland (SMG) duct cells, 
forskolin stimulation resulted in PLC-(3 mediated and IP3 dependent Ca^^ release from 
internal stores (Xu et al.’ 1996). These findings suggest that, at least in some cell types, 
stimulation ofPKA can activate PLC-(3 to generate a Ca"^ signal. 
1.2 Receptor theory 
1.2.1 Introduction 
Over the past few years, evidence has accumulated, mainly in molecular cloning and 
expression systems, that the same receptor, when coupled to different G protein 
effector pathways, can exhibit different agonist potency orders or affinity / efficacy 
patterns (Negishi et al, 1995a; Perez et al, 1996; Richards & van Giersbergen, 1995; 
Robb et al, 1994). Because, traditionally, such pharmacological behaviour would be 
attributed to differences in receptor types, a theoretical understanding of the conditions 
under which it can occur when only a single receptor type is involved, is fundamental 
to receptor classification and analysis. 
Efficacy relates to what happens to the receptor system as a result of ligand 
binding. In the development of receptor theory, several scientists have reviewed this 
term with different methods and the description of this term becomes an important 
basis for receptor pharmacology (Kenakin, 1995a). Ligand binding to a receptor may 
promote a physiological response. According to this idea, the ligand demonstrates 
positive efficacy and is therefore defined as an agonist. Conversely, the ligand may do 
nothing to the receptor but bind to it and by its presence preclude activation of the 
receptor by an agonist; this would make it a neutral antagonist with zero efficacy 
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(Kenakin, 1996). More recently, certain antagonists have been referred to as inverse 
agonists that display negative efficacy (Milligan et ai, 1995). In the absence of 
constitutive receptor activity, however, neutral antagonists and inverse agonists would ‘ 
be indistinguishable in terms of their intrinsic effects on the receptor system. 
1.2.2 Two-state model 
The simplest model that can be proposed for a two-state mechanism of receptor 
activation is schematically identical to the model introduced by Monod, Wyman and 
Changeux except it is applied to the interaction of agonists and receptor rather than to 
oxygen and haemoglobin (Kurganov, 1974). In the scheme shown in Figure 3，R 
represents receptors in the resting state, and R* represents receptors in the active state. 
L is equilibrium constant that determines the distribution of receptors between the two 
states in the absence of ligand. Interaction of an agonist, A, with the receptor is 
assumed to displace this equilibrium towards one or other of the two states. If A has 
higher affinity for R*，it is an agonist. If A has higher affinity for R, it is an inverse 
agonist. This is determined by the values of K^ and K^*, the equilibrium dissociation 
constants for A at the two receptor states (Fig. 3). 
The two-state model has explained many of the phenomena occurring in 
pharmacology. These include, for example, the tendency for a ligand to behave as a 
partial agonist in one experimental system and as a full agonist in another, and the 
effects of irreversible antagonists on agonist-concentration effect curves. An important 
property of the two-state model is that such variations in the expression of agonist 
efficacy are explained without the necessity to consider the issue of receptor reserve, 
where the maximum physiological response can occur from limited amount of receptor 
being activated. According to the model, such phenomena are explained at the receptor 
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level. This is a fundamental difference between the two-state model and traditional 
receptor theory, since, in the latter, a receptor reserve is an obligatory assumption. 
1-2.3 Three-state model 
In order to account for the pharmacological observations that the same receptor type 
can exhibit different agonist pharmacology when coupled to different effector 
pathways, the three-state receptor model has been proposed (Fig. 4) (Leffer al., 1997). 
It is assumed that the active form of the receptor, R*, is able to activate more than one 
G-protein. In the two-state model, agonists act by enriching R*, with activities 
dependent on K^ and K / . The interaction between the R* form of the receptor and the 
G-protein is a property of R* only. These interactions may be different but the ways in 
which agonists enrich R* to participate in them are the same. Therefore, agonists can 
only act to increase the number of interactions between R* and the two G-proteins in a 
proportionally similar way. Absolute agonist potencies could be different between the 
two pathways, but the potency orders would be the same. The same logic applies even 
if more complex versions of the two-state model are considered. An example is that 
given by Kenakin (1995b), which is a form of the ternary complex model, extended to 
allow for two states and for coupling to two G-proteins. 
1.2.4 Extended ternary complex model 
The extended ternary complex model predicts that the same maximal response that is 
produced by an agonist should be observed with high receptor expression levels. This 
model proposes that the receptor exists in equilibrium of two fiinctionally distinct 
states: the inactive (R) and the active (R*) state. In the absence of agonists, the level of 
basal receptor activity is determined by the equilibrium between R and R*. The 
efficacy ofligands is thought to be a reflection of their ability to alter the equilibrium 
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between these two states. 
The scheme proposed by Samama (1993), although described in that 
publication as a two-state scheme, is in fact a multi-state model. The fact that different 
affinities are used for the binding of A to the R* and the R*G state means that a 
different conformation is assumed for R* when bound and when not bound to G protein. 
In other words, there are at least three states. The use of this scheme enables one to be 
completely accurate with the thermodynamic measurement, but it prevents one from 
making the simplistic two-state arguments, which are the attraction of the model. 
1.2.5 Multiple receptor state 
An increasing number of experimental observations indicate that the extended ternary 
complex model cannot sufficiently explain the molecular mechanism underlying 
GPCR activation. First, Chidiac (1994) showed that certain p2-adrenoceptor agonists 
could either act as partial agonists or as inverse agonists depending on whether effector 
system activity is assessed in intact cells or in cell membranes. Second, the extended 
ternary complex model proposes that inverse agonists stabilize an inactive and G 
protein-uncoupled state of GPCRs (Gether & Kobilka, 1998; Lefkowitz et ai, 1993). 
However, the results from various studies suggest that inverse agonists induce a 
specific conformation in the GPCR that actively inhibits G-protein function 
(Bouaboula et al., 1997). Third, the extended ternary complex model cannot explain 
why defined mutations in the dopamine Dj receptor results in agonist-dependent 
changes in signaling (Wiens et al, 1998). Fourth, the observation that not only agonists 
but also antagonists can promote GPCR internalization (Roettger et al., 1997) and that 
some receptor ligands behave as antagonists with respect to G protein activation but as 
agonists with regard to ternary complex formation (Brown & Pasternak，1998) cannot 
be reconciled with the extended ternary complex model. Based on these and several 
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other observations, it has been proposed that there are multiple, ligand-specific GPCR 
conformations which can be described by the cubic ternary complex model (Fig. 5) 
(Kenakin, 1996). 
1.2.6 Constitutively active mutant receptors 
This is a term used to explain the construction of mutant receptors which can actually 
be induced into a conformation that constitutively signals through a particular pathway. 
Such mutants are useful for ultimately designing signaling-specific drugs (agonists or 
negative agonists) that can induce the receptor to adopt a single activated conformation, 
thus achieving pharmacological diversity through a single receptor subtype and so 
reduce the induction of side-effect from multiple receptor subtypes activation. Such 
compounds not only would allow the contribution of each distinct receptor-activated 
pathway to be evaluated but also may form an important new class of therapeutic 
agents. These receptors provide an attractive way for screening orphan receptors, 
which not only could discover the ligands for excitatory response, but also ligands for 
inhibitory responses could be found using the same strategy. This approach is not 
available in nonconstitutively active screening condition (Chen et al., 2000). One 
approach to the screening of GPCRs is to overexpress the receptor to the point of 
observing constitutive activity and then allowing ligands with affinity to redistribute 
the receptor species (Chen et al, 2000). Ultimately, this approach could expand the 
screening window in drug development. 
In experimental systems, spontaneous activity can be achieved through 
receptor mutation, overexpression, or G-protein overexpression (Lefkowitz etal, 1993; 
Milligan et al, 1995) as has been shown for adrenergic, dopaminergic, and 5-
hydroxytryptamine receptors (Allen et al, 1991; Barker et al., 1994; Chidiac et al, 
1996; Ren et al, 1993; Samama et al, 1994; Tiberi & Caron，1994). The spontaneous 
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receptor activity can be demonstrated using antagonists that produce an inverse 
response (Costa & Herz，1989). A new class of ligands called protean agonists has been 
proposed on theoretical grounds. Depending on the basal activity of the receptor, these 
should either act as agonists or inverse agonists (Kenakin, 1995b). The inverse 
response to a ligand that in some systems acts as a weak agonist on the same subtype is 
possible to explain by using the model of Kenakin (1995b). A protean agonist will 
normally produce an activated receptor state that has, however, lower affinity for the 
G-protein than the spontaneously produced active receptor state. In systems in which 
there is little spontaneous formation of the activated receptor state, the receptor-
activating property of the ligand will therefore be seen and positive agonism will be 
observed. On the other hand, when there is a considerable spontaneous formation of the 
active receptor state, the lower efficacy of the ligand will result in inverse agonism 
(Kenakin, 1995b). Protean agonists represent a new and promising class of targeted 
drug therapy. This applies to cases in which a constitutively active mutated receptor or 
possible overactivity of G-protein-modulatory proteins (Dohlman & Thomer，1997; 
Sato et aL, 1996) can cause pathophysiological elements of disease. It will be 
beneficial to be able to restore the tonus of receptor activation without interfering 
significantly with the normal activation of the receptor. 
1.3 Agonist trafficking 
1.3.1 Introduction 
According to section 1.2，the idea of the extended ternary complex model and the cubic 
ternary complex model suggests the existence of multiple receptor conformations after 
agonist binding. Agonist binding can activate numerous biochemical-response 
pathways and this might result from selective G-protein activation. The hypothesis of 
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agonist-directed trafficking of receptor signaling (ADTRS) (Kenakin, 1995a) predicts 
that when a receptor signals through two or more independent signal transduction 
pathways, the relative efficacies of a series of agonists may differ for the different 
pathways. This hypothesis develops on the ideas that a receptor can exist in distinct 
states (or conformations) and that the ability of those states to activate different G 
protein types or subtypes may differ. 
The idea of ADTRS led to the development of the "N-state receptor models", 
in which the receptor is assumed to exist in N states that may be "inactive" (R) or 
"active" (R*，R**，etc). As a special case of the N-state receptor models, Leffs group 
(1997) developed a mathematical model for three receptor states that accommodates 
the concept of ADTRS. They were able to predict differential relative efficacy from 
this model. 
In order to make ADTRS possible, Berg et al. (1998) suggested that 
divergence at the receptor/G-protein level is important. It is critical to involve two or 
more G-proteins which leads to the transduction of the stimulus through two 
independent effector pathways. Based on this idea, two cases can be distinguished 
according to the three-state model of Leff (1997). The first is when the two effector 
pathways result in two independently measurable responses, such as 5-
hydroxytryptamine (5-HT)2a and (5-HT)2c receptors when looking at the PLC and 
phospholipase Aj (PLAj) signal transduction pathways. Second, the two pathways can 
diverge and eventually recombine to modulate one measurable response (e.g., 
regulation of AC by both G„s and G„i proteins). If inactivating the other selectively in 
order to isolate one pathway, relative efficacy can be determined for the active pathway. 
It should now be possible to obtain an estimate of the relative efficacy for each pathway 
independently, and theoretically their relative efficacy may be different. 
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1.3.2 Effect of agonist efficacy on receptor coupling 
Activation of multiple signal transduction pathways might relate to the differential 
strength of signal for various agonists rather than production of different active 
receptor states. According to Kenakin's idea, the number of measurable responses 
relates to the efficacy of agonist. These data could not be used to support the existence 
of agonist trafficking but rather the result of differential strength of signals from the cell 
system. In systems where multiple ternary complexes are formed by agonists, it 
theoretically should be possible to test whether certain agonists selectively favour 
receptor coupling to one G-protein over another. However, the influence of strength of 
signal must be considered here as well. It is possible for an agonist of high efficacy to 
promote a single activated state of receptor, which may have high affinity for one G-
protein but a lower affinity for another. However, an agonist of low efficacy may 
promote coupling to only the most efficiently coupled G-protein. Under these 
circumstances, it would appear that the former agonist activates two G-proteins while 
the latter one activates only one G-protein. This may suggest that the former agonist 
can produce an activated receptor state, which can couple to both G-proteins, while the 
latter one can produce another unique activated receptor state, which can couple to one 
G-protein only. However, it is possible that the strength of signal phenomenon may be 
the crucial factor: the former agonist may produce more activated receptor thereby 
producing coupling to both susceptible G-proteins. As a result, it is necessary to 
consider the usefulness of agonists in ADTRS study. 
1-3.3 Effect of receptor expression level on receptor coupling 
While there is considerable evidence for the presence and absence of receptor 
promiscuity under physiological conditions, the likelihood of producing multiple 
couplings of a single receptor to various G-proteins increases as the stoichiometry is 
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biased towards a high concentration of reactants. Thus, the probability of multiple 
coupling increases as receptor density increases. The term 'receptor overexpression' is 
relative as a certain level of receptor expression may be suitable for obtaining a stable 
and large pharmacological signal, but unsuitable for preserving order in receptor 
signaling, that is, there may be more than enough receptors to functionally saturate the 
primary G-proteins, and an overflow to other receptor-G-protein couples may ensue. 
Thus, increased receptor expression may lead to receptor-G-protein promiscuity. Eason 
et al. (1992) showed that G^i and G^s coupling to aj-adrenoceptors was dependent on 
the expression level of receptors in transfected CHO cells. 
1.3.4 Receptor promiscuity 
In ADTRS, the theory depends on receptor promiscuity, which reflects the association 
between receptor and different G-proteins. Agonist-specific coupling (agonist 
trafficking) of GPCRs to different second messenger systems has been demonstrated 
for a number of receptors (Evans et al, 1995; Kenakin, 1995; Robb et al, 1994). This 
can be seen as a development of the extended ternary complex model for receptor 
conformation (Leff et al, 1997). In this model, the number of conformational states of 
the receptor is defined. In agonist-specific coupling, the receptor would adopt different 
conformations, either as a result of the induced fit between an agonist and the receptor, 
or as a result of the agonist stabilizing a particular conformation spontaneously adopted 
by the receptor (Fig. 6) (Gether & Kobilka, 1998). These different agonist-promoted 
conformations would then couple the receptor preferentially to specific second 
messenger pathways. 
1.3.5 Agonist-induced conformational changes 
In order to understand the ADTRS, it is possible to dissect the sequence of ADTRS into 
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different steps. The first step in ADTRS involves the activation of receptor through 
agonist binding. Since the idea of agonist-directed trafficking of receptor signaling 
based on the ability of different agonists to induce different agonist-receptor complex 
formation, mechanistic interpretations of the methods by which the agonists changed 
receptor conformation have been proposed. In general, two mechanisms have been 
suggested, as defined by Burgen (1981). 
1.3.5.1 Conformational induction 
This model predicts that transition from the inactive to the active state is extremely rare 
in the absence of agonist because of the energy barriers R and R* (Fig. 7) (Bennett & 
Steitz, 1978). The free energy of agonist binding to R is used to overcome the energy 
barrier and facilitates (or induces) the transition to R*. This model is similar with the 
mechanism of activation of rhodopsin upon photon activation and rapidly converts the 
inverse agonist cz^-retinal to the agonist trans-XQXmdX, such interaction cause a rapid 
conformational change in the protein (Chabre，1983). However, certain GPCRs have 
very high basal activity and this model seems could not explain this issue, possibly the 
energy barrier between R and R* is relatively small in the absence of agonist. 
1.3.5.2 Conformational selection 
This idea is based on the model proposed by Koshland & Neet (1968) and the extended 
ternary complex model for GPCRs (Samama et ai, 1993). Transitions between R and 
R* can occur in the absence of agonists (Fig. 8). Agonists bind preferentially to the R* 
conformation and cause the equilibrium shift towards the R* state and so increase the 
... proportion of receptor in R*. In contrast, inverse agonists bind preferentially to R and 
so reduce the population of receptor in R*. The model can explain the basal activity of 
GPCRs in the absence of agonist and suggest the possible action of inverse agonists on 
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GPCRs. However, the model cannot explain the slow kinetics of p2-adrenoceptor 
agonist-induced conformational changes in the absence of G protein while the 
association rate for agonist binding is very rapid (Gether & Kobilka, 1998). 
1.3.6 Receptor/G-protein system 
After the agonist binds to the receptor, the second step involves activation of G-protein 
by activated receptor. As a result, investigation of receptor/G-protein systems will 
allow an understanding of how receptors selectively activate different G-proteins and 
could provide more information about ADTRS. Theoretically, selective receptor and 
G-protein interaction is logical, as the discernment of receptor-G protein coupling 
would appear to be a useful control mechanism for cells utilizing common proteins. 
However, a case could be made for multiple interactions at the membrane level, as then 
the cell has an input on the signaling pathway by controlling the stiochiometry of 
receptors and G proteins, or perhaps more importantly, on the access of receptors to 
various G protein pools (Neubig，1994). Experimentally, there is evidence of receptors 
that couple to many G proteins in the membrane, as well as those receptors that are 
selective for one or two G-proteins. It is more common to observe receptor promiscuity 
in heterologous expression system under conditions of high level of receptor 
expression (Kenakin, 1995). For example, the muscarinic acetylcholine receptor, 
reconstituted with three different G proteins, shows an equal ability to form high-
affinity complexes with various G-proteins (Haga et al, 1989). Such data can also be 
observed in physiological systems. However, there is evidence that some receptors do 
not interact with some G-proteins. For example, it is known that adenosine A丨 receptors 
• 肌d dopamine Dj receptors transfected into human embryonic kidney (HEK 293) cells 
activate G^i, but when transfected into human hepatocytes, they do not interact with 
G„q (Conklin et al, 1993). Similarly, the G-protein selectivity for 5-HT,a receptors 
20 
was shown in Escherichia coir, in this study a number of different a subunits were 
introduced, but only some of them promoted high-affinity binding to the agonist 
[^H]8-hydroxy-2-(di-A7-propylamino) tetralin (Berlin et al., 1992). At present, in view 
of the available data there can be no general statements made about receptor-G protein 
coupling, except that multiple coupling can occur and does so in selected systems. 
The formation of agonist-specific receptor active states becomes important 
from a cellular signaling point of view when multiple G-proteins are involved. It is 
known that many GPCRs are pleiotropic with respect to the G-proteins with which they 
interact (Watson et al., 2000). This could be important for signaling because studies 
have shown that different regions of the cytosolic loops of GPCRs activate different 
G-proteins (Wade et al, 1999; Watson et aL, 2000). Under these circumstances, it 
would be expected that different overall receptor conformations would expose these 
different G protein-interacting sequences to signaling mechanisms in a different 
manner. These ideas, taken in conjunction, open the theoretical possibility that 
different active receptor conformations selectively activate different G-proteins to 
direct stimulus to different biochemical pathways in cells. 
1.3.7 Implication of agonist trafficking 
In drug discovery programs designed to find agonists, there usually are two possible 
targets: a complete mimic of the physiologically endogenous agonist or a mimic of a 
subset of agonism produced by the physiological agonist. Previously, the latter profile 
has been achieved solely by finding agonists for receptor subtypes. The production of 
selective receptor active states theoretically offers another level of selective agonism. 
- Specifically, if the pleiotropic nature of the endogenous receptor signaling is associated 
with activation of other signal transduction pathways, which are not desired in the 
therapeutic field, then reducing these may lead to a better mating of replacement 
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agonist therapy for pathophysiological disorders. From this standpoint, agonist-
selective receptor active states could represent the next effective level of agonist 
selectivity (Kenakin, 1997; Watson et al, 2000). 
It is clear that receptors can be promiscuous with respect to the G-proteins 
with which they interact and that this occurs in natural systems. What is still not clear is 
whether agonist activation uniformly causes activation of multiple G-proteins, or 
whether different agonists direct receptors to different G-proteins. Further study on 
ADTRS could provide another way of drug development and improve the production 
of clinically useful drugs. 
1.4 Receptor switching 
1.4.1 Introduction 
Persistent signaling of GPCRs provokes an attenuation of the biological response, a 
universal paradigm in biology often termed "desensitization". In general, protein 
phosphorylation is responsible for the GPCR desensitization process. GPCRs are 
well-known substrates for protein phosphorylation by both PKA and PKC (Freedman 
& Lefkowitz，1996). Prolonged exposure of the p-adrenergic receptor with agonists 
causes attenuation in cAMP generation, which implicates a negative-feedback loop for 
signal termination. Also, desensitization can be classified into two types, homologous 
and heterologous. Contribution of these two processes fine-tunes the intracellular 
signaling pathway and in turn regulates the physiological response. Due to the 
important role of desensitization in the regulation of signal transduction pathways, 
marked progress has been made in the study of phosphorylation of GPCRs in the past 
decade, i.e. sites of phosphorylation, classes of protein kinases and role of other protein 
components in GPCR regulation. However, few studies had focused the role of GPCRs 
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phosphorylation on GPCRs signal transduction capacity until 1997，when Daaka et al. 
proposed the switching of p2-adrenergic receptor signal from G„s to GJ. The 
flmctional role of GPCR phosphorylation involves not only tuming-off over-stimulated 
pathways, but also allows activation of other signal transduction pathways. 
1.4.2 Receptor switching 
G s - � G i - and Gq-coupled receptors have been shown to stimulate mitogen activated 
protein kinase (MAPK) activity leading to changes in gene expression. G J stimulated 
MAPK activity is inhibited by expression ofpy-subunit scavengers but independent of 
Py mediated effects on PLC (Selbie et al., 1997). G,q mediated effects on MAPK are 
distinct and are sensitive to PKC inhibition, but are not inhibited by expression of Py-
subunit scavengers or dorminant negative Ras mutants (Faure et al.，1994; Hawes et al.， 
1995). GaS coupling to MAPK activity are regulated differently in different cell types. 
In COS-7 cells, Gs-coupled receptor activation stimulates MAPK activity (Faure etal., 
1994)，while in other cell types; G,s stimulated increases in cAMP production may 
inhibit MAPK (Cook & McCoimick，1993). As G,s couple to MAPK are regulated by 
PKA，Daaka et al (1997) tried to understand the relationship between Gs-coupling and 
MAPK activation and they suggested that PKA-mediated phosphorylation of p2_ 
adrenergic receptors switches receptor coupling from G,s to mediated increases in 
MAPK activity, and this pathway is dependent on Src (Fig. 9) (Daaka et al, 1997). 
Phosphorylation-dependent switching of receptor specificity for G-proteins 
is another mechanism by which a single receptor could activate more than one G-
“ protein (Daaka et aL, 1997). Receptor dependent activation of G^i could thus release 
sufficient Py subunits to activate PLC-P (Wu et al, 1993). Activation of PLC-P 
generates IP3 and DAG to activate PKC. Hence, PKA-dependent switching of receptor 
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coupling to different classes of G-protein is a potential mechanism for activation of 
multiple signal transduction cascades by the same receptor. Recent study using 
vasoactive intestinal peptide (VIP) stimulation of pancreatic acinar cells and 
isoprenaline stimulation of SMG duct cells was performed to show that switching or 
augmentation of receptor coupling to G„i could account for activation of cAMP and 
Ca2+ signaling systems in vivo (Luo et al, 1999). According to this study, results 
suggested the existence of receptor switching model for dual signaling of GPCRs in a 
physiological situation. Although the physiological significance of receptor switching 
is unclear, Luo et al (1999) proposed that receptor switching is a general mechanism 
for Gs-coupled receptors for second signal generation in a distinct signaling cascade 
after a period of agonist stimulation. 
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Figure 2. Schematic diagram of GPCR activation cycle. Abbreviations: R (receptor), 
T1 (effector protein 1)，T2 (effector protein 2), GDP (guanosine diphosphate), GTP 
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Figure 3. Schematic diagram of two-state model of receptor activation. Abbreviations: 
A (agonist), K^ (dissociation equilibrium constant for inactive state receptor), K^* 
(dissociation equilibrium constant for active state receptor), L (equilibrium constant), 
R (resting state receptor), R* (active state receptor). 
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Figure 4. Schematic diagram of three-state model of receptor activation. 
Abbreviations: A (agonist), Gl，G2 (G protein), L，M (equilibrium constant), K^ 
(dissociation equilibrium constant for inactive state receptor), K /，K / * (dissociation 
equilibrium constant for active state receptor), R (resting state receptor), R*，R** 
(active state receptor). 
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Figure 5. Schematic diagram of cubic ternary complex model. Abbreviations: A 
(agonist), Gl, G2 (G-protein), R (inactive state receptor), R* (active state receptor) 
(Kenakin, 1995). 
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Figure 6. Schematic diagram represents the formation of agonist-specific receptor 
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Figure 7. Schematic diagram for conformational induction. Agonist (A) is the crucial 
factor for the formation of agonist-specific receptor conformation (R* or R"). Different 
receptor conformation will have preference for different G-proteins (Gl or G2). 
Thickness of arrow indicates the selectivity for different protein interactions. 
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Figure 8. Schematic diagram for conformational selection. Different agonists (A) have 
different affinity towards different specific receptor conformations (R* or R"). 
Different receptor conformation will have preference for different G-proteins (Gl or 
G2). Thickness of arrow indicates the selectivity for different protein interactions. 
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Figure 9. Schematic diagram for p2-adrenergic receptor-mediated G-protein switching 





2.1 General properties of prostacyclin 
2.1.1 Synthesis of prostacyclin 
Cyclo-oxygenase (prostaglandin G/H synthase) is the critical enzyme in the production 
of prostaglandins and thromboxanes. Activation of cytosolic (PLAj) causes the release 
of arachidonic acid from membrane phospholipids and subsequent metabolism by the 
cyclo-oxygenase pathway to produce prostanoids such as prostacyclin (Nanuniya et al, 
1999). PGHj, which is an essential intermediate in the prostanoid biosynthesis pathway, 
generates different prostaglandins dependent on the presence of particular 
isomerase/reductase enzymes in various tissues and cells (Narumiya et al., 1999). 
Prostacyclin synthase converts PGHj to the chemically unstable prostacyclin 
(Fig. 10)，which has a biological half-life of 2 to 3 min, subsequently forming 6-oxo-
PGF,„ (Moncada, 1982). The prostacyclin synthase gene has been assigned to human 
chromosome 20 (Wang & Chen, 1996), and prostacyclin synthase mRNA is widely 
expressed in the human vascular system (Tanabe & Ullrich，1995). As a result, it is not 
surprising to understand the high expression level of prostacyclin in human tissue, 
especially in heart, skeletal muscle and lung, which have a high blood flow per mass of 
tissue (Tanabe & Ullrich, 1995). 
2.1.2 Prostacyclin and its mimetics 
Prostacyclin, the endogenous ligand for the prostacyclin (IP)-receptor, has been shown 
to reduce the platelet consumption in vascular system (Higgs et al, 1978). In order to 
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understand the functional significance of prostacyclin, many analogues have been 
synthesized and biologically evaluated. 
Prostacyclin itself is rarely used when studying IP-receptors because of its 
short half-life and its ability to stimulate other prostanoid receptors (Dong et al,, 1986). 
Instead，one can use a variety of prostacyclin analogues, which are more selective 
towards IP-receptors (Fig. 10). So far, cicaprost is the most potent and selective 
prostacyclin analogue, primarily because of the lack of EP,-receptor agonist activity 
associated with iloprost, carbacyclin and isocarbacyclin as observed in ligand binding 
studies using cloned human prostanoid receptors (K, values for hEP,-receptor: cicaprost 
> 1340 nM; iloprost = 11 nM; carbacyclin = 23 nM) (Abramovitz et al., 2000). Also, 
cicaprost has only very little EPj-receptor agonist activity compared with these other 
prostacyclin analogues from studies using human prostanoid receptors (K, values for 
hEP3-receptor: cicaprost = 255 nM; iloprost = 56 nM; carbacyclin = 14 nM) 
(Abramovitz et al., 2000). Similarly, cicaprost also have very little mEPj- and mEP]-
receptor activity compared with mlP-receptor from studies using mouse prostanoid 
receptors (K丨 values from mEPj-receptor = 1300 nM; mEPs-receptor = 170 nM; mlP-
receptor =10nM) (Kiriyama et al., 1997). Altogether, result suggests cicaprost is useful 
to study the property of mlP- or hIP-receptor. 
In addition to these prostacyclin analogues, other compounds, which are 
structurally dissimilar to prostacyclin such as EP 035 and EP 157，can also be used to 
activate IP-receptors (Armstrong et al., 1986). Anti-platelet and vasodilator activity is 
seen with octimibate, which forms the basis of a series of non-prostanoid prostacyclin 
mimetics developed by Bristol-Myers Squibb (Fig. 11). Later development of non-
prostanoid prostacyclin mimetics called BMY 45778 demonstrates that non-prostanoid 
prostacyclin mimetics can bind with high affinity to the IP-receptor (Jones et al” 1997; 
Seller et al, 1997). 
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2.1.3 Characterization of IP-receptors 
2.1.3.1 Classification of IP-receptors 
Prostaglandin and thromboxane receptors are GPCRs that mediate the physiological 
actions of the five principal prostanoids: PGD,, PGE,, PGF,„, PGI, (prostacyclin) and 
TXA2. Within the superfamily of GPCRs, the prostanoid receptors constitute a 
subfamily, with remarkably low overall homology ranging from 24 to 44% (Versteeg et 
aL, 1999). Phylogenetic analysis of receptor sequences led to the development of the 
hypothesis that the IP-receptor evolved from an ancestral EP-receptor (Regan et “/.’ 
1994). 
Due to the relatively high sequence homology in the transmembrane domain 
in various types and subtypes of prostanoid receptors (Watabe et al., 1993), Namba's 
study constructed degenerated oligonucletides corresponding to the conserved 
sequence within the second and seventh transmembrane domains of the EP- and TP-
receptors, and isolated the mouse IP-receptor cDNA using the reverse transcription 
polymerase chain reaction and hybridization screening of a cDNA library prepared 
from P-815 mouse mastocytoma cells (Namba et aL, 1994). The same team using 
cross-hybridization of cDNA libraries with a probe prepared from the mouse IP-
receptor cDNA then rapidly isolated cDNA for the human and rat IP-receptor. 
2.1.3.2 Distribution of IP-receptors in the peripheral system 
In order to understand the functional significance of IP-receptors, it is necessary to 
identify the distribution of IP-receptors in various tissues and organs. Although the 
detection of IP-receptor expression usually depends on the sensitivity of assay system, 
detection of IP-receptor mRNA in unexpected places, could provide important 
information about the contribution of IP-receptor in those tissues. The site of expression 
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of IP-receptor varies in different species. For example, mouse has the highest 
expression level of IP-receptor mRNA in the thymus and spleen, but no detection could 
be obtained from the same human tissues (Hirata et al., 1995). On the other hand, rat 
aorta and lung show the highest expression level although rat thymus still has detectable 
level of IP-receptor mRNA expression. For human, liver and kidney express the IP-
receptor but lack of expression in mouse and rat species within similar area. 
For human IP-receptor mRNA expression, detection of IP-receptor in a wide 
range of megakaryocytic (e.g. MEG-01) and megakaryocytic/erythroid (e.g. HEL) cell 
lines indicate the functional significance of IP-receptor within the vascular system 
(Schwaner et al, 1992a). In addition, the effect of cytokines-induced enhancement of 
IP-receptor mRNA expression during megakaryocytopoiesis proposes the role of IP-
receptor in regulating vascular homeostasis. As those cytokines are involved in 
coagulation activity in response to endotoxemia, it is thought that the homeostatic 
balance could be regulated by enhanced IP-receptor expression in megakaryocytes. In 
addition, high level of IP-receptor mRNA expression could be detected in mouse 
neurons of the dorsal root ganglion (DRG) cells (Oida et al, 1995). About 40% of 
mouse DRG expressed IP-receptor mRNA. Due to high level of co-expression of IP-
receptor mRNA within substance P-containing cells (about 70%) (Oida et al” 1995), 
further study on the role of IP-receptor in the transmission of analgesic response could 
provide more information about the property of IP-receptor within peripheral nervous 
system. 
As IP-receptor mRNA has been detected in a wide range of megakaryocytes, 
it is not surprising that IP-receptors also appear in blood platelets. Prostacyclin and its 
chemically stable analogue are potent inhibitors of platelet function (Grant & Goa, 
1992). There is evidence suggesting that elevated endogenous prostacyclin might result 
in platelet prostacyclin receptor desensitization in vivo in patients with acute ischemic 
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heart disease (Kahn et al., 1990). Also, adminstration of iloprost shows beneficial 
effects in patients with peripheral vascular disease (Grant & Goa，1992). Further study 
at molecular biology level suggests that the inhibitory effect from IP-receptor is exerted 
through the cross talk mechanism (Jones et al., 1995). As a result, the homeostatic 
balance in vascular system is regulated through the balance between prostacyclin and 
thromboxane stimulation. 
The function of prostacyclin in the cardiovascular system is also important. 
Activation of IP-receptors mediates arteriolar dilatation and reduction of blood pressure 
(Wise & Jones，2000). The effect of prostacyclin administration on therapeutic function 
and side effect has been studied from several groups (Pickles & 0，Grady，1982; 
FitzGerald et al, 1980). In order to improve the therapeutic profile of prostacyclin, 
generation of prostacyclin analogues still continues. Apart from effects on the 
cardiovascular system, prostacyclin also has strong effects on gastrointestinal function. 
For example, prostacyclin and its analogues can remove the spontaneous motility of the 
rat isolated colon (Dong et al, 1986). However, the effect of prostacyclin on ileum may 
be due to the activation of EP,-receptors rather than IP-receptors (Lawrence et al., 
1992). IP-receptors are also expressed in guinea-pig vas deferens although the 
mechanism involved in enhancing neurotransmitter release is not fully established 
(Jones et al, 1997; Tarn et al., 1997). 
2.1.3.3 Distribution of IP-receptors in the central nervous system 
Due to the cytoprotective effect of prostacyclin being identified in CNS as mentioned 
from previous section, it is interesting now to consider the role of this neuronal IP-
receptor in the CNS. As prostaglandins do have some protective effect in vitro and can 
protect rat cortical neurons from glutamate-induced toxicity (Cazevieille et al，1994)，it 
is interesting to search for any prostaglandin which can have neuroprotective activity 
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without any side-effects on peripheral systems. Recent study suggested that this 
cytoprotective action could be performed by the presence of a new IP-receptor ligand, 
(15R)-TIC (Cui et al, 1999). Based on electrophysiological study on rat brain, Takechi 
et al. (1996) identified the existence of IP-receptor expression in several brain regions 
e.g. thalamus, hippocampus, striatum, dorsal cochlear nucleus, nucleus of the solitary 
tract and spinal trigeminal nucleus using [^H]-iloprost and pH]-isocarbacyclin (Takechi 
et al, 1996). Takechi suggests that several brain area except in the nucleus of the 
solitary tract and spinal trigeminal nucleus express IP-receptor subtype, which activate 
different signal transduction pathway compared with platelet-like IP-receptor (Takechi 
et al., 1996). 
2.1.3.4 Structure of IP-receptors 
In general, the IP-receptor has several features in common with other rhodopsin-type 
receptors (Fig. 12). Therefore, the proposed amino acid sequence suggested the 
formation of ternary structure similar to other GPCRs, with seven transmembrane 
domains. In general, all four clones have similar primary structure and their sequence 
similarity will be discussed later. All four clones have similar structural property within 
their amino acid sequence. Firstly, there are the putative N-glycosylation sites within 
the N-terminus of the extracellular portion of IP-receptor. Secondly, putative 
phosphorylation sites are widely distributed in the cytoplasmic portion of the IP-
receptor (Namba et al., 1994). Recent studies have suggested that the ligand binding 
pocket of this prostanoid receptor is formed mainly by the second, sixth and seventh 
transmembrane domains, of which the former is involved in the recognition of the ring 
structure and the latter two in that of the side chains (Kobayashi et al, 1997; Kobayashi 
et fl/.,2000). . 
At this moment, four species of IP-receptor (rat，mouse, bovine and human) 
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have been cloned. Based on the primary sequence homology, the rat IP-receptor shows 
68% amino acid identity compared with the same region within the mouse IP-receptor. 
However, the mouse and rat IP-receptor have 30 amino acids longer at N-terminus than 
that of the cow and human IP-receptor (Wise & Jones，2000). Excluding those 30 amino 
acids, high sequence homology have been identified between the mouse and rat IP-
receptor (98%), whereas the human IP-receptor is only 79% identical to mouse and rat 
as difference arise mainly from the C-terminal tail (Wise & Jones, 2000). As IP-
receptors mainly couple to the AC system, the fact that the second cytoplasmic loop is 
almost completely conserved suggests that this region may be important for coupling to 
Gs. Except for the human IP-receptor, all the other cloned IP-receptors have a potential 
PKA phosphorylation site at the first cytoplasmic loop (Fig. 12). Also, all four clones 
have consensus sequences for phosphorylation by PKC at the third cytoplasmic loop 
and C-terminal tail (Fig. 12). 
Certain positions within the prostacyclin molecule have been suggested to be 
important for ligand-receptor interactions. For high agonist potency at IP-receptors, 1-
carboxyl and 11-and 15-hydroxyIs group are crucial for binding to the IP-receptor (Fig. 
10，PGy. With the continuous development of more powerful computing methods and 
the generation of data on point mutated and chimeric IP-receptors, a much clearer 
picture about IP-receptor activation will emerge in the future. 
2.1.4 Anti-thrombotic role of prostacyclin 
In order to study the interaction between IP-receptor and different signal transduction 
pathways, collection of human platelets has provided convenient ways for studying the 
prostacyclin receptor systems and so detailed information about IP-receptor function in 
human platelets have been produced for a long time. It was soon realized that arterial 
walls are protected against deposition of platelet thrombi by producing prostacyclin, 
40 
and the concept was developed that a balance between the amount of thromboxane 
formed by platelets and prostacyclin formed by blood vessel walls might be critical for 
thrombus formation (Gryglewski et a l , 1976). Based on the clinical significance of 
prostacyclin in vascular systems, interest in prostacyclin as an antithrombotic agent has 
resulted in an intensive search for more clinically useful IP-agonists, with high 
chemical and metabolic stability, and selectivity of action on platelets (Grant & Goa， 
1992). As a result of these studies, a large amount of structure-activity relationship data 
is available, which can be summarized in terms of prostacyclin analogues and non-
prostanoid prostacyclin mimetics. 
The prospect of obtaining a therapeutic agent that would inhibit platelet 
activation without causing excessive vasodilation has stimulated much research into the 
identification of IP-receptor subtypes. Unfortunately, the absence of any IP-receptor 
antagonists made the research about IP-receptor subtypes identification become 
difficult，and the value of agonist potency data has been complicated due to cross-
species comparisons and to tissue-specific factors such as receptor-effector coupling. 
However, several developments may provide an improvement in order to clarify the 
role of prostacyclin in vascular systems at the molecular biology level. First, an IP-
receptor has now been cloned and expressed in cell lines. Second, some structurally 
diverse IP-receptor agonists of high potency have become available. Third, more 
researchers are using the stable PGI^ analogue cicaprost as the standard IP-receptor 
agonist，owing to its relatively high selectivity. 
2.1.5 Cytoprotective role of prostacyclin 
Apart from the anti-thrombotic property of prostacyclin, Cui et al (1999) have 
suggested a contribution of prostacyclin in protecting against neuronal cell death. 
Electrophysiological studies performed in the CAl region of the hippocampus in rat 
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brain suggests that prostacyclin analogues i.e. isocarbacyclin, provide an enhancing 
effect on the excitatory transmission through an IP-receptor (Takechi et aL, 1996). It 
seems that the expression of IP-receptors in the CNS is important for neuronal activity. 
Takechi's study indicated the possible existence of IP-receptor subtypes that are 
expressed in the CNS and this IP-receptor subtype was suggested to be responsible for 
isocarbacyclin-mediated activation in CAl region (Takechi et al, 1996). Later, two new 
IP-receptor specific ligands, (15R)-16-m-tolyl-17, 18,19,20-tetranorisocarbacyclin 
(15R-TIC) and 15-deoxy-16-m-tolyl-17, 18,19,20-tetranorisocarbacyclin (15-deoxy-
TIC), significantly prevented high (50%) oxygen-induced apoptotic neuronal death in 
cultured hippocampal neurons (Cui et al., 1999). Results also suggested that these IP-
receptor specific ligands exerted their neuroprotective effect with direct interaction with 
the CNS-specific IP-receptor (Cui et al., 1999). In the peripheral system, IP-agonists 
increase cAMP and activate PKA (Moncada, 1982). However, there is no link to the AC 
and PLC system from these two IP-ligands in the CNS (Takechi et al, 1996). Also, 
these two new ligands have no effect on platelet aggregation (Cui et al., 1999). 
Surprisingly, cicaprost is almost inactive for the CNS-specific IP-receptor and it is 
therefore that we should be looking for quite different types of molecules that have been 
developed so far. Further study through biochemical and pharmacological methods 
could clarify the molecular mechanism of IP-agonist mediated neuroprotection. 
2.1.6 Role of prostacyclin in adipogenesis 
Prostacyclin was initially thought to be an autocrine effector of differentiation in 
preadipose cells (Negrel et al, 1989). To prove this hypothesis, antibodies directed 
against a stable analogue of PGI :�6P-PGI2, and which were able to neutralize the 
biological effect of carbacyclin (cPGy, were used and shown to strongly diminish the 
adipogenic effect induced by arachidonic acid (Catalioto et al, 1991). Thus, 
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prostacyclin secreted into the culture medium of Ob 1771 preadipocytes upon exposure 
to arachidonic acid, behaved as a paracrine effector of adipose cell differentiation. 
Aubert et al. (2000) suggested that activation of Obl771 and 3T3-F442A 
preadipose cells through IP-agonists is sufficient to up-regulate the early critical and 
rapid expression of C/EBPp and C/EBP5, which behave as initial transcriptional 
triggers of the adipose cell differentiation cascade. Carbacyclin (cPGy is unique in its 
capacity to replace a combination of a PPAR5 activator and PPARy ligand for the 
expression of early and late markers during adipose cell differentiation, from PPAR5-
transfected 3T3-C2 fibroblasts including PPARy (Bastie et al., 1999). This strongly 
suggests the paracrine role of prostacyclin (Fig. 13). Altogether, this led to the 
conclusion that prostacyclin was the link between adipocyte able to release it and 
preadipose cells able to respond to this prostanoid. 
In order to understand the effect of IP agonist towards adipose cell 
differentiation, Aubert et al. (2000) using prostacyclin and cPGIj are known to trigger 
the AC pathway after binding to the cell surface IP-receptor and to promote or enhance 
terminal differentiation of adipose precursor cells to adipose cells (Aubert et a/., 2000). 
Same study suggested the critical role of prostacyclin in C/EBPp and C/EBP6 
activation and in turn mediate activation of other key genes for adipose cell 
differentiation. Altogether, result possibly concludes the outline of IP-receptor 
mediated terminal differentiation of adipocyte. 
2.2 Coupling capacity of IP-receptors 
2.2.1 Introduction 
Because of the clinical significance of IP-receptors in different diseases, IP-receptor 
pharmacology have been studied for a long time (Narumiya et al, 1999; Negishi et al, 
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1995b). For example, IP-receptor activation causes terminal differentiation of 
preadipocytic cells by increasing cAMP and intracellular Ca^^ concentration (Oka et al, 
1993). Also, IP-receptors can activate pertussis toxin (PTX)-sensitive pathways in 
Bnu-2cl3 mast cells (Oka et al., 1993). Evidence for coupling between IP-receptor and 
Gi is controversial. In HEL cells and rat adipocytes, [Ca^ ]^； response to IP agonists is 
PTX-insensitive (Schwaner et al, 1992b; Vassaux et al, 1992) suggesting the 
involvement of Gq in IP-receptor mediated PLC activation. However, in mast cells, the 
iloprost-stimulated increase in pH]-inositol phosphate production was PTX-sensitive 
suggesting a role of Gi (Oka et al, 1993). Although IP-receptors can activate PTX-
sensitive pathways in Bnu-2cl3 mast cells, activation of multiple signal transduction 
pathways was suggested to occur through different IP-receptor subtypes (Oka et al, 
1993). Besides, in megakaryocytic cells (MEG-01 cells), human platelets and rat inner 
medullary collecting duct, IP agonists lack the ability to activate the PLC pathway, 
although increases in [Ca^ ""]； were detected in MEG-01 cells (Nasrallah et al, 2001; 
Watanabe et al, 1991). Activation of multiple pathways by IP agonists could arise from 
several possibilities: (1) IP-receptor subtypes; (2) poor selectivity of IP agonists; or (3) 
coupling of IP-receptors to multiple G-proteins. Only one IP-receptor has been cloned 
so far from human lung, heart, kidney and megakaryocytes (Boie et al., 1994; 
Nakagawa et al., 1994)，although there is pharmacological evidence to suggest the 
presence of an IP-receptor subtype in the central nervous system (Takechi et al., 1996). 
2.2.2 Interaction with Gs 
The findings in various systems suggest that prostacyclin stimulates AC and produces 
cAMP (Halushka et al., 1989). IP-receptors mainly couple to the AC pathway to 
mediate important physiological responses such as platelet dis-aggregation as 
mentioned in the previous section. Further study using cloned IP-receptors transfected 
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into Chinese hamster ovary (CHO) cells supports the evidence that the IP-receptor 
indeed couples to Gs (Namba et al., 1994). Iloprost stimulated CHO cells transfected 
with mlP-receptor cDNA and generates cAMP in a concentration-dependent fashion, 
while no response was found in untransfected CHO cells (Namba et al., 1994). The 
presence of cholera toxin, which can terminate G^s proteins mediated AC activation, 
eliminated the iloprost-induced cAMP generation providing further evidence for 
coupling between IP-receptors and Gs proteins. 
Before considering the multiple signaling pathways for IP-receptors using 
various G-proteins, constant speculation to the existence of IP-receptor subtypes have 
been made through either normal or transformed cell lines studies (Oka et al., 1993). 
Studies using normal cells, e.g. rat dorsal root ganglion (DRG) cells in vitro, and in 
transformed cell lines suggests similar potencies of IP agonists stimulated cAMP and 
IP3 production and increasing Ca^ ^ mobilization (Smith et al., 1998; Watanabe et al, 
1991). However, study using cloned IP-receptor could estimate about 1000-fold higher 
IP agonists stimulated AC activation as compared with PLC activation in CHO cells 
(Namba et al, 1994). Due to the primary coupling ability of IP-receptor towards Gs 
protein, the IP-receptor is therefore classified as a Gs-coupled receptor within the 
prostanoid receptor family. 
2.2.3 Interaction with Gi 
It is very difficult to conclude the interaction between IP-receptor and Gi protein as due 
to lack of sufficient data to support the interaction with Gi protein. The only available 
data suggest the coupling between IP-receptor and Gi protein is from isolated perfused 
rabbit cortical collecting ducts (Hebert et al., 1998). Iloprost and carbacyclin inhibit 
arginine vasopressin-dependent increase in cAMP production in rat medullary thick 
ascending limb, indicating the possible role of IP-receptor in Gi protein activation 
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(Hebeit et al., 1998). In order to explain the inhibitory effect of these IP-agonists, 
Hebert et al. (1998) proposed the existence of three subtypes of IP-receptor: IP,-
receptors mediated PLC activation and increases in IPj-receptors couple to AC 
activation and increases in cAMP and IPj-receptors which couple to inhibition of cAMP 
formation via a PTX-sensitive pathway. As there is no IP-antagonist to help identify the 
site of action of iloprost and carbacyclin, it is difficult to conclude the coupling between 
IP-receptor and Gi subunit. Possibly the IP-agonists used in this study act on EP3-
receptors, which normally couple to Gi to inhibit cAMP formation, thus mediating the 
inhibition of AVP-Zp. In order to study the GTPase activity from fusion protein between 
the GPCR and various G-proteins, Milligan's group fused the IP-receptor with various 
G-proteins and results showed that under such close proximity, it is still not possible to 
produce any Gi activation in response to IP-receptor activation (Fong & Milligan，1999). 
Therefore, it is possible to exclude an interaction between Gi and IP-receptors. 
2.2.4 Interaction with Gq 
Of particular interest is the observation that cloned IP-receptors not only couple to AC 
via Gs, but are activated by iloprost to produce IP3 and DAG through PLC activation. 
The effect of iloprost on phosphatidylinositol metabolism was insensitive to PTX 
pretreatment (suggesting the effects may be mediated by Gq), was not mimicked by the 
addition of dibutyryl cAMP, and was unaffected by the loss of G^s (Namba et al.，1994). 
These results suggest that the same IP receptor can couple to both Gs and Gq (Namba et 
al, 1994). 
Apart from getting evidence about Gq coupling in transfection systems, IP-
receptors are coupled to the AC and PLC systems in cultured microvascular smooth 
muscle cells obtained from the cortex of piglet brains (Parfenova & Leffler，1996; 
Parkinson et al, 2000). There is evidence that cAMP might inhibit phosphoinositide 
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hydrolysis in smooth muscle cells (Ding et al.，1997). Such an effect could explain why 
only low concentrations of iloprost stimulated increases in IP3 and DAG contents 
whereas higher concentrations had minimal effects. With low iloprost concentrations 
the absence of AC activation causes the production of IP3 and DAG under conditions 
lacking any inhibitory effect from AC pathway. The generation of IP3 and DAG in turn 
activates PKC and shows sensitizing effect for AC pathway (Parkinson et al, 2000). 
However, high concentrations of iloprost increase the production of cAMP, which may 
provide negative feedback to inhibit phosphoinositide hydrolysis, thereby attenuating 
or abolishing the generation of IP3 and DAG (Parkinson et al” 2000). Therefore, this 
study provides evidence to support the Gq-coupling capacity of IP-receptor in normal 
cells. 
In order to study the property of IP-receptor in the platelets, HEL cells 
(human erythroleukaemia cells) are often used as a model of human platelet but results 
seems to be different from platelet studies. In HEL cells, IP agonists increase cAMP 
production and [Ca^^；release from internal store (Feoktistov et al., 1997). The increase 
in [Ca2+]i is not mimicked by dibutyryl cAMP and is PTX-insensitive, indicating the 
mobilization of Ca^^ ion is not related to the activation of Gs or Gi proteins. Before 
considering multiple coupling capacity of IP-receptor, presence of IP-receptor subtypes 
or tumour cell-associated disruption in receptor-effector coupling were suggested to be 
responsible for the effect of IP agonists (Schwaner et al 1992b). Current evidence from 
the cloned IP-receptor would suggest the multiple coupling capacity of IP-receptor 
towards multiple G-proteins i.e. Gs and Gq proteins (Kam et al., 2001). Despite 
evidence that the IP-receptor can increase [Ca'^； mobilization in transfection systems 
and transformed cell lines, normal cells seem to behave differently. All these studies are 
complicated by the poor selectivity of IP agonists, for example, studies using HEK 293 
cells，which endogenously express the hIP-receptor, suggests that the Ca^" mobilization 
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response from IP-agonists might be related to the activation of EP,- rather than IP-
receptors (Walsh & Kinsella，2000b). Due to the lack of available IP-receptor antagonist, 
it is still difficult to conclude the actual mechanism about IP-agonist mediated Ca^ ^ 
mobilization. 
At this moment, it is difficult to conclude any general idea about the coupling 
capacity between IP-receptor and Gq pathway in different cells. Due to the non-specific 
property of IP agonists towards different prostanoid receptors as mentioned in Section 
2.1.2, it is necessary to pay attention on interpreting the result obtained from agonist-
based data e.g. effect of prostaglandin E! (PGE,) at a novel prostanoid receptor in HEL 
cells (Feoktistov et al, 1997). 
2.2.5 Interaction with PPARs 
COXl and C0X2 are expressed in both the endoplasmic reticular (ER) membrane and 
the nuclear envelope (Spencer et al, 1998), suggesting that prostaglandins are poised to 
function via two different classes of receptor systems. Prostaglandins synthesized in the 
ER can exit cells and function through GPCRs that are linked to different cytoplasmic 
signaling pathways (Negishi et al., 1995b). In contrast, prostaglandins produced via 
nuclear COX can exert their effects directly on the nucleus by interacting with 
peroxisome proliferator-activated receptors (PPARs), which belong to a nuclear 
hormone receptor superfamily (Mangelsdorf & Evans，1995). Current study 
demonstrated that C0X2-derived prostacyclin participates in implantation and 
decidualization via the nuclear receptor PPAR6 in the uterus (Lim et al, 1999). Further 
study from the same group suggested the PPARS behaves as an IP-receptor within the 
nucleus and mediates the molecular mechanism for blastocyst implantation (Lim & Dey， 
2000). Altogether, all this information can be concluded as shown in Figure 14. PPARS 
is shown as a receptor for both arachidonic acid and prostacyclin. With the translocation 
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ofcPLAj to nuclear envelope, it can cause generation of arachidonic acid in the nucleus, 
where it can bind to PPAR5. RXR- PPAR5 dimer formation and cofactor recruitment 
stimulate the expression of the gene encoding C0X2 thereby enhances prostacyclin 
generation. As prostacyclin accumulates, it acts as a stronger ligand for PPAR5 to 
induce target genes in implantation. However, certain steps are unclear, i.e. the linkage 
between prostacyclin stimulation and cPLAj translocation, and the regulatory 
mechanism for prostacyclin-mediated PPRE activation. Given the role of PPAR5 
during implantation and embryonic development (Kliewer et al.’ 1994)，activity of 
these drugs under development toward PPAR5 should also be carefully monitored to 
avoid possible complications in pregnancy. It is necessary to re-access the role of 
prostacyclin in embryo development. However, Bhattacharya et al (1999) identified 
the localization of EP3- and EP4-receptors in the nuclear envelope from neonatal porcine 
brain and adult rat liver, it is necessary to clarify whether the effect of prostacyclin acts 
through the PPARs or nuclear membrane prostaglandin receptor. 
2.2.6 IP-receptor isoprenylation 
Apart from understanding the coupling capacity of IP-receptor either in normal or 
transfected systems, it is necessary to understand any regulatory mechanism controlling 
the coupling capacity of IP-receptors. Isoprenylation is a newly identified regulatory 
mechanism for IP-receptors. As there is still no evidence to suggest the involvement of 
isoprenylation for other GPCRs, the IP-receptor might be unique among GPCRs in that 
it is isoprenylated (Hayes et al, 1999). Isoprenylation of IP-receptor does not influence 
ligand binding but is required for efficient coupling to the effectors AC and PLC (Hayes 
e广 al, 1999). The formation of isoprenylation motifs in proteins has been proposed to 
facilitate specific protein-protein interactions in vivo (Zhang & Casey, 1996). As 
isoprenylation is a stable, permanent modification of proteins, it raises the possibility of 
49 
the formation of the fourth intracellular loop in the IP-receptors, which might be 
required for its functional coupling to effector systems. Clinically, reduced platelet 
activation has been reported in patients on long term administration of the Statins, 
which are inhibitors of HMG-CoA reductase, used in the regulation of de novo 
cholesterol biosynthesis in situations of hypercholesterolemia (Famier & Davignon， 
1998). The major application of this clinically useful drug is the therapy of 
hypercholesterolemia, a main risk factor for heart attack and stroke (Blauw et al, 1997; 
Lipid study group, 1998). Significant reduction in morbidity associated with coronary 
artery disease has been observed from study using statins according to its lipid lowering 
property. However, statin therapy also has potential to produce pleiotropic effects on 
other isoprenylated proteins (Guijarro et al., 1998). As a result, the balance between the 
clinical benefit from statin therapy and adverse effect due to interference in other 
signaling process remains to be determined. Thus, in view of the central role of 
isoprenylation on IP-receptor function, concerns relating to the long term use of the 
Statins on prostacyclin action and, in turn, on prostacyclin-mediated vascular 
hemostasis are important. 
2.3 Regulation of IP-receptors 
2.3.1 Mechanism of signal termination 
Agonist-induced regulation of GPCRs is a multistep process (Bunemaim & Hosey， 
1999a). In the classical pathway of GPCR regulation, agonist-induced receptor 
phosphorylation is mediated by the GPCR kinase (GRKs)，or second messenger 
activated kinases, PKC or PKA. Binding of an adapter protein, e.g. arrestin, to receptors 
leads to uncoupling of the receptor from the G-protein .and receptor sequestration 
through clathrin coated vesicles (CCVs). The internalization step is dependent on 
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dynamin, a GTPase that drives pinching off of the endocytotic vesicles. The sequestered 
receptor may be recycled to the cell surface to undergo another round of signal 
transduction, be down regulated via lysosomal degradation or may direct activation of 
additional signaling systems (Bunemann et al, 1999b). 
The factors that regulate tissue responsiveness to prostacyclin are poorly 
understood. Conventionally, activation of GPCRs may induce a loss of responsiveness 
to ligand via two processes (Hausdorff et al., 1990). In the following sections, I would 
like to discuss the current knowledge of IP-receptor regulation either in physiological 
conditions or transfection systems. The desensitization process will be focused on IP-
receptor regulation through receptor phosphorylation. 
2.3.2 Desensitization of IP-receptors 
Desensitization is an adaptive mechanism in biological systems thought to facilitate 
responsiveness of the cell to successive multiple extracellular stimuli over time. For 
GPCRs the desensitization process appears as a multistep phenomenon. Two major 
patterns of rapid desensitization process have been characterized, agonist-specific or 
homologous desensitization and agonist-nonspecific or heterologous desensitization 
(Chuang et al., 1996). 
It is likely that similar mechanism may govern prostanoid receptor regulation. 
Smyth et al. (1996) suggested that exposure of the IP-receptor to a stable prostacyclin 
analog resulted in rapid receptor phosphorylation in HEK 293 cells, and this 
phosphorylation appears to be largely dependent on activation of PKC rather than PKA. 
Although GPCR phosphorylation is thought to play a key role in receptor 
desensitization and in cross talk between signaling pathways, little is known about how 
such events relate to IP desensitization. Phosphorylation by PKC, and perhaps GRK, 
may play a functionally important role in regulating homologous desensitization of the 
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IP-receptor. Later, further study from the same group indicated that PKC-dependent 
phosphorylation is critical for homologous regulation of hIP-receptors (Smyth et al., 
1998). Using site-specific mutagenesis methods, Serine-328 was suggested to be the 
primary site for PKC phosphorylation of the hlP-receptor and this amino acid residue is 
important for IP-receptor desensitization. The finding that the hIP-receptor is a 
substrate for PKC raises the possibility of a role for this kinase in homologous and/or 
heterologous regulation of this receptor (Smyth et al, 1998). 
In vitro studies using human platelets have demonstrated the desensitization 
process occurs after prolonged exposure to IP-agonists (Jaschonek et al, 1988). Also, 
the desensitized IP-receptor wi l l recycle back to the platelet surface in a functionally 
active form after withdrawal of the agonist (Fisch et al, 1997). Actually, resensitization 
of IP-receptors has also been demonstrated in various neuroblastoma (NCB-20, 
NG108-15) cell lines (Krane et al, 1994a; Leigh & MacDermot，1985). In contrast to 
HEK 293 cells, studies on NG108-15 cells indicated that the desensitization process is 
not related to the activation of PKC (Krane et al，1994b). Therefore, the desensitization 
process for IP-receptors seems to be cell/tissue specific. 
I f IP-receptor desensitization behaves in a cell/tissue specific manner, the 
reason may due to cell specific expression of different regulatory components in 
different cell types. This highlights the importance of using native tissues to study the 
properties of IP-receptors. In recent studies using human fibroblasts which naturally 
express IP-receptors, much slower desensitization kinetics are observed compared with 
the rapid desensitization seen in HEK 293 cells (Nilius et al, 2000). Data from this 
study suggested that desensitization processes involving several distinct, but 
overlapping mechanisms that do not require the action ofGRKs or classical/novel PKC 
isoforms in human fibroblasts to attenuate the signaling capacity of hlP-receptors. 
Possible mechanisms may include receptor phosphorylation by tyrosine kinases as 
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described for the ^-opioid receptor (Pak et al., 1999). Budd et al. (2000) suggested that 
casein kinase l a is able to mediate m3-muscarinic receptor phosphorylation in an 
agonist-dependent manner. 
2.3.3 Internalization of IP-receptors 
After desensitization, receptors wil l be internalized into the cytoplasm for subsequent 
processing; this step is called sequestration (Menard et al，1997). In a similar manner to 
desensitization, the internalization process is quite different in different cells or tissues. 
In human platelets, the internalized IP-receptor wil l recycle back to the platelet surface 
rapidly and function efficiently after agonist removal (Fisch et al, 1997). As human 
platelets are incapable to perform de novo protein synthesis, de novo process seems to 
be unnecessary in IP-receptor resensitization. However in NG108-15 cells, the 
internalized receptor wi l l be transported for lysosomal degradation (Krane et al，1994a). 
Other unknown mechanism is important for resensitization of the IP-receptor in 
NG108-15 cells, although another study suggested that IP-receptor internalization is not 
important for resensitization (Mundell & Kelly，1998). 
Smyth et al (2000) have also suggested that the hIP-receptor is sequestered in 
response to agonist via a PKA- and PKC-independent pathways that are distinct from 
desensitization. Trafficking is dependent on determinants at the C-terminus, is 
GRKyarrestin-independent and proceeds via a dynamin-dependent clathrin-coated 
vesicular endocytotic pathway although other dynamin-independent pathways may be 
involved (Smyth et al, 2000). A l l this information suggests the tight control of IP-
receptor activity within the protein kinase network. Until now, there is still not enough 
evidence to conclude the general mechanism about IP-receptor internalization. 
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Figure 12. Structure of mouse prostacyclin (mlP) receptor. Membrane receptors 
contain seven hydrophobic membrane-spanning a-helical segments, linking the 
extracellular ligand-binding region of the receptor to the intracellular domain which is 
involved in signaling. Picture adapted from GPCR database 
(http://www.gpcr.org/7tm/). 
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Figure 13. Possible signal transduction pathway mediated by prostacyclin in 
adipogenesis. Arrow indicates activation pathway. Abbreviations: a-FABP, 
adipocyte fatty acid binding protein; AT, angiotensin; AA, arachidonic acid; C/EBP, 
CAAT/enhancer binding protein; COX, cyclo-oxygenase; PGHj, prostaglandin Hj； 
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Figure 14. A hypothetical scheme for dual ligand recognition by PPAR5 during 
implantation. Abbreviations: cPLA]，cytoplasmic phospholipase A:; C0X2, cyclo-
oxygenase 2; PGHj, prostaglandin Hj； PGIS, prostacyclin synthase; PPAR, peroxisome 
proliferator-activated receptor; PPRE, PPAR-response element; RXR, retinoic X 
receptor. Adapted from Lim & Dey (2000). 
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CHAPTER 3 
Materials and solutions 
3.1 Materials 
Aqueous solutions were prepared in ultra-pure HjO (i.e. double distilled, deionised 
water). 
[^H]-iloprost (specific activity 17 Ci/mmol) was purchased from Amersham and 
stored at-20°C. 
8-[^H]-adenme (specific activity 27 Ci/mmol) was purchased from Amersham and 
stored at 4°C. 
Acetic acid (glacial 100%, Merck) 
Agarose (genetic technology grade, FMC) 
Alumina (alumina, neutral type WN-3, Sigma) 
Ammonium formate (Sigma) 
Ammonia solution (25%, BDH) 
Ampicil l in (Sigma) was dissolved in ultra-pure water at 50 mg/ml, aliquoted and 
stored at -20°C. 
ATP (adenosine 5'-triphosphate, Sigma) was prepared fresh on day of assay. 
Benzaraide HCI (Merck) 
BMY45778 (a gift from Bristol-Myers-Squibb, USA) was reconstituted at 10 mM in 
DMSO and stored at -20°C. 
Bovine serum albumin (Sigma) was dissolved in 0.5 M NaOH at 1 mg/ml and stored 
at 4。C. 
Bradykinin (Sigma) was prepared as a 1 mM stock solution in ultra-pure water and 
stored at -20°C. 
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Calcium chloride (Sigma) 
Carbachol (Sigma) was dissolved in ultra-pure water at 100 mM and stored at -20°C. 
Carbacyclin (Calbiochem) was dissolved in 1% NaHCOj at 10 mM and stored at -
20。C. 
Cicaprost (gift from Schering AG, Germany) was supplied in aqueous solution or 
prepared as a 1 mM stock solution in ultra-pure water and stored at -20°C. 
Dibutyryl cAMP (Biomol) was dissolved in ultra-pure water at 10 mM and stored 
at-20°C. 
Diethyl ether (Labscan) 
Dimethyl sulphoxide (Sigma) 
Dowex (AG 50W-X4 resin, hydrogen form, 200-400 mesh, Bio-Rad) 
Dowex (AG 1-X8 resin, formate form, 100-200 mesh, Bio-Rad) 
DTT (dithiothreitol, Pharmacia Biotech) 
EcoKL (Roche) 
(Roche) 
EDTA (ethylenediamine-tetraacetic acid, Sigma) 
EGTA (ethylene glycol-bis (|3-aminoethyl ether) N, N, N，，N'-tetraacetic acid, Sigma) 
Ethanol (Absolute, Merck) 
Fetal bovine serum (FCS, Sigma). 
Formic acid (BDH) 
Forskolin (Sigma) was dissolved in absolute ethanol at 10 mM and stored at-20°C. 
Fura-2-AM (fura-2 acetoxy methyl ester, Sigma) was dissolved in ultra-pure water at 
1 mM, aliquoted and stored at -20°C, protected from light. 




GaQwt cDNA (a gift from Dr. Y.H. Wong, HKUST) was cloned in pcDNAl . l 
expression vector. 
GaSwt cDNA (a gift from Dr. Y.H. Wong, HKUST) was cloned in pcDNAl . l 
expression vector. 
H-89 (Biomol) was dissolved in DMSO at 10 mM and stored at 一20°C. 
Hepes (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid], Sigma) 
Hindill (Roche) 
HiSafe 3 scintillant (Pharmacia Biotech) 
Hydrochloric acid (12.1 M, Merck) 
IBMX (3-isobutyl-l-methyl-xanthine, Sigma) was dissolved in DMSO at 100 mM 
and stored at -20°C. 
Iloprost (gift from Schering AG, Germany) was supplied in aqueous solution or 
dissolved in ultra-pure water to a final concentration of 1 mM and stored at -20°C. 
Imidazole (Sigma) 
Indomethacin (Sigma) was dissolved in absolute ethanol at 10 mM and stored at -
20°C. 
Lipofectamine (GibcoBRL) 
Li thium chloride (Sigma) was prepared as a 1 M solution in ultra-pure water and 
stored at 4°C. 
Lovastatin (Sigma) was dissolved in DMSO at 10 mM and stored at -20。C. 
LY294002 (Sigma) was dissolved in DMSO at 10 mM and stored at -20。C. 
Magnesium chloride (Sigma) 
Methanol (Merck) 
MOPS (3-[N-Morpholino] propanesulfonic acid, Sigma) 
Mouse prostacyclin receptor (mlP) cDNA (a gift from Dr. Kobayashi, Kyoto 
University) was cloned in pCMX expression vector. 
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Mj;o-inositol-[2-^H(N)] (specific activity 22.2 Ci/mmol) was purchased from NEN 
and stored at 4°C. 
Ndel (Roche) 
Opti-mem I (GibcoBRL) 
pcDNAl . l vector DNA (Invitrogen, San Diego, CA) 
Penicillin/Streptomycin solution (Sigma, Cat. No. 80K2337) was reconstituted with 
20 ml sterile ultra-pure water and stored at 4°C. 
Perchloric acid (BDH) 
PMA (phorbol 12-myristate 13-acetate, Sigma) was dissolved in DMSO at 10 mM 
and stored in aliquots at -20°C. 
PMSF (phenylmethylsulfonyl fluoride, Sigma) 
Potassium acetate (Sigma) 
Potassium chloride (Sigma) 
Potassium dihydrogen phosphate (Merck) 
Potassium hydroxide (Sigma) 
Prostaglandin D: (Sigma) was dissolved in absolute ethanol to a concentration of 10 
mM, and stored at -20°C. 
Prostaglandin E! (Sigma) was dissolved in absolute ethanol to a concentration of 10 
mM, and stored at -20°C. 
Prostaglandin E2 (Sigma) was dissolved in absolute ethanol to a concentration of 10 
mM, and stored at -20°C. 
Prostaglandin Fj^ (Sigma) was dissolved in absolute ethanol to a concentration of 5 
mM, and stored at -20°C. 
Rp-cAMPS (Biomol) was dissolved in ultra-pure water at 10 mM and stored at -
20。C. 
Sodium bicarbonate (Sigma) 
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Sodium chloride (Sigma) 
Sodium dodecyl sulfate (Bio-Rad) 
Sodium hydroxide (NA Chemicals) 
SQ22536 (Biomol) was dissolved in ultra-pure water at 10 mM and stored at 一 2 0 ° C . 
Staurosporine (Biomol) was dissolved in DMSO at 10 mM and stored at 一20。C. 
Trichloroacetic acid (Sigma) was dissolved in ultra-pure water to a concentration of 
5% (w/v) and stored at 4°C. 
Trizma®base (Tris [hydroxymethyl] amino-methane, Sigma) 
Trypan blue (Sigma) 
0.25% Trypsin/EDTA (Sigma, Cat. No. 36H2326) 
Tryptone (Oxoid) 
U46619 (Sigma) was dissolved in absolute ethanol at 100 ^ M and stored at -20°C. 
U73122 (Biomol) was dissolved in DMSO at 10 mM and stored at 一 2 0 ° C . 
U73343 (Biomol) was dissolved in DMSO at 4 mM and stored at -20°C. 
Wortmannin (Biomol) was dissolved in DMSO at 10 mM and stored at -20°C. 
Xbal (Roche) 
Xhol (Roche) 
Yeast extract (Oxoid) 
Al l disposable tissue culture dishes were supplied by Nunc. Variable size of 
disposable tissue culture flasks was supplied by Coming. The size of tissue culture 
flasks includes 25 cm^ (small flask), 75 cm^ (medium flask), 150 cm: (large flask). 
3.2 Culture media, buffers and solutions 
3.2.1 Culture media 
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Ham's Nutrient Mixture F-12 (Sigma) was reconstituted with 1000 ml ultra-pure 
water, and supplemented with NaHCO〕（1.18 g/L). The pH was adjusted to 6.8 with 1 
M HCI and filter sterilized through a 0.22 ^m filter into a 1000 ml bottle to give a 
final pH of 7.0. Penicillin (100 units/ml) and streptomycin (100 }ig/ml) were added to 
each 1000 ml bottle to form incomplete medium and stored at 4。C. Fetal bovine 
serum (10% v/v) was added to form complete media for culture maintenance. 
RPMM640 (Sigma) was reconstituted with 1000 ml ultra-pure water, and 
supplemented with NaHCO〗（2.0 g/L). The pH was adjusted to 6.8 with 1 M HCI and 
filter sterilized through a 0.22 urn filter into a 1000 ml bottle to give a final pH of 7.0. 
Penicillin (100 units/ml) and streptomycin (100 ng/ml) were added to each 1000 ml 
bottle to form incomplete medium and stored at 4°C. Fetal bovine serum (10% v/v) 
was added to form complete media. 
Dulbecco's Modified Eagle's Medium DMEM (Sigma) was reconstituted with 
1000 ml ultra-pure water, and supplemented with NaHCOj (3.7 g/L). The pH was 
adjusted to 6.8 with 1 M HCI and filter sterilized through a 0.22 ixm filter into a 1000 
ml bottle to give a final pH of 7.0. Penicillin (100 units/ml) and streptomycin (100 
|ig/ml) were added to each 1000 ml bottle to form incomplete medium and stored at 
4°C. Fetal bovine serum (5% v/v) was added to form complete media. 
3.2.2 Buffers 
Dulbecco's PBS (PBSA: free) was prepared with the following ACS 
reagents supplied by Sigma: KCl (2.7 mM), KH2PO4 (1.4 mM), NaCl (137 mM) and 
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Na2HP04 (8.1 mM) in ultra-pure water. The pH was adjusted to 7.5 with 1 M NaOH 
and the solution was filter sterilized giving a final pH of 7.4 and stored at 4°C. 
HEPES buffer saline (HBS) was prepared with the following ACS reagents supplied 
by Sigma: CaCl2.2H20 (2.2 mM), Hepes (15 mM), KCI (4.7 mM), KH2PO4 (1.2 mM), 
MgCl2-6H20 (1.2 mM), NaCl (140 mM) in ultra-pure water. The pH was adjusted to 
7.5 with 1 M NaOH and the solution was filter sterilized giving a final pH of 7.4 and 
stored at 4°C. Glucose (11 mM) was added on the day of experiment. 
3.2.3 Solutions 
5% Trichloroacetic acid (TCA) was prepared by dissolving 25 g/L TCA with ultra-
pure water. The solution was stored at 4。C. On the day of experiment, ATP (1 mM) 
was added to 5% TCA before use. 
1 M formic acid was prepared by adding 37.73 ml 26.5 M formic acid stock solution 
to ultra-pure water and the volume was made up to 1000 ml. The solution was stored 
at room temperature. 
20 mM formic acid was prepared by adding 20 ml 1 M formic acid to ultra-pure 
water and the volume was made up to 1000 ml. The solution was stored at 4°C. 
4 M ammonium formate was prepared by dissolving 252.24 g/L ammonium formate 
in ultra-pure water. The solution was stored at room temperature. 
2 M ammonium formate/0.1 M formic acid was prepared by mixing 1000 ml of 4 
M ammonium formate with 200 ml 1 M formic acid. Ultra-pure water was added to 
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the solution and the volume was made up to 2000 ml. The solution was stored at 
room temperature. 
40 mM ammonium formate/0.1 M formic acid was prepared by mixing 20 ml of 4 
M ammonium formate with 200 ml 1 M formic acid. Ultra-pure water was added to 
the solution and the volume was made up to 2000 ml. The solution was stored at 
room temperature. 
0.05% ammonia was prepared by adding 2 ml 25% ammonia solution to ultra-pure 
water and the volume was made up to 1000 ml. The solution was stored at room 
temperature. 
Imidazole (0.5 M) was prepared by dissolving 52.25 g/L imidazole in ultra-pure 
water and the pH was adjusted to 7.5 with 1 M NaOH. This stock solution was 
diluted to 0.1 M with ultra-pure water before use. The solution was stored at room 
temperature. 
LB broth was prepared by dissolving 10 g NaCl, 10 g tryptone and 5 g yeast extract 
in 1000 ml ultra-pure water. The LB broth was autoclaved and antibiotic was added 
as required to the solution after cooling. The solution was stored at 4°C. 
Agar plates were prepared by dissolving 10 g NaCl, 10 g tryptone, and 5 g yeast 
extract and 15 g agar powder in 1000 ml ultra-pure water. The agar solution was 
~ autoclaved and antibiotic was added as required to the solution after cooling. Five ml 
agar solution was poured into each petri-dish and left to solidify at room temperature. 




4.1 Cell culture 
Chinese Hamster Ovary (CHO) cells were cultured in F-12 medium supplemented 
with 10% FCS, 100 units/ml penicillin and 100 )ig/ml streptomycin in a humidified 
atmosphere of 5% COJ^SVo air at 37。C. Cells were passaged twice weekly on reaching 
approximately 80% confluency. The medium was removed from the small flask and 
cells were washed with 4 ml PBSA. The PBSA was then discarded and 1 ml 
trypsin/EDTA was added to the flask. The flask was left at room temperature for 5 - 10 
min. When the cells were completely detached from the flask, 10 ml complete F-12 
was added to the flask. The cell suspension (0.37 ml) was added to a new small flask 
containing 5.6 ml complete F-12 medium (split ratio 1:30). When counting cells, 10 |il 
of cell suspension was transferred into hemocytometer slide and counted under the 
microscope. 
Human Neuroblastoma (SK-N-SH) cells were cultured in RPMI-1640 medium 
supplemented with 10% FCS, 100 units/ml penicillin and 100 p.g/ml streptomycin in a 
humidified atmosphere of 5% C02/95% air at 37°C. Cells were passaged once weekly 
on reaching approximately 80% confluency. The medium was removed from the 
medium flask and cells were washed with 7 ml PBSA. The PBSA was then discarded 
and 2 ml trypsin/EDTA was added to the flask. The flask was left at room temperature 
for 5 - 1 0 min. When the cells were completely detached from the flask, 20 ml 
complete RPMI-1640 was added to the flask. The cell suspension (1 ml) was added to a 
new medium flask containing 19 ml complete RPMI-1640 medium (split ratio 1:20). 
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When counting cells, 10 |J.1 of cell suspension was transferred into hemocytometer slide 
and counted under the microscope. 
Rat/mouse Neuroblastoma/Glioma Hybrid (NG108-15) cells were cultured in 
DMEM medium supplemented with 5% FCS，100 units/ml penicillin and 100 )ag/ml 
streptomycin in a humidified atmosphere of 5% QOJ^SVo air at 37°C. Cells were 
passaged twice weekly on reaching approximately 80% confluency. The medium was 
removed from the medium flask and 7 ml PBS A was added into the flask. The flask 
was left at room temperature for 10-15 min. When the cells were completely detached 
from the flask, 13 ml complete DMEM was added to the flask. The cell suspension (1 
ml) was added to a new medium flask containing 19 ml complete DMEM medium 
(split ratio 1:20). When counting cells, 10 j i l of cell suspension was transferred into 
hemocytometer slide and counted under the microscope. 
4.2 Mammalian cell transfection 
4.2.1 Preparation of plasmid DNA 
Competent E. coli were prepared using CaCl〗 treatment (Dower etal, 1988). Five ml E. 
coli (JM 109 or MC 1061 as required) were washed by centrifuging at 1100 x g for 10 
min at 4°C and resuspending in 5 ml 0.1 M CaClj at 4°C. The supernatant was removed 
and the bacteria were washed twice with 5 ml 0.1 M CaClj at 4°C. The supernatant was 
decanted and final pellet was resuspended in 1 ml 0.1 M CaClj at 4。C. The competent E. 
coli were aliquoted (100 into Eppendorf tubes either stored at 一70。C as stock or 
stored at 4°C for use on the following day. 
Plasmid DNA was bulked up in competent E. coli. Plasmid DNA (5 - 10 ng) 
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was mixed with one tube of competent E. coli and incubated on ice for 30 min. Next, 
the bacteria were heat shocked by incubating at 42°C for 2 min, and then transferred to 
ice for 2 min. Then, the bacteria were incubated with 500 j^l LB at 37°C for 1 h. The 
transformed E. coli were selected using suitable antibiotics on agar plates and the 
plasmid DNA extracted and purified using Qiagen maxi-prep columns (Cat. 
No.12162). 
mlP cDNA was transfected into JM 109 cells and the transformed E. coli 
were selected on an ampicillin (50 |ig/ml) containing agar plate. pcDNA 1.1，G^^ swt 
cDNA, Gaqwt cDNA were transfected into MC 1061 cells and the transformed E. coli 
were selected using ampicillin (50 fj.g/ml) containing agar plates. 
In order to confirm the purity of extracted plasmid DNA, absorbance 
measurements at 260 and 280 nm were used to detect any protein contamination in the 
extracted plasmid DNA. A ratio of absorbance 1.8 一 2.0 was taken as suitable plasmid 
DNA purity for use. Restriction digestion methods were used to confirm the identity of 
extracted plasmid DNA. mlP cDNA was located within the pCMX expression vector. 
Gaqwt cDNA and G<,swt cDNA were located within the pcDNA 1.1 expression vector. 
pcDNA 1.1 is a mammalian expression vector, which contains the SV40 replication 
origin together with the human cytomegalovirus (CMV) promoter, supporting high 
level transient expression in mammalian cells. Any restriction site within the multiple 
cloning site i.e. HincRll, Xba\ was useful for pcDNA 1.1 cDNA identification. 
Restriction sites for identifying the extracted plasmid DNA and band size of DNA after 
restriction digestion is shown in Table 1. 
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Plasmid 
Restriction enzyme mlP G ^ Q ^ pcDNAl.l 
EcoRI — — 0.9，4.5 -
EcoRV + Hindm 1.3,4.5 — 一 一 
Hincail 一 1.5,4.1 — 4.0 
Ndel — 0.9，4.7 — — 
Xbal — 一 5.4 4.0 
Table 1. Band size of plasmid DNA after digestion by different restriction enzymes (all 
values are in kb). 
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4.2.2 Transient transfection of mammalian cells 
Cells were transfected at approximately 80% confluency using lipofectamine and 
Opti-Mem I reduced serum medium according to manufacturer's instructions. First, 
plasmid DNA was mixed with Opti-mem I medium and made up the volume to 400 \ i l 
Also, lipofectamine was mixed with Opti-mem I medium and made up the volume to 
400 1^1 i.e. transfection in large flask. Next, two solutions were combined (ratio 
between plasmid DNA and lipofectamine is 1 |ag:5 jal) and allowed to stand at room 
temperature for 20 min. Details of information about volume of Opti-mem I mixed 
with either cDNA or lipofectamine is listed in Table 2. The resulting transfection 
cocktail was made up to a certain volume with the addition of Opti-mem I medium. 
The transfection cocktail was left on each well/flask for incubation at 37°C for 5 h. 
Then, the transfection cocktail was removed and fresh complete medium added as 
appropriate. Cells were always tested 48 h after transfection. 
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Culture plate 
12-welI 6-well Small Medium Large 
Reagent mixtures plates plates flask flask flask 
cDNA + Opti-mem I 0.02 0.04 0.15 0.20 0.40 
Lipofectamine + Opti-mem I 0.02 0.04 0.15 0.20 0.40 
H M A / I W r ^ w f . ,、 0.40 1.00 3.00 8.00 15.00 
cDNA/lipofectamine (1 [xg:5 i^l) 
Table 2. Transfection protocol summary table (all volumes are in ml) 
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4.2.3 P-galactosidase assay 
4.2.3.1 Introduction 
Transfection of cells with the (3-gal gene can be used to estimate the efficiency of 
plasmid cDNA transfer into mammalian cells. The high sensitivity P-galactosidase 
assay kit (Stratagene, Cat. No. 200710)，which determines the P-galactosidase activity 
in the lysates of cells transfected with a P-galactosidase expression construct, was used 
to compare the transfection efficiency between different cell types. The enzyme P-
galactosidase catalyzes the hydrolysis of P-galactosides, including lactose and the 
galactoside analog chlorophenol red-P-D-galactopyranoside (CPRG). The enzyme 
converts the yellow-orange CPRG into galactose and the chromophore chloroprene red， 
yielding a dark red solution. Endogenous p-galactosidase activity was tested using 
mock-transfected cells. 
4.2.3.2 Preparation of cell lysate 
The cell lysate was prepared according to manufacturer's instructions. Transfected cells 
from 12-well plates were washed with 1 ml PBSA, and lysed with 100 |al lysis buffer 
using one freeze-thaw cycle. The cell lysates were centrifliged (12,000 x 容 for 5 min at 
4°C) and supematants transferred to micro tubes. The cell lysate should be tested 
immediately. 
4.2.3.3 Micro p-galactosidase assay 
Samples of cell lysate (20 |il) were put into a 96-well plate, followed by 130 of 1 x 
CPRG substrate, and incubated at 37°C for 30 min. The reaction was terminated by 
addition of 80 stop solution, and O.D. measured at 570 nm within 2 h. The protein 
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content of cell lysates was determined according to the Bradford method using a kit 
purchased from Pierce (Cat. No. BJ44362) using albumin as the standard. Results are 
expressed as specific activity of P-galactosidase (U/mg), i.e. (P-galactosidase activity, 
U) / (amount of protein in cell lysate，mg). 
4.3 Measurement of adenylate cyclase activity 
4.3.1 [^H]-adenme prelabelling method 
The activity of AC, the enzyme that catalyses the formation of cyclic AMP from ATP, 
can be measured by labeling cells with [^H]-adenine and measuring the conversion of 
[^H]-ATP to [^H]-cyclic AMR This method has the advantages of high sensitivity and 
reproducibility, as demonstrated previously by other work conducted in this laboratory. 
The phosphodiesterase inhibitor iso-butyl-methyl-xanthine (IBMX) at 1 mM 
was included in the assay buffer to prevent the breakdown of cyclic AMP, and the 
non-selective cyclooxygenase (COX) inhibitor, indomethacin at 3 jiM, was added to 
prevent endogenous production of prostaglandins. 
4.3.1.1 Preparation of columns 
Dowex columns (AG50W-X4) were prepared by mixing 50 g of dowex with 100 ml 
HCI (1 M) and placing evenly in 50 Bio-Rad chromatography columns. The columns 
were washed with 4 ml HCI (1 M)，followed by 10 ml ultra-pure water prior to the 
experiment. Alumina columns were prepared by adding 0.6 g of neutral alumina to 
each of 50 columns, followed by 8 ml imidazole buffer (0.1 M, pH 7.5). These columns 
are reusable; dowex columns were rinsed with 4 ml HCI (1 M)，followed by 10 ml 
ultra-pure water, repeated three times. Alumina columns were rinsed with 8 ml 
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imidazole buffer (0.1 M，pH 7.5) three times, prior to use. 
4.3.1.2 Incubation of cells 
For those cells being transfected with plasmid DNA，cells were harvested from flasks 
using trypsin/EDTA treatment on the morning of the day after transfection. Cells (2 x 
105 cells/well) were seeded to each well of a 12-well plate containing 1 ml medium 
containing 1% FCS plus antibiotics. In the late afternoon, 10 \xl of [^H]-adenine at a 
final concentration of 1 |LiCi/ml was added to each well. For those cells not transfected 
with plasmid DNA, cells were seeded to each well of 12-well plate containing 1 ml 
complete medium. After reaching approximately 80% confluency, each well was 
added 10 of [^H]-adenine at a final concentration of 1 fiCi/ml. 
Following overnight (18 -20 h) incubation, the medium was aspirated and 
each well washed twice with 1 ml HBS buffer to remove unincorporated [^H]-adenine. 
HBS (1 ml) containing 1 mM IBMX and 3 |nM indomethacin was added to each well. 
Test compounds (10 }il) were added to each well and the 12-well plates were placed in 
a 37。C water bath for 30 min. To stop the reaction, plates were transferred onto ice, 
buffer was aspirated and 1 ml ice cold 5% trichloroacetic acid containing 1 mM ATP 
was added to lyse the cells. The plates were left on ice for at least 30 min before loading 
the cell lysates onto Dowex columns. 
4.3.1.3 Measurement of [^H]-cyclic AMP production 
fH]-cyclic AMP was separated from total [^H]-adenine nucleotides (AXP) by column 
chromatography using dowex and alumina columns in a method adapted from Barber 
”al (1980). The reaction samples were placed into dowex columns followed by 3 ml 
ultra-pure water. The eluant was collected into 20 ml scintillation vials and mixed with 
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5 ml scintillant (Optiphase Hi-safe 3). These samples were then counted in a liquid 
scintillation counter (Beckman LS6000 or Packard LS2900TR) to determine the total 
[^H]-AXP activity. The dowex columns were washed with 10 ml ultra-pure water and 
directly eluted to the alumina columns. Once the water had completely passed through 
both sets of columns, the alumina columns were placed above 20 ml scintillation vials 
and the [^H]-cyclic AMP eluted with 6 ml imidazole buffer (0.1 M, pH 7.5). The eluant 
was mixed with 7.5 ml scintillant and counted in a liquid scintillation counter. Blank 
samples (i.e. no cells) were run through the columns in parallel to the test samples in 
order to determine the background count for the columns (typically 100 — 150 dpm) 
and these values were then subtracted from all the test values. 
4.3.1.4 Data analysis 
Each experiment was performed in duplicate or triplicate as noted in figure legends. 
Cyclic AMP production is expressed as %conversion, i.e. ([^H]-cyclic AMP) / (total 
[^H]-adenine nucleotides) x 100%. Agonist log concentration-response curves were 
fitted using GraphPad Prism (Ver.3) non-linear regression analysis, with the minimum 
value for each curve being constrained to the mean basal value for each individual 
experiment (n = 4 - 6). The pEQ。values (negative log of ECjo value) of these 
individual curves were calculated, and combined to give a mean 土 S.E.M. To account 
for the different levels of basal cyclic AMP production under different experimental 
conditions, the results were often expressed as fold basal cyclic AMP production, 
where fold basal is (stimulated cyclic AMP production) divided by (basal cyclic AMP 
production). A fold basal value of unity therefore indicates a lack of stimulation. 
Results also expressed as stimulated minus basal, where stimulated minus basal is 
(stimulated cyclic AMP production) minus (basal cyclic AMP production). 
Statistical levels of significance (p < 0.05) were calculated using one-way 
76 
analysis of variance. 
4.3.2 cAMP [1251�scintillation proximity assay (SPA) 
4.3.2.1 Introduction 
The sensitivity of cAMP scintillation proximity assay kit is high; it can detect the 
least concentration of cAMP from 78 fmol/tube. The assay is based on the competition 
between ['^^I]-cAMP (the tracer) and unlabelled cAMP in the standard or samples for 
binding to an antibody (rabbit anti-cAMP). Any ['^'l]-cAMP that is bound to the 
primary rabbit antibody will, therefore, be immobilised on the fluomicrosphere that 
wil l produce light. According to this method, the concentration of bound unlabelled 
cAMP could be determined by interpolation from a standard curve. 
4.3.2.2 Cell lysis method 
The reagents for cAMP (Amersham) were prepared according to the 
manufacturer's instructions. Cells were cultured in standard 12-well plates (Nunc), to a 
cell confluency of 80%. Procedures for cell transfection have been mentioned in 
section 4.2.2. and cells were lysed 48 h after transfection. Excess culture media was 
aspirated and 1 ml of diluted lysis reagent 1 (working solution) was added to the 12-
well plates. Cells were agitated after lysis reagent 1 is added. Cells were then incubated 
for 5 min and it was necessary to perform microscope evaluation to check cells had 
lysed. When cells were lysed, they were immediately processed for cAMP 
measurement with the SPA radioimmunoassay. 100 aliquots of cell lysates were 
used for assay. 
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4.3.2.3 cAMP [i25l]-scintiIlatioii proximity assay 
The standards for cAMP [⑵I]-SPA immunoreagent solutions were prepared according 
to the manufacturer's instructions. After adding all necessary reagents in appropriately 
labeled vials (13x55 mm), all vials were capped and mixed using an orbital shaker for 
15 - 20 h at room temperature. The amount of ['^^I]-cAMP bound was determined by 
counting the vials in a liquid-scintillation counter (Beckman LS6000). The amount of 
cAMP contained in a cell sample was determined according to the standard curve that 
generated according to the manufacturer's instructions. 
4.4 Measurement of phospholipase C activity 
4.4.1 Introduction 
The activity of PLC, the enzyme that results in formation of inositol 1,4,5-
trisphosphate (IP3) and DAG was measured by determining the accumulation of [^H]-
inositol phosphates compared to total [^H]-inositol phospholipids (Berridge & Irvine, 
1984a). LiCl (20 mM) was included in the assay buffer to prevent the recycling of 
inositol phosphate back into inositol phospholipids (Berridge & Irvine，1984b), and the 
non-selective cyclooxygenase (COX) inhibitor, indomethacin (3 ^iM), was added to 
prevent endogenous production of prostaglandins. 
4.4.1.1 Preparation of columns 
Dowex resin (Bio-Rad AG 1-X8) was washed twice with an equal volume of ultra-pure 
water. Resin suspension (2 ml) was transferred to each polyprep column (Bio-Rad). 
The columns were washed with 5 m l 2 M ammonium formate/OA M formic acid, prior 
to use. 
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4.4.1.2 [^H]-inositoI phosphate assay 
After transfecting the cells with plasmid cDNA directly into 12-well plates, the 
medium was replaced with 1 ml complete medium and 10 fil of ^^^-[^Hl-inositol was 
added into each well at a final concentration of 2 ^Ci/ml, and plates were returned to 
the 37°C incubator for 40 h incubation. 
After incubating with ^^^-[^H]-inositol for 40 h, cells were treated with 
different test compounds for assaying [^H]-inositol phosphate production. The medium 
was aspirated and each well was washed twice with 1 ml HBS buffer to remove free 
[^H]-inositol. To each well was added 1 ml HBS containing 20 mM LiCl and 3 ] M 
indomethacin (assay buffer) and plates were incubated in a water bath at 37。C for 10 
min. The assay buffer was aspirated and another 1 ml of assay buffer was added to each 
well. Test compounds (10 \il) were added to each well and the 12-well plates were 
placed in a 37°C water bath for 60 min. Transferring plates onto ice stopped the 
reaction, buffer was aspirated and 0.75 ml 20 mM ice-cold formic acid was added to 
lyse the cells. The plates were left on ice for at least 60 min before loading the cell 
lysates onto columns. 
4.4.1.3 Measurement of [^H]-inositol phosphate production 
[^H]-inositol phosphate was separated from total [^H]-inositol phospholipids by 
column chromatography using dowex in a method adapted from Berridge (1984a). The 
columns were washed with 5 ml 2 M ammonium formate/O.l M formic acid, followed 
by 2 ml ultra-pure water, then 2 ml of 0.05% ammonia solution prior to the experiment. 
The reaction samples were placed into dowex columns with immediate addition of 3 ml 
of ammonia solution. The eluant containing [^H]-inositol phospholipids was collected 
into 20 ml scintillation vials and mixed with 7.5 ml scintillant (Optiphase Hi-safe 3), 
The columns were then placed over a waste container and 4 ml of 40 mM ammonium 
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formate/O.l M formic acid was added to each column. Next, the [^H]-inositol 
phosphates were eluted with 5 ml of 2 M ammonium formate/O.l M formic acid and 
mixed with 10 ml scintillant (Optiphase Hi-safe 3). Blank samples (i.e. no cells) were 
run through the columns in parallel to test samples in order to determine the 
background count for the columns (typically 100 - 150 dpm), and these values were 
then subtracted from all the test values. These samples were counted in a liquid 
scintillation counter (Beckman LS6000 or Packard LS2900TR) 
4.4.1.4 Data analysis 
Each experiment was performed in duplicate or triplicate as shown in figure legends. 
Inositol phosphate production is expressed as %conversion, i.e. (fH]-inositol 
phosphates)/(total pH]-inositol phospholipids) x 100%. Agonist log concentration-
response curves were fitted using GraphPad Prism (Ver.3) nonlinear regression 
analysis, with the minimum value for each curve being constrained to the mean basal 
value for each individual experiment (n = 4 - 6). To account for the different levels of 
basal inositol phosphate production under different experimental conditions, the results 
were often expressed as fold basal inositol phosphate production, where fold basal is 
(stimulated inositol phosphate production) divided by (basal inositol phosphate 
production). A fold basal value of unity therefore represents a lack of stimulation. 
Results also expressed as stimulated minus basal, where stimulated minus basal is 
(stimulated inositol phosphate production) minus (basal inositol phosphate 
production). 
Statistical levels of significant {p < 0.05) were calculated using one-way 
analysis of variance. 
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4.4.2 D-myo-Inositol 1,4,5-trisphosphate (IP3) assay system 
4.4.2.1 Introduction 
The sensitivity of D-myo-Inositol 1,4,5-trisphosphate (IP3) [^H] assay system is high; it 
can detect the least concentration of IP3 from 0.1 pmol/tube. The assay is based on 
competition between ['H]-IP, (the tracer) and unlabelled IP3 in the standard or samples 
for binding to a binding protein prepared from bovine adrenal cortex as supplied from 
the assay system. The bound IP3 is then separated from the free IP3 by centrifiigation. 
Lastly，the radioactivity in the tubes enables the amount of unlabelled IP3 in the sample 
to be determined by interpolation from a standard curve. 
4.4.2.2 Sample preparation 
Procedures for cell transfection have been mentioned in section 4.2.2. and cells were 
lysed 48 h after transfection with plasmid DNA. Cell lysate was mixed with 0.2 volume 
ice-cold 20% perchloric acid in disposable polypropylene tubes (10 x 55 mm) and 
incubated on ice for 20 min. Proteins were sedimented by centriftigation at 2000 x g for 
15 min at 4°C and the suspension was decanted into plastic test tubes. The supernatant 
was neutralized to pH 7.5 by titrating with ice-cold 10 M KOH. KCIO4 was then 
sedimented by centrifiigation at 2000 x g for 15 min at 4°C. The supernatant was 
decanted into plastic test tubes and used for subsequent analysis. Alternatively, cell 
lysate was extracted using trichloroacetic acid extraction method. Cell lysate was 
mixed with equal volume ice-cold 15% trichloroacetic acid in disposable 
polypropylene tubes (10x55 mm), and proteins were sedimented by centrifiigation at 
2000 X g for 15 min at 4°C. The supernatant was extracted three times with 10 volume 
of water-saturated diethyl ether and neutralized to pH 7.5 by titrating with NaHCOj. 
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4.4.2.3 D-myo-Inositol 1,4,5-trisphosphate (IP3) [^ H] assay 
The reagents for [^H]-IP3 assay (Amersham) were prepared according to the 
manufacture's instruction. After all necessary reagents were added into appropriately 
labelled tubes, the tubes were vortex mixed and incubated on ice for 15 min. Al l tubes 
were centrifiiged except total count (TC) tube at 2000 x g for at least 10 min at 4°C. 
After centrifligation, the tubes were placed in suitable decantation racks, and the 
supernatant was discarded. The tubes were inverted, placed on absorbance tissues and 
draining for 2 min. The inverted tubes were firmly blotted on the tissues, and any 
droplet of liquid was removed by carefully wiping the inside of the tubes using a 
suitable swab. Al l tubes except TC were added with 1 ml of 0.15 M sodium hydroxide. 
Al l tubes were vortex mixed ensures that each pellet is fully resuspended and incubates 
at room temperature (15 - 30°C) for 10 min. After 10 min incubation, 50 of 10% 
acetic acid was added to all tubes except TC. Al l tubes were vortex mixed again, and 
decanted immediately into scintillation vials. Scintillation fluid (10 ml) was added to 
each vial and the radioactivity was measured for 4 min in a liquid-scintillation counter 
(Beckman LS6000). 
4.5 Measurement of changes in intracellular Ca^ ^ concentration 
4.5.1 Introduction 
The concentration of intracellular calcium ([Ca^""]；) in adherent cells is measured using 
the MiraCal PRO ratio imaging system which measures the fluorescence emitted from 
Fura-2 loaded cells. When the cells are stimulated with a Ca-^-mobilising agonist, the 
changes in fluorescence allows the user to record changes in [Ca^ "]； within the cell in 
real time. Since the intensity of the fluorescence is directly proportional to the it 
is therefore possible to assess the effect of a particular agonist on Ca"^  release in an 
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individual cell at a certain time. 
The [Ca^^i was calculated automatically by the Mira Cal PRO software 
using the equation described by (Grynkiewicz et al., 1985): 
where Kd is the dissociation constant for the Fura-2 dye (224 nM at 37°C), R is the ratio 
of fluorescence (F340/F380), R i^^  and R^^ ^ are the ratio of fluorescence when the dye is 
completely free of Ca^ "" and saturated with Ca^ ^ respectively, and p is the ratio of 
saturated to free fluorescence at 380 nm. Calibration for determining the values ofR^i„, 
Rn,ax and P was performed by using fura-2 free acid solutions. 
4.5.2 Cell preparation 
Sterile glass coverslips (22 mm diameter, Chance Propper) were put to 6-well plates with 
1.5 ml complete medium. Cells (2 x 1cel ls/well) were seeded onto each coverslip and 
the plates were incubated overnight in a 37。C incubator. On the next day, each well was 
washed twice with 2 ml HBS containing 3 |aM indomethacin. Then, 1 ml incubation 
buffer (HBS buffer plus 1% BSA) and 7 1 mM fiira-2/AM were added to each well 
giving a final concentration of 7 |j,M fiira-2/AM in each well. The plates were 
incubated in a 37°C incubator for 45 min, after which the incubation buffer was 
removed and another 1 ml incubation buffer was added to each well. 
4.5.3 Measurement of Fura-2 fluorescence 
Fura-2 fluorescence was measured using a MiraCal PRO ration imaging fluorescence 
microscope and performed according to Gilabert & McNaughton，1997. The coverslips 
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with the fura-2 loaded cells attached were placed in stainless steel coverslip holders 
that had been greased with high vacuum silicone to prevent leakage from the resulting 
chamber. The cells were then re-immersed in 500 of prewarmed (37°C) HBS 
containing 3 )j,M indomethacin, and then the entire chamber inserted into a temperature 
controlled chamber holder. The cells were allowed to settle for 2 min at a constant 
temperature of 37°C and bright field light was then used to focus the image. Selected 
agonists (5 )_il) were then added to the chamber and the fluorescence was read at 
wavelengths of 340 and 380 nm every 0.8 sec for 5 min. Background fluorescence at 
both wavelengths was measured and subtracted from all subsequent calculations. 
4.6 Radioligand binding 
4.6.1 Introduction 
Radioligand binding provides a direct approach to the in vitro investigation of 
receptors. The expression of receptor protein on membrane surfaces can be measured 
by the formation of radioactive ligand-receptor complexes with removing the free 
radioactive ligand by filtration machines. According to this method, the level of 
receptor protein expression can also be estimated by ligand binding experiment. 
Results from ligand binding can be used to determine the plasmid DNA transfection 
concentration in order to express similar amount of protein for functional analysis. As a 
result, this method could be used to estimate a similar expression level of mutant 
mlP-receptor protein on CHO cell membranes compared with the wild type mlP-
receptor. 
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4.6.2 [^H]-iIoprost ligand binding 
At 48 h after transfection, cells were washed with 10 ml PBS A containing 10 mM 
EDTA and then removed from the 150 cm^ flask with a cell scraper. The cell pellet was 
resuspended in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4，2.5 mM MgCl】，1 mM 
EGTA, 1 mM benzamide HCl, 1 mM DTT, 0.1 mM PMSF) and homogenized using a 
Polytron homogeniser, at half-maximum speed, for 30 sec, twice. The whole procedure 
was performed on ice. Cell membranes were pelleted by centrifugation of the cell 
homogenate at 48,000 x g for 30 min at 4。C. The membrane pellet was washed once by 
resuspension in fresh lysis buffer and centrifiigation. The final crude membrane pellet 
was resuspended in a small volume of lysis buffer (400 |il) and stored at 一80。C until 
used for assay. Protein content of cell membrane preparation was determined according 
to the Bradford method using a kit purchased from Pierce and albumin as the standard. 
To determine the density of receptors in CHO cell membranes, 20 
membranes (50 一 150 |Lig) were incubated for 60 min at 30。C with 0.2 - 50 nM [^H] 
iloprost in 1 0 0 o f assay buffer (20 mM HEPES, pH 7.0,10 mM MgC l ! � 1 mM EDTA, 
0.1 mM PMSF and 3 \xM indomethacin) in duplicate. Non-specific binding was 
defined as [^H]-iloprost bound in the presence of 20 | iM iloprost. Incubation was 
terminated by vacuum filtration over glass fibre filters (Whatman GF/C), using a 
Brandel cell harvester. Filters were washed three times with ice-cold 20 mM HEPES 
pH 7.0，10 mM MgClj and 1 mM EDTA to remove unbound radioactivity, and filters 
were left overnight in 3 ml Hi Safe 3 scintillant before counting. Radioactivity was 
measured for 5 min in a liquid-scintillation counter (Beckman LS6000). The usual 
expression level of mlP-receptor in CHO cells membranes is about 100 fmol/mg 
membrane protein (Wise, 1999). • 
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4.6.3 Data analysis 
Ligand binding data were analyzed using the computer program GraphPad Prism 
(Yer.3), Binding constants were determined by nonlinear regression analysis. 
4.7 Cytotoxicity test using trypan blue exclusion test 
The potential toxicity of different chemicals was checked using the trypan blue 
exclusion test. This method is based on the principle that live (viable) cells do not take 
up certain dyes, whereas dead (non-viable) cells do. 
On the day of assay, cells were treated with different chemicals to mimic the 
AC or PLC assays with the presence of enzyme inhibitors. After aspirating the medium 
from 12-well plates, each well was washed twice with 1 ml HBS buffer. Then, 1 ml of 
HBS buffer (assay buffer) containing 1 mM IBMX and 3 | iM indomethacin (mimic AC 
assay) or 20 mM LiCl and 3 i^M indomethacin (mimic PLC assay) was added to each 
well. The cells were incubated at 37°C for 10 min. Then, assay buffer was removed and 
another 1 ml of assay buffer including 1 mM IBMX or 20 mM LiCl and 3 }iM 
indomethacin was added to each well. Test compounds (10 yd) were added to each well 
and the 12-well plates placed in a 37。C water bath for either 30 (mimic AC assay) or 60 
(mimic PLC assay) min. The assay buffer was removed from the well, and 0.3 ml 0.2% 
trypan blue solution was added to each well. The cells were exposed to the cell 
impermeant dye trypan blue for 15 sec and then were examined immediately by phase 
contrast microscopy (Walker et al., 1998). Photos were taken immediately for 
qualitative comparison. 
Use of a hemocytometer slide provides a method to quantify the viability of 
cells treated with different chemicals. After aspirating the assay medium, the cells were 
washed with 1 ml PBSA. PBSA was removed and 0.5 ml trypsin/EDTA was added to 
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the cells. Then, cells were incubated for 10 min and centrifliged at 250 x g for 5 min. 
After the incubation, cells were resuspended in 500 f^l complete medium and 10 cell 
suspension was mixed with 10 [xl 0.2% trypan blue and wait for 4 min. Cell viability 
was determined by transferring 10 i i l of mixtures into hemocytometer slide. The 
number of viable and dead cells was counted under the microscope. 
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CHAPTER 5 
Multiple coupling capacity of prostacyclin receptors in CHO 
cells 
5.1 Introduction 
Based on the clinical significance of IP-receptors in different diseases, IP-receptor 
pharmacology has been studied for a long time (Narumiya et al, 1999; Negishi et al, 
1995b). I have already discussed some evidence about the coupling capacity of 
IP-receptors in Chapter 2. Activation of multiple pathways by IP agonists could arise 
from several possibilities, for example, IP-receptor subtypes, poor selectivity of IP 
agonists, or coupling of IP-receptors to multiple G-proteins. According to information 
from Chapter 2, the most likely possibility for activating multiple pathways by 
IP-receptors is due to activation of multiple G-proteins. In order to replicate and verify 
the reports of multiple signaling by IP-receptors, this chapter is aimed to assess the 
G-protein coupling capacity of the IP-receptor using transient transfection of CHO 
cells. 
5.2 Method 
CHO cells were transiently transfected with mlP-receptor cDNA using Lipofectamine 
as described in section 4.2. The agonist-stimulated [^H]-cAMP and [^H]-inositoI 
phosphate production was assayed by metabolically labeled the cells with [^H]-adenine 
for 20 h or [^H]-inositol for 40 h as described in section 4.3 and 4.4. When CHO cells 
were co-transfected with mlP-receptor cDNA (mlP-CHO cells) and varying 
concentrations of G-proteins cDNA, total cDNA transfected was made constant using 
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pcDNAl.l. 
5.3 Results and Discussion 
5.3.1 IP agonist log concentration-response curves for [^H]-cAMP and 
[^H]-inositol phosphate production in mlP-CHO cells 
The results provided in Figures 15 and 16 were kindly provided by Kevin Chow 
(Pharmacology Dept. CUHK) and are needed here to set the scene for further 
discussion. As shown in Figures 15 and 16，results confirmed the multiple coupling 
capacity of the IP-receptor using various IP-agonists. All IP agonists show higher 
coupling efficiency towards the AC pathway compared with the PLC pathway 
(cicaprost, AC pECso = 8.36 土 0.01，PLC pECso = 6.87 土 0.02; iloprost, AC pECso = 
8.16 土 0.06，PLC pECso = 7.11 土 0.02; PGEi, AC pECso = 7.03 土 0.05，PLC pECso = 
5.93 土 0.09; carbacyclin, AC pECso = 7.60 土 0.03，PLC pECso = 6.15 土 0.04). 
Theoretically, the effective coupling between receptor and G-protein depend on 
matching with several structural requirements and result usually reflected from the 
slope of concentration-response curve. However, the steep slope of IP-receptor towards 
PLC activation compared with AC activation might relate to the desensitization process, 
which in turn counteract with the IP agonist stimulated AC activation, as discussed in 
Chapter 2. As a result, IP agonists show higher coupling efficiency towards the AC 
pathway but have steep slope of concentration-response curve for PLC pathway. 
The three BMY compounds and PGE2 stimulated [^H]-cAMP production 
only (BMY 22389, AC pECso = 6.66 土 0.04; BMY 42393，AC pECso = 6.78 土 0.16; 
BMY 45778, AC pECso = 6.40 ±0.10; PGE2, AC pECso = 4.83 土 0.37). Also, the three 
BMY compounds apparently showed partial agonist activity in [^H]-cAMP production 
compared with other IP agonists such as cicaprost. These results might be produced due 
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to the activation of Gi proteins by BMY compounds. In order to clarify this issue, the 
IP-receptor mediated [^H]-cAMP production was assayed in the presence of PTX to 
inactivate Gi proteins. As shown in Figure 17, results suggest that the partial agonist 
activity of AC activation in response to BMY compounds was unrelated to activation of 
Gi subunit (Kam et al, 2001). Previous study from Milligan's group using fusion 
protein between IP-receptor and various G-protein members, have already suggested 
the lack of interaction between IP-receptor and Gi (Fong & Milligan, 1999). Altogether, 
results suggested that IP-receptor could only couple to Gs and Gq proteins. 
As the IP-receptor possesses the multiple coupling capacity, I would like to 
know the limiting factor controlling the level of stimulation by IP agonists. 
5.3.2 Effect of varying GaS cDNA concentration on cicaprost-stimulated 
[^H]-cAMP and [^H]-inositol phosphate production in mlP-CHO cells 
It was necessary to confirm the function of the GaS cDNA for CHO cells transfection 
study. The iloprost-stimulated [^H]-cAMP production from mlP-CHO cells increased 
on increasing the transfection concentration of GaS cDNA (Fig. 18). Results suggest the 
GaS cDNA is active and can be used for further study. 
As shown from Figure 19(A) and Table 4, transfection of GaS cDNA had no 
consistent effect on cicaprost-stimulated [^H]-cAMP production in mlP-CHO cells. 
This is contrast with the preliminary trial of GaS cDNA transfection on 
iloprost-stimulated [^H]-cAMP production from mlP-CHO cells. Possibly 
co-transfection of GaS cDNA with pcDNAl.l might affect the total amount of cDNA 
being transfected into mlP-CHO cells. It is unclear whether the presence of pcDNAl.l 
affects the total amount of GaS cDNA transfection into mlP-CHO cells. Preliminary 
results from Figure 19(B) and Table 4 showed that transfections of GaS cDNA 
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suppressed the maximal response in terms of PLC activation. However, there is not 
enough evidence to make a firm conclusion on the effect of GaS cDNA transfection on 
IP-receptor mediated PLC response. Possibly the level of activity in AC pathways 
regulate the coupling capacity between the IP-receptor and the PLC pathway. I suspect 
whether any cross talk exists between the AC and PLC pathway and this intracellular 
interaction might regulate the response from receptor activation. Possibly the 
suppressed cicaprost-stimulated PLC activation is due to transfection of GaS cDNA 
which in turn activate PKA and exert its inhibitory effect towards PLC pathway 
components in mlP-CHO cells. These results will be discussed further in Chapter 8. 
In order to examine further the effect of GaS cDNA transfection on 
IP-receptor coupling capacity, results were expressed as %maximum cicaprost 
response and shown in Figure 20(A) and (B). Transfection of GaS cDNA had no effect 
on either [^H]-cAMP or [^H]-inositol phosphate production (Table 5). The result 
indicated that there is no consistent pattern in measuring the AC response and could not 
improve the coupling capacity of IP-receptor towards the PLC pathway by increasing 
the transfection concentration of GaS cDNA. As a result, it seems that increasing the 
expression level of GaS protein only affects the IP-receptor mediated maximal PLC 
response; there is no effect on coupling efficiency between the IP-receptor and PLC 
pathway component as reflected by the pECso values. 
The lack of effect on AC response from GaS cDNA transfection might be 
explained by a previous study on NG108-15 cells, where no effect on the potency of 
IP-agonists for stimulation of AC was seen as increasing the expression level of GaS 
(Mullaney et al., 1996). This result suggested that the GaS protein does not limit the 
signal transduction capacity of NG108-15 cells. This may not be surprising in 
NG108-15 cells as the expression level of GaS protein was already 10 fold higher 
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compared with the IP-receptor protein (Kim et al,, 1994). Further expression of GaS 
protein might therefore be anticipated to have a rather limited capacity to modify signal 
transduction efficiency. Previous study on murine hearts also showed rather little 
functional modulation in the heart by overexpression the GaS protein (Gaudin et al, 
1995). If this explanation is valid, that may explain the lack of effect of GaS cDNA 
transfection on mlP-CHO cells with regard to AC activity. 
As I used forskolin as a control agent to confirm the functionality of 
transfected cells in our assay system, CHO cells transfected with various 
concentrations of GaS cDNA were also stimulated with forksolin and [^H]-cAMP 
production was measured. Results in Figure 21 suggested that the forksolin response 
could be suppressed with higher GaS cDNA transfection. This result was unexpected as 
forskolin is generally thought to exert a direct action on the catalytic domain of AC 
(Darfler et al, 1982). The results seem to support a reciprocal allosteric link between 
forksolin, AC and GaS protein. A recent study indicated that forskolin affected GaS 
dispersion in low receptor expressing cells, an effect that was similar to that elicited by 
P2-adrenergic receptor stimulation or direct cholera toxin-mediated activation of GqS 
protein (Can et al, 2000). As a result, if I increase the expression level by GaS cDNA 
transfection, forskolin will interact with 0«5 protein and so reduce the interaction 
between forskolin and AC. However, the molecular mechanism is still unclear. Possibly 
the western blotting technique could confirm whether transfection of GaS cDNA into 
mlP-CHO cells actually increases the level of GaS protein expression as predicted. 
5.3.3 Effect of varying Gaq cDNA concentration on cicaprost-stimulated 
[^H]-cAMP and [^H]-inositol phosphate production in mlP-CHO cells 
Before starting these experiments, it is necessary to confirm the function of the Gaq 
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cDNA for CHO cells transfection study. The iloprost-stimulated [^H]-inositol 
phosphate production from CHO cells increased as the transfection concentration of 
Gaq cDNA increased (Fig. 22). Results suggest the Gaq cDNA is active and can be 
used for further study. 
As shown in Figure 23(A) and Table 7，transfection of Gaq cDNA has no 
effect on the maximal cicaprost-stimulated [^H]-cAMP production in mlP-CHO cells. 
Also, results from Figure 23(B) and Table 7 showed that transfection of Gaq cDNA 
have no effect on the maximal response in terms of PLC activation. These results 
suggest that the level of activity in PLC pathways does not regulate the IP-receptor 
mediated AC or PLC activation. 
Apart from studying the maximal response from IP agonist stimulation, I 
expressed the data in terms of %maximum cicaprost response. As shown in Figure 24，I 
could increase the potency of cicaprost-stimulated PLC activity with increasing the 
Gaq cDNA transfection concentration (Table 8). However, Gaq cDNA transfection 
would suppress the potency of cicaprost-stimulated AC activation (Table 8). 
Activation of IP-receptors is expected to activate PKC and cause IP-receptor 
phosphorylation and desensitization as described in Chapter 2. However, results 
suggested that I could observe change of potency in terms of AC activation in 
mlP-CHO cells transfected with Gaq cDNA (Fig. 24(A)). As mentioned in Chapter 2, 
IP-receptors mainly couple to the AC pathway and so the Gaq cDNA transfection 
concentration in this experiment may only have little effect on the coupling between 
IP-receptor and AC pathway. The result is unexpected and so it is worth to repeat this 
experiment, in order to verify the result in Figure 24(A). The results indicate the 
possible role of regulation between IP-receptor and AC pathway under the constraining 
effect from IP-receptor-mediated PLC activation. Although in Chapter 8，I used PKC 
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inhibitor and demonstrated the lack of PLC activation effect on IP-receptor mediated 
AC activation, this contradictory result could be explained according to the relative 
coupling efficiency of different G-proteins with the IP-receptor. The GaS subunit has a 
higher coupling capacity toward IP-receptors than the Gaq subunit (Fig. 15). As a result, 
transfection of Gaq cDNA into CHO cells decreases the coupling capacity between 
IP-receptor and GaS subunit. However, the use of PKC inhibitor only removes the 
inhibitory effect of PKC on IP-receptors. The inhibitory effect from PKC is relatively 
small as the affinity between IP-receptor and Gaq subunit is lower than G^s subunit. 
On the other hand, I could observe an enhanced potency of [^H]-inositol 
phosphate accumulation in mlP-CHO cells transfected with Gaq cDNA (Fig. 24(B)). 
Also, results suggest that I could use sub-maximal concentrations of IP agonist e.g. 
cicaprost (30 nM), to observe the enhancement in [^H]-inositol phosphate accumulation 
from Gaq cDNA transfection. However, there is not enough evidence yet for a firm 
conclusion. Results possibly suggest that Gaq is a limiting factor in PLC pathway and 
so enhanced PLC activation through Gaq cDNA transfection could suppress the 
IP-receptor mediated AC activation. However, G^s seems to have no limiting effect in 
AC pathway. 
Apart from examining the coupling between IP-receptor and PLC pathway in 
CHO cells, it is possible to examine other cell lines such as SK-N-SH and NG108-15 
using sub-maximal concentrations of IP agonists to look for changes in [^H]-inositol 
phosphate accumulation after Gaq cDNA transfection. Further discussion will be 
provided in Chapter 6. 
I also observed a significant stimulating effect of Gaq cDNA transfection 
following ATP stimulation of CHO cells, as shown in Figure 25.1 tested another GPCR, 
which normally couples to PLC activation, in order to confirm the result of Gaq cDNA 
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transfection in CHO cells. The purinergic (P2Y)-receptor, which is classified as 
Gq-coupled receptor, can stimulate [^H]-inositol phosphate production in response to 
ATP (Murray-Whelan et al, 1995). As a result, I tested the effect of Gaq cDNA 
transfection on ATP stimulation in mlP-CHO cells. For CHO cells transfected with 
mlP-receptor cDNA plus Gaq cDNA, both iloprost- and ATP-stimulated [^H]-inositol 
phosphate productions were significantly enhanced by Gaq cDNA transfection at 
sub-maximal agonist concentrations. Also, Figure 23(B) showed that only 
sub-maximal agonist concentrations could see the stimulating effect of Gaq cDNA 
transfection from cicaprost stimulation. Altogether, result suggests that transient 
transfection of Gaq cDNA can enhance the PLC activity. 
5.4 Conclusion 
In conclusion, I used transient transfection method to verify the multiple coupling 
capacity of prostacyclin receptors expressed in CHO cells. Also, I could identify the 
limiting factor regulating the IP-receptor mediated PLC activation. Transfection of GaS 
cDNA could not enhance the IP-receptor mediated AC activation. However, GaS cDNA 
transfection seems to suppress the maximal PLC activation, possibly related to 
inhibitory effect through PKA activation in preliminary experiment. Increasing 
expression level of Gaq subunit could enhance the IP-receptor mediated PLC activation. 
Transfection of Gaq cDNA into CHO cells shift the coupling capacity of IP-receptor 
towards PLC pathway and in turn reduce the coupling between IP-receptor and AC 
pathway. Effect of Gaq cDNA transfection on AC activation and GaS cDNA 
transfection on PLC activation indicates certain level of cross talk between AC and 
PLC pathways through IP-receptor activation. 
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Figure 15. Log concentration-response curves for IP agonist-stimulated [^H]-cAMP 
and [^H]-inositol phosphate production from mlP-CHO cells. CHO cells were 
transfected with 
mlP-receptor cDNA at 0.5 ^g/ml. Results are expressed as 
%maximum cicaprost response. Basal [^H]-cAMP production: 0.08 ± 0.01 
%conversion. Maximum [^H]-cAMP response to cicaprost: 7.72 土 1.29 fold basal. 
Basal [^H]-inositol phosphate production: 9.28 土 1.66 %conversion. Maximum [^H]-
inositol phosphate response to cicaprost: 3.66 土 0.69 fold basal. Results represent 
mean ± S.E.M. of 3 - 9 experiments, each performed in duplicate. 
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Figure 16. Log concentration-response curves for IP agonist- and PGE2-stimulated 
[^H]-cAMP and [^H]-inositol phosphate production from mlP-CHO cells. CHO cells 
were transfected with mlP-receptor cDNA at 0.5 )ig/ml. Results are expressed as 
%maximum cicaprost response. Basal [^H]-cAMP production: 0.08 士 0.01 
o/oconversion. Maximum [^H]-cAMP response to cicaprost: 7.72 土 1.29 fold basal. 
Basal [^H]-inositol phosphate production: 9.28 土 1.66 %conversion. Maximum [^H]-
inositol phosphate response to cicaprost: 3.66 土 0.69 fold basal. Results represent 
mean 土 S.E.M. of 3 - 6 experiments, each performed in duplicate, 
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Figure 17. Effect of pertussis toxin on IP agonist-stimulated [^H]-cAMP production 
in mlP-CHO cells. CHO cells were transfected with mlP-receptor cDNA (0.5 |ig/ml). 
Maximum response to cicaprost in mlP-CHO cells: 6.82 士 1.54 fold basal. Basal 
[^H]-cAMP production: 0.11 士 0.02 %con vers ion. Results are expressed as %max. 
cicaprost response. Results represent mean 土 S.E.M. of 4 experiments, each 
performed in duplicate. 
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Figure 18. Effect of GaS on iloprost-stimulated [^H]-cAMP accumulation. CHO cells 
were transfected with mlP-receptor cDNA (0.5 |j,g/ml) plus varying concentration of 
GaS cDNA. Results represent mean 土 S.D. of 1 experiment, performed in duplicate. 
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Figure 19. Effect of GaS on cicaprost-stimulated AC and PLC activity in mlP-CHO 
cells. CHO cells were transfected with mlP-receptor cDNA (0.5 ^g/ml) and different 
concentrations of GaS cDNA as shown. The total amount of cDNA transfected was 
balanced at 1.83 jug/ml using pcDNAl.l. Result (A) represents mean ± S.D. of 2 - 3 
experiments, or mean values alone when n = 1. All experiments were performed in 
duplicate. Result (B) represents mean value of 1 experiment, performed in duplicate. 
Basal activity values are shown in Table 3. 
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cDNA transfection Basal [^H]-cAMP Basal [^H]-inositol 
concentration accumulation phosphate accumulation 
pcDNAl.l (1.33 i^g/ml) 0.44 士 0.33 (n = 3) 4.14 (n = 1) 
GaS (0.01 i^g/ml) 0.12 (n= 1) 
GaS (0.025 i^g/ml) 0.15 (n= 1) 
GaS (0.05 |Lig/ml) 0.13 ( n = 1) 
GaS (0.25 ^g/ml) 0.26 土 0.15 (n = 2) 5.21 (n = 1) 
GaS (0.75 i^g/ml) 0.17 土 0.06 (n = 2) 4.86 (n = 1) 
GaS (1.33 i^g/ml) 0.18 土 0.03 (n = 2) 5.18 (n = 1) 
Table 3. Basal AC and PLC activity in mlP-CHO cells. All results are expressed as 
% conversion data. Basal [^H]-cAMP accumulation data represents mean 土 S.D. of 
2 - 3 experiments, or mean values alone when n = 1. All experiments were performed 
in duplicate. Basal [^H]-inositol phosphate accumulation data represents mean values 
of 1 experiment, performed in duplicate. 
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cDNA transfection Maximal [^H]-cAMP Maximal [^H]-inositol 
concentration accumulation phosphate accumulation 
(o/oconversion) (%conversion) 
pcDNAl.l (1.33 ^ig/ml) 3.53 士 0.21 (n = 3) 38.59 (n = 1) 
GaS (0.01 |Lig/ml) 7.15 ( n = l ) 
GaS (0.025 |Lig/ml) 5.00 (n= 1) 
GaS (0.05 |ig/ml) 6.59 (n= 1) 
GaS (0.25 i^g/ml) 3.24 士 0.09 (n = 2) 32.75 (n = 1) 
GaS (0.75 |Lig/ml) 3.23 土 0.21 (n = 2) 25.28 (n = 1) 
GaS (1.33 |ag/ml) 3.39 土 0.23 (n = 2) 28.11 (n= 1) 
Table 4. Effect of GaS on cicaprost-stimulated AC and PLC activity in mlP-CHO 
cells. Maximal [^H]-cAMP accumulation data represents mean 土 S.D. of 2 - 3 
experiments, or mean values alone when n = 1. All experiments were performed in 
duplicate. Maximal [^H]-inositol phosphate accumulation data represents mean values 
of 1 experiment, performed in duplicate. 
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cDNA transfection [^H]-cAMP accumulation [^H]-inositol phosphate 
concentration (pECso) accumulation (pECsp) 
pcDNAl.l (1.33 |Lig/ml) 8.44 土 0.26 (n = 3) 7.08 (n = 1) 
GaS (0.01 |Lig/ml) 7.26 (n = 1) 
GaS (0.025 )ag/ml) 8.21 (n= 1) 
GaS (0.05 |Lig/ml) 7.19 (n = 1) 
GaS (0.25 |ug/ml) 8.41 土 0.07 (n = 2) 7.08 (n = 1) 
GaS (0.75 i^g/ml) 8.89 ± 0.18 (n = 2) 7.10 (n = 1) 
GaS (1.33 |Lig/ml) 8.08 ± 0.18 (n = 2) 6.82 (n = 1) 
Table 5. Effect of GaS on cicaprost-stimulated AC and PLC activity in mlP-CHO 
cells. [^H]-cAMP accumulation pECso data represents mean 土 S.D. of 2 - 3 
experiments, or mean values alone when n = 1. All experiments were performed in 
duplicate. [^H]-inositoI phosphate accumulation pECso data represents mean values of 
1 experiment, performed in duplicate. 
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Figure 20. Effect of GaS on cicaprost-stimulated AC and PLC activity in mlP-CHO 
cells. CHO cells were transfected with mlP-receptor cDNA (0.5 jag/ml) and different 
concentrations of GaS cDNA as shown. The total amount of cDNA transfected was 
balanced at 1.83 |Lig/ml using pcDNAl.l. Results (A) represent mean 土 S.D. of 2 - 3 
experiments, or mean values alone when n = 1. All experiments were performed in 
duplicate. Results (B) represent mean values of 1 experiment performed in duplicate. 
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Figure 21. Effect of 0«5 cDNA transfection on forskolin-stimulated and cicaprost-
stimulated [^H]-cAMP production by mlP-CHO cells. The total amount of cDNA 
transfected was balanced at 1.83 |_ig/ml using pcDNAl.l. Basal [^H]-cAMP 
accumulation: 0 |Lig/ml = 0.14 土 0.01; 0.25 |ug/ml = 0.13 土 0.01; 0.75 |Lig/ml = 0.17 土 
0.03; 1.33 jLig/ml = 0.17 土 0.03 %conversion. Results represent mean 土 S.D. of 2 
experiments, each performed in duplicate. 
105 
50「 
B 丁 - ^ I l o p r o s t (10 nM) 
�� 40- - o - Basal 
1 1 g X ^ 
03 30 - / 
o I ^ ^ / 




1 I I I I 1 I 
0.00 0.25 0.50 0.75 1.00 1.25 1.50 
[Gaq cDNA ng/ml] 
Figure 22. Effect of Gaq cDNA transfection on iloprost-stimulated [^H]-inositol 
phosphate accumulation in mlP-CHO cells. CHO cells were transfected with mlP-
receptor cDNA (0.5 )Lig/ml) plus varying concentrations of Gaq cDNA. Results 
represent mean 土 S.D. of 1 experiment, performed in duplicate. 
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Figure 23. Effect of Gaq on cicaprost-stimulated AC and PLC activity in mlP-CHO 
cells. CHO cells were transfected with mlP-receptor cDNA (0.5 |ag/ml) and different 
concentrations of Gaq cDNA as shown. The total amount of cDNA transfected was 
balanced at 1.83 i^g/ml using pcDNAl.l. Result (A) represents mean values of 1 
experiment performed in duplicate. Result (B) represents mean 土 S.D. of 2 - 3 
experiments, or mean values alone when n = 1. All experiments were performed in 
duplicate. Basal activity values are shown in Table 6. 
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cDNA transfection Basal [^H]-cAMP Basal [^H]-inositol 
concentration accumulation phosphate accumulation 
pcDNAl.l (1.33 i^g/ml) 0.08 (n = 1) 8.61 土 2.60 (n = 3) 
Gaq (0.01 i^g/ml) 12.39 (n = 1) 
Gaq (0.025 i^g/ml) 11.45 (n= 1) 
Gaq (0.05 )ag/ml) 11.04 (n= 1) 
Gaq (0.25 i^g/ml) 0.07 (n = 1) 10.36 ± 6.10 (n = 2) 
Gaq (0.75 ^ig/ml) 0.07 (n = 1) 8.21 土 3.70 (n = 2) 
Gaq (1.33 |Lig/mI) 0.06 ( n = 1) 11.53 ± 7.60 (n = 2) 
Table 6. Basal AC and PLC activity in mlP-CHO cells. All results are expressed as 
% conversion data. Basal [^H]-cAMP accumulation data represents mean value of 1 
experiment, performed in duplicate. Basal [^H]-inositoI phosphate accumulation data 
represent mean ± S.D. of 2 - 3 experiments, or mean values alone when n = 1. All 
experiments were performed in duplicate. 
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cDNA transfection Maximal [^H]-cAMP Maximal [^H]-inositol 
concentration accumulation phosphate accumulation 
(%conversion) (%conversion) 
pcDNAl.l (1.33 jug/ml) 3.35 (n = 1) 55.08 土 1.06 (n = 3) 
Gaq (0.01 ^g/ml) 63.51 (n = 1) 
Gaq (0.025 i^g/ml) 55.81 (n = 1) 
Gaq (0.05 |ug/ml) 61.15 (n= 1) 
Gaq (0.25 M-g/ml) 3.68 (n = 1) 55.69 ± 1.31 (n = 2) 
Gaq (0.75 fig/ml) 3.68 (n = 1) 55.86 土 1.45 (n = 2) 
Gaq (1.33 ^ig/ml) 3.00 (n = 1) 60.94 土 1.37 (n = 2) 
Table 7. Effect of Gaq on cicaprost-stimulated AC and PLC activity in mlP-CHO 
cells. Maximal [^H]-cAMP accumulation data represents mean value of 1 experiment, 
performed in duplicate. Maximal [^H]-inositoI phosphate accumulation data represent 
mean 土 S.D. of 2 - 3 experiments, or mean values alone when n = 1. All experiments 
were performed in duplicate. 
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cDNA transfection [^H]-cAMP accumulation [^H]-inositol phosphate 
concentration (pECso) accumulation (pECsp) 
pcDNAl.l (1.33 |ig/ml) 8.59 (n = 1) 7.15 土 0.04 (n = 3) 
Gaq (0.01 lag/ml) 7.26 (n= 1) 
Gaq (0.025 i^g/ml) 7.60 (n= 1) 
Gaq (0.05 |Lig/ml) 7.47 (n= 1) 
Gaq (0.25 |Lig/ml) 8.60 (n = 1) 7.85 土 0.06 (n = 2) 
Gaq (0.75 ixg/m\) 7.97 (n = 1) 7.97 土 0.07 (n = 2) 
Gaq (1.33 ^ig/ml) 7.95 (n = 1) 7.96 土 0.06 (n = 2) 
Table 8. Effect of Gaq on cicaprost-stimulated AC and PLC activity in mlP-CHO 
cells. [^H]-cAMP accumulation pECso data represents mean value of 1 experiment, 
performed in duplicate. [^H]-inositol phosphate accumulation pECso data represent 
mean 土 S.D. of 2 - 3 experiments, or mean values alone when n = 1. All experiments 
were performed in duplicate. 
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Figure 24. Effect of Gaq on cicaprost-stimulated AC and PLC activity in mlP-CHO 
cells. CHO cells were transfected with mlP-receptor cDNA (0.5 |ag/ml) and different 
concentrations of Gaq cDNA as shown. The total amount of cDNA transfected was 
balanced at 1.83 |Lig/ml using pcDNAl.l. Result (A) represents mean values of 1 
experiment, performed in duplicate. Result (B) represents mean 土 S.D. of 2 — 3 
experiments, or mean values alone when n = 1. All experiments were performed in 
duplicate. 
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Figure 25. Effect of Gaq on iloprost- and ATP-stimulated [^H]-inositol phosphate 
production by mlP-CHO cells. CHO cells were transfected with mlP-receptor cDNA 
(0.5 )ag/ml) plus either pcDNA 1.1 vector (1.0 |ig/ml) or Gaq cDNA (1.0 |ig/ml). 
Basal [^H]-inositol phosphate accumulation: control = 6.23 ± 1.16; Gaq = 7.58 土 1.95 
% conversion. Results represent mean 土 S.E.M. of 4 experiments, each performed in 
duplicate. Statistical level of significance (* p < 0.05) calculated using one way 
analysis of variance followed by Bonferroni's Multiple Comparison Test. 
112 
CHAPTER 6 
Multiple coupling capacity of prostacyclin receptors in 
neuroblastoma cells 
6.1 Introduction 
Human neuroblastoma cells, which express the human IP-receptor, have been used to 
investigate the second messenger system for a long time. A previous study has 
suggested that the hIP-receptor expressed in SK-N-SH cells looks more like the platelet 
than the neuronal IP-receptor (Wise & Chow，1997). Another neuroblastoma 
(NG108-15) cell line, which expresses the mouse/rat IP-receptor, has also been used to 
study the limiting factors regulating IP-receptor mediated AC activation (Mullaney et 
al., 1996). 
In situ hybridization studies suggested the expression of platelet-like IP-
receptor mRNA in mouse dorsal root ganglia (Oida et al, 1995). Classically, 
neuroblastoma cells are used as models of CNS neurons. As neuroblastoma cell lines 
derive from neural crest cells that ordinarily give rise to spinal ganglionic cells 
(Camahan & Patterson，1991)，this cell line could provide more information about 
hIP-receptor activity and compared with dorsal root ganglion cell study. Before 
characterizing the hlP-receptor in SK-N-SH cells, I would like to identify whether any 
other prostanoid receptors are also expressed in SK-N-SH cells, which may produce 
confounding results due to the broad recognition ability of IP agonists towards other 
prostanoid receptors, e.g. EP丨 or EP3-receptors. Next, I would like to assess the second 
messenger systems stimulated by IP-receptors in neuroblastoma cells in some detail. 
113 
6.2 Method 
Measurement of [^H]-cAMP and [^H]-inositol phosphate production was performed as 
described in sections 4.3 and 4.4, unless otherwise stated. For SK-N-SH cells, pH]-
cAMP production was assayed by metabolically labels the cells with [^H]-adenine for 
20 h. [^H]-inositol phosphate production was assayed by metabolically labels the cells 
with m少[3H]-inositol for 40 h. SK-N-SH cells were then stimulated with various 
prostanoid receptor agonists and the pH]-cAMP or [^H]-inositol phosphate produced 
was measured by column chromatography method. Investigating the changes in [Ca^^]； 
level was assayed as described in section 4.5，unless otherwise stated. [^H]-inositol 
phosphate production upon G^ q^ cDNA transfection was assayed by transient 
transfection of G^q cDNA (1.0 |Lig/ml) into SK-N-SH or NG108-15 cells using 
Lipofectamine reagent. 
6.3 Results and Discussion 
6.3.1 Characterization of prostanoid receptors in SK-N-SH cells 
In order to characterize prostanoid receptor expression in SK-N-SH cells, I measured 
the [^H]-cAMP accumulation after treating the cells with different types of prostanoid 
receptor agonists. In the presence of cicaprost (1 )iM), I observed a 50-fold increase in 
[^H]-cAMP accumulation relative to basal levels and a 6-fold increase in response to 
PGE2 (1 }iM) (Fig. 26(A)). None of the other prostanoids tested stimulated pH]-cAMP 
accumulation in SK-N-SH cells. PGDj, which activates the Gs-coupled DP-receptor 
had no effect on [^H]-cAMP accumulation, indicating that there are no DP-receptors 
expressed by SK-N-SH cells. Sulprostone, which is EP^-receptor agonist, had no 
inhibitory effect on forskolin-stimulated [^H]-cAMP accumulation, indicating that 
there are no EPj-receptor expressed by SK-N-SH cells. Altogether, these results 
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suggest that the SK-N-SH cell only express the IP- and EP2/4- receptor, which normally 
couple to the AC pathway. In order to confirm whether the action of PGEj on [^H]-
cAMP production is act on EPjyr receptors or IP-receptors, it is necessary to use an 
IP-receptor or EP2/4 antagonist, but due to the lack of IP-receptor antagonist 
development, I still have no answer to this issue. 
I also measured the [^H]-inositol phosphate accumulation after treating the 
cells with different prostanoid receptor agonists as shown in Figure 26(B). PGEj, 
PGFja and U46619 would all be expected to stimulate Gq-coupled receptors (EP„ FP 
and TP, respectively). However, none of these agonists increased [^H]-inositol 
phosphate accumulation in SK-N-SH cells relative to basal level. Cicaprost had no 
effect on [^H]-inositol phosphate accumulation in SK-N-SH cells, although I could 
easily detect [^H]-cAMP accumulation in SK-N-SH cells treated with cicaprost. Low 
expression level of G^q protein could not be used to explain this matter as two positive 
control agonists (bradykinin and carbachol) increased [^H]-inositol phosphate 
accumulation in SK-N-SH cells relative to basal level (Fig. 26(B)). Poor coupling 
between the IP-receptor and PLC pathway may be the reason to explain this result. 
The lack of cicaprost-stimulated [^H]-inositol phosphate accumulation in 
SK-N-SH cells may be due to the sensitivity of the assay system. In order to clarify this 
issue，Kevin Chow measured the change in [Ca^^j due to different prostanoid receptor 
agonists (Fig. 26(C)). As seen with the fH]-inositol phosphate accumulation 
measurements, we could not detect any change in [Ca^^； with DP, FP, TP or EP, 
receptor agonists. In order to confirm whether the lack of PLC response from those 
prostanoid receptor agonists related to the failure of the assay condition being used, 
two control agonists, bradykinin and carbachol were tested for change in [Ca^^； from 
SK-N-SH cells. Bradykinin and carbachol have been suggested to trigger the PLC 
activation through the Gq activation in human neuroblastoma cells (Nishizuka, 1984; 
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Willars & Nahorski，1995). From bradykinin and carbachol stimulation, results 
indicated that these two agonists could indeed trigger the activation of PLC pathway in 
SK-N-SH cells (Fig. 26(C)). As a result, the lack of response from prostanoid receptor 
agonists indicated the lack of these receptors being expressed in SK-N-SH cells rather 
than a failure of the assay. However, this result still could not explain the lack of 阳]-
inositol phosphate accumulation in SK-N-SH cells in response to cicaprost. Altogether, 
results suggested that SK-N-SH cells appeared to express only EP2/4- and IP-receptors 
coupled to stimulation of AC. 
6.3.2 Property of IP-receptor signaling in SK-N-SH cells 
Results indicated that in SK-N-SH cells, the IP-receptor could couple only to the AC 
pathway. As shown in Figure 27，cicaprost increased the [^H]-cAMP production by 
SK-N-SH cells in a concentration-dependent manner (cicaprost, pECjo = 7.48 土 0.03; 
cicaprost + PTX, pECjo = 7.51 土 0.03) (Kam et al., 2001). Also, the cicaprost-
stimulated [^H]-cAMP production was PTX-insensitive, indicating that the IP-receptor 
did not couple to Gi (Fig. 27). Octimibate, which is non-prostanoid prostacyclin 
mimetic, gives much lower level of fH] -cAMP production compared with cicaprost-
stimulated [^H]-cAMP production in SK-N-SH cells (Fig. 27). This result suggests that 
octimibate show partial agonist activity within the IP-receptor agonist series in SK-N-
SH cells. Also, the bell-shape log concentration-response curve for octimibate-
stimulated [^H]-cAMP production in SK-N-SH cells is contrast to result obtained from 
mlP-CHO cells in Chapter 5，Figure 17. We suspected that this result could be caused 
by an inhibitory effect of octimibate on IP-receptor mediated AC activation through 
activation of an unknown Gi-coupled receptor. However, the lack of PTX effect on 
octimibate-mediated AC activation excludes this possibility (Fig. 27). In addition, 
neither cicaprost nor octimibate, tested over a large concentration range, could 
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stimulate pH]-inositol phosphate production (Fig. 28)，confirming the data in Figure 
26. However, Smyth's study using epitope-tagged human IP-receptor suggests the 
multiple coupling capacity towards AC and PLC pathways (Smyth et al., 1996). As 
SK-N-SH cells endogenously express the hlP-receptor, it is unclear why the IP agonists 
could not stimulate the [^H]-inositol phosphate production as shown in Figure 28. 
6.3.3 Effect of G^q subunits on PLC activation in SK-N-SH cells 
As I suspect the lack of PLC activity in SK-N-SH cells is due to the low expression 
level of Gaq，I would like to test whether the coupling capacity of the hlP-receptor 
towards PLC pathway could be improved by transfecting G^ q^ cDNA into SK-N-SH 
cells. However, in order to monitor the transfection efficiency relative to the degree of 
signal transduction activation, I need to use biochemical method and measure the 
amount of marker being expressed by transfected cells. The simplest means of 
determining transfection efficiency is to use the p-galactosidase enzyme as a 
transfection marker as described in Section 4.2.3. 
From Chapter 5，I suggest that the EC50 concentration of agonist is suitable to 
observe the effect of G-protein cDNA transfection on IP-receptor activity. As a result, I 
applied this idea in SK-N-SH cells and used the EC5。concentration of iloprost to test 
the fH]-inositol phosphate production upon G^q cDNA transfection in SK-N-SH cells. 
As shown in Figure 29，using EC，。concentration (in terms of PLC activation) of 
iloprost (30 nM) and carbachol (2 |iM), I failed to observe any enhancement of 阳 , 
inositol phosphate production by SK-N-SH cells transfected with G„q cDNA. In 
contrast, I got unexpected result using maximal concentrations of iloprost (10 }iM) and 
carbachol (200 i^M) (Fig. 29)，where PLC activity was significantly suppressed by G„q 
cDNA transfection. The reason for suppressed agonist-stimulated PLC response is 
unclear. 
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As shown in Table 9，results indicated that the SK-N-SH cells are poor 
candidates for transfection. Efficient methods for DNA transfection are important to 
study gene regulation by devising better ways to deliver DNA into the mammalian 
cells. Ghosh's study also suggests the poor transfection efficiency using either 
electroporation or calcium phosphate method on SK-N-SH cells (Ghosh et al., 2000). 
Although our result suggests the SK-N-SH cells showed low transfection efficiency, it 
is difficult to explain the significant suppression by G^ q^ cDNA transfection on [^H]-
inositol phosphate accumulation using maximal concentration of agonists. Cytotoxic 
effect of transfection reagents could be excluded as no significant cell death occurs 
with the concentration of cDNA being used throughout the whole experiment. We 
could not exclude the possibility that the transfection process wi l l stimulate some 
unknown signal transduction pathway and thus exert an inhibitory effect towards the 
PLC pathway. 
As I could not use transient transfection method to increase the expression 
level of G„q protein in SK-N-SH cells, I still cannot explain the poor coupling of the 
hlP-receptor towards the PLC pathway in SK-N-SH cells. Kinsella's group also 
showed that IP-receptors endogenously expressed in HEK 293 cells, lack coupling 
capacity towards PLC pathway even when cells are transiently transfected with G„q 
cDNA (Walsh et al, 2000a). However, Kinsella's group also has contradictory results 
using HEK 293 cells, stably transfected with hIP-receptor cDNA, demonstrating the 
coupling between the hlP-receptor and PLC pathway (Hayes et al., 1999). Those 
studies indicated the problem that we tried to characterize the property of GPCRs 
endogenously expressed from a specific cell type, although we still need to consider the 
problem of agonist specificity. Recent study suggest that the activation of PLC pathway 
by PGI2，in terms of [Ca^^； mobilization, was due to the activation of EP,-receptor 
which is endogenously express in HEK 293 cells (Walsh & Kinsella, 2000b). As 
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cicaprost give no EP,-receptor activating property, it is safe to use cicaprost to exclude 
the specificity problem. On the other hand, the property of endogenously expressed 
hlP-receptor is quite different as compare with the hlP-receptor being expressed in 
transfection systems. This difference has been studied in IP-receptor desensitization 
experiment (Nilius et al., 2000). According to Nilius idea, hIP-receptor desensitization 
process is much slower in human tissue as compared with transfected cells. It is likely 
that more tight regulatory mechanism control the activity of hIP-receptor in native 
tissue. At present, I still have no clear answer about the coupling between hIP-receptors 
and the PLC pathway in SK-N-SH and HEK 293 cells. 
6.3.4 Coupling capacity of IP-receptor in rat/mouse neuroblastoma (NG108-
15) cells 
Human neuroblastoma (SK-N-SH) cells have been studied but our results showed that 
the hIP-receptor in SK-N-SH cells only couples to the AC pathway. Further study using 
G„q cDNA transiently transfected into SK-N-SH cells failed to enhance the production 
of [^H]-inositol phosphate due to low transfection efficiency. In order to understand 
whether this special feature is related to the cell type or receptor species difference, the 
neuroblastoma-glioma hybrid (NG108-15) cell line was selected and tested. This cell 
line was formed by Sendai viruse-induced fusion of the mouse neuroblastoma clone 
N18TG-2 and the rat glioma clone C6 BV-1 and therefore express either mlP- or rlP-
receptor (Hamprecht et al., 1985). It is not necessary to consider the type of IP-receptor 
in NG108-15 cells due to the high sequence homology between mlP- and rlP-receptor 
described in Chapter 2. 
Results from Figures 30 and 31 indicated that NG108-15 cells possess the 
multiple coupling capacity of IP-receptors (AC activation, pECj。= 8.55 土 0.01; PLC 
activation, pEC，。= 6.38 士 0.05). However, the IP-receptor mediated [^H]-inositol 
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phosphate production was not improved by increasing the expression level of G^q 
protein as shown in Figure 32. 
First, I assayed the coupling capacity of IP-receptor in NG108-15 cells. 
According to results from Figure 30(A) and (B), the potency of cicaprost-stimulated 
[^H]-cAMP accumulation is similar as in CHO cells transfected with mlP-receptor 
(mlP-CHO, pEQo : 8.36 士 0.01，n = 8; NG108-15，pEC;。： 8.55 土 0.01，n = 3; SK-N-
SH, pECjo = 7.48 土 0.03，n = 4). As the IP-receptor being expressed in NG108-15 cells 
is rat/mouse type, I would expect a similar EC50 value for AC activation in NG108-15 
cells compared with the mlP-CHO cells. 
Also, the potency of cicaprost-stimulated [^H]-inositol phosphate 
accumulation in NG108-15 cells is similar compared with mlP-CHO cells, pEC，。value 
in NG108-15 cells is 6.38 士 0.05 and 6.87 土 0.01 in mlP-CHO cells as shown in Figure 
31(A) and (B). Besides the coupling efficiency in PLC pathway is similar as compare 
with the CHO cells，results also demonstrate the multiple coupling capacity of IP-
receptor in NG108-15 cells. Cicaprost gave about 6-fold increase in [^H]-inositol 
phosphate production relative to basal level; this fold increase in [^H]-inositol 
phosphate level is similar to that observed in mlP-CHO cells. Altogether, the property 
of IP-receptors in NG108-15 cells is similar to mlP-CHO cells with regard to AC and 
PLC activation. 
Fan et al (1998) suggested that NG108-15 cells have G-protein / AC and 
G-protein / PLC pathway in response to ATP stimulation. As I could not use SK-N-SH 
cell to examine the effect of G^q cDNA transfection on IP-receptor mediated [^H]-
inositol phosphate production, NG108-15 cells could be another good candidate for 
investigation. J.Luty et al. (1995) study of the IP-receptor signal transduction pathway 
indicated the partial inhibition of L- and N-type calcium channel currents with iloprost, 
which seem to be mediated through PKA activation, may be important in regulating the 
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function of glial cells. Altogether, NG108-15 cell seems to be a good candidate for 
studying IP-receptor function. As compare with SK-N-SH cells, previous study 
overexpressing G^s subunit in NG108-15 cells suggested that NG108-15 cells seem to 
be efficient in plasmid DNA transfection (Kim et al, 1995). 
According to results from Figure 32’ the PLC response to either EC，。or 
maximal concentrations of IP agonists could not be enhanced by transfection of G^q 
cDNA into NG108-15 cells. I think this result could be due to the poor transfection 
efficiency in NG108-15 cells. In addition to performing the [^H]-inositol phosphate 
assay, I used p-galactosidase assay system to monitor the transfection efficiency in 
each experiment as described in section 4.2.3. Results suggested that the transfection 
efficiency is lower than in CHO cells, although the transfection efficiency is much 
higher than the SK-N-SH cells, as shown in Table 9. Next, I compared the P-
galactosidase activity in CHO and NG108-15 cells and the result suggested that the 
NG108-15 cells take up 24-fold less cDNA than CHO cells. As the transfection 
concentration of G^q cDNA being used in CHO cells is 1.0 |ig/ml as shown from 
Chapter 5，this suggests the actual transfection concentration of G„q cDNA in 
NG108-15 cells is likely to be 0.042 ^g/ml. According to previous section from 
Chapter 5 Figure 24, using various concentrations of G„q cDNA transfected into CHO 
cells，the results showed that I could observe an enhancement in [^H]-inositol 
phosphate production starting from 0.025 }ig/ml G^q cDNA transfection. As a result, I 
could not use the low transfection efficiency to explain the absence of [^H]-inositol 
phosphate accumulation enhancement with G„q cDNA transfection in NG108-15 cells. 
As I have no data about the expression level of G^q subunit in NG108-15 cells, it is 
speculated that the expression level of G„q subunit is much higher as compare with the 
IP-receptor and the effector molecule PLC. This condition has been observed in 
NG108-15 cells which have much higher expression level of G„s subunit as compared 
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with IP-receptor and AC molecules (Mullaney et al, 1996). I f this explanation is valid, 
further increase of the expression level of G^ q^ subunit would give no significant 
enhancement in IP-receptor signal capacity and the IP-receptor mediated fH]-inositol 
phosphate production would not be affected in NG108-15 cells. 
I also used some drugs that act as control agents to indicate the response of 
cells. According to our results, the forskolin-stimulated [^H]-cAMP production is 
relatively smaller compared with maximum cicaprost-stimulated [^H]-cAMP 
production (Fig. 30). In G„s cDNA transfected mlP-CHO cells, cicaprost-stimulated 
[^H]-cAMP production is also bigger than forskolin-stimulated pH]-cAMP production 
(Chapter 5，Figure 21). Result is unexpected as both IP agonist-stimulated and 
forskolin-stimulated [^H]-cAMP production requires the AC activation, forskolin 
should give bigger AC activation than IP-receptor mediated response from mlP-CHO 
cells (Chapter 9, Figure 53 and 54). According to my result, SK-N-SH, NG108-15 and 
GaS cDNA transfected mlP-CHO cells give bigger cicaprost-stimulated [^H]-cAMP 
production than forskolin-stimulated [^H]-cAMP production (Chapter 5, Figure 21; 
Chapter 6, Figure 30; Chapter 9，Figure 53 and 54). It is unclear whether the bigger AC 
activation from IP-agonist stimulation is due to high expression level of G„s protein, 
which alter the interaction between forskolin and AC, as discussed in Chapter 5. 
In assaying PLC activation, we used bradykinin，which can activate the 
bradykinin receptor endogenously expressed in NG108-15 cells (Nishizuka, 1984). 
The bradykinin receptor couples to the Gq family of G-proteins and has been reported 
to stimulate the metabolism of inositol phospholipids in NG108-15 cells by activation 
of PLC (Nishizuka, 1984). In my previous study using SK-N-SH cells, both carbachol 
and bradykinin could be used to act as control agonists in assaying PLC activation. 
However, in contrast to SK-N-SH cells, stimulation of NG108-15 cells with carbachol 
gave no PLC activation (Fig. 33). This is the first time to suggest the lack of muscarinic 
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receptor being expressed in neuroblastoma cells, as there is no literature mention the 
use of carbachol in NG108-15 cells. 
6.4 Conclusion 
In conclusion, I have characterized the property of IP-receptors from different 
neuroblastoma cell lines. In SK-N-SH cells, the hlP-receptor can only couple to the AC 
pathway only. However, in another neuroblastoma cell line, NG108-15, the mouse/rat 
IP-receptor has multiple coupling capacity similar to mlP-receptors transfected into 
CHO cells. Due to the low efficiency of G„q cDNA transfection into SK-N-SH cells 
and failure to observe any effect of cDNA transfection in NG108-15 cells, the 
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Figure 26. Effect of prostanoids on adenylate cyclase (A), phospholipase C activity 
(B) and [Ca2+],. mobilization (C) in SK-N-SH cells. Basal [ 'H]-cAMP accumulation: 
0.11 士 0.04 %conversion. Basal [^H]-inositol phosphate accumulation: 0.61 土 0.24 
o/oconversion. Basal [Ca^^；: 26 土 11 nM. Results represent mean 土 S.E.M. of 3 - 4 
experiments, each performed in duplicate. 
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Figure 27. Effect of PTX on IP agonist-stimulated [^H]-cAMP production in SK-N-
SH cells. Maximum response to cicaprost in SK-N-SH cells: 34.29 土 18.63 fold basal. 
Basal [^H]-cAMP accumulation: 0.07 士 0.03 %conversion. Results are expressed as 
%max. cicaprost response. Results represent mean 土 S.E.M. of 4 experiments, each 




i C 4 -
I I I , 
Q. ~ CO o -
— 目 m 
CO o O o 0 o u_ 2 -
.E 03 ^ 
1 
0 -
I 1 1 1 I I I I I I 
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4 
log [Cicaprost, M: 
5 厂 
① 
I c 4_ 
0 ~ ra 
^：^ S 3 -
- ^ DO 
S 8 £ 2-




I 1 1 1 I I I I I I 
-13 -12 -11 -10 -9 -8 -7 -6 -5 -4 
log [Octimibate, M: 
Figure 28. Log concentration-response relationship for IP agonist-stimulated [^H]-
inositol phosphate production in SK-N-SH cells. Basal [^H]-inositol phosphate 
accumulation: 9.86 土 4.53 %conversion. Results represent mean 土 S.E.M. of 3 
experiments, each performed in duplicate. 
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Figure 29. Effect of G„q on agonist-stimulated [^H]-inositol phosphate accumulation 
by SK-N-SH cells. SK-N-SH cells were transfected with G^q cDNA (1.0 jig/ml) or 
pcDNAl . l (1.0 |J.g/ml). Basal fH]-inositol phosphate accumulation: control = 0.86 土 
0.08; G^q = 1.18 土 0.19 %conversion. Results represent mean 土 S.E.M. of 4 
experiments, each performed in duplicate. Statistical level of significance {* p < 0.05， 
*** P < 0.001) calculated using one way analysis of variance followed by 
Bonferroni's Multiple Comparison Test. 
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Specific P-galactosidase activity (U/mg) 
Plasmid g a O SK-N-SH NG108-15 
pcDNAl . l 1.28 土 0.33 2.01 ± 1.36 25.78 土 12.49 
(1.0 ixg/ml) 
p-gal cDNA 7644.44 ± 1138.34 36.10 ±3.50 342.86 ± 108 27 
(1.0 i^g/ml) 
Table 9. Specific P-galactosidase activity in CHO, SK-N-SH and NG108-15 cells 
transfected with P-gal cDNA (0.5 fig/ml) or pcDNAl . l (1.0 ng/ml). A l l results are in 
U/mg. Results represent mean 土 S.E.M. of 3 - 4 experiments, each performed in 
duplicate. 
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Figure 30. [^H]-cAMP accumulation in NG108-15 cells. Basal [^H]-cAMP 
accumulation: 0.18 土 0.06 %conversion. Results represent mean 土 S.E.M. of 3 
experiments, each performed in duplicate. 
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Figure 31. [^H]-inositol phosphate production in NG108-15 cells. Basal [^H]-inositol 
phosphate accumulation: 6.66 土 1.35 %conversion. Results represent mean 土 S.E.M. 
of 3 experiments, each performed in duplicate. 
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Figure 32. Effect of G„q on agonist-stimulated [^H]-inositol phosphate accumulation 
in NG108-15 cells. NG108-15 cells were transfected with G„q cDNA (1.0 |ig/ml) or 
pcDNAl . l (1.0 )ag/ml). Basal [^H]-inositol phosphate accumulation: pcDNAl. l = 
7.69 土 0.50; G„q = 8.39 土 1.30 %conversion. Results represent mean 土 S.E.M. of 4 
experiments, each performed in duplicate. 
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Figure 33. Agonist-stimulated [^H]-inositol phosphate accumulation in NG108-15 
cells. As data extracted from experiment investigating the effect of G^q on agonist-
stimulated [^H]-inositol phosphate accumulation in NG108-15 cells, NG108-15 cells 
transfected with pcDNAl. l (1.0 |j.g/ml) for comparison and showed in this figure. 
Basal [^H]-inositol phosphate accumulation: 7.69 土 0.50 %conversion. Results 
represent mean 土 S.D. of 1 experiment, performed in triplicate for carbachol-
stimulated NG108-15 cells, and mean 土 S.E.M. of 4 experiments, each performed in 





In the past, selectivity of drug action at GPCRs depends on the presence of different 
receptor subtypes that expressed in different tissues. Recent studies suggest that certain 
agonists can target receptor signaling toward a specific G-protein. This phenomenon, 
known as agonist trafficking, is relevant to GPCRs that possess the capacity to couple 
to multiple G-proteins and involves separate agonist-specific active receptor states. 
These states selectively promote G-protein coupling in response to activation by 
different agonists as described in Chapter 1. According to this idea, we would like to 
see i f different agonists could couple to separate signaling pathways with different 
efficacy via the same receptors. I f the order of efficacy of various agonists depends on 
the intrinsic activity of the ligands only, we should observe the same order of efficacy 
of various agonists in any response being measured. However, it has sometimes been 
observed that the order of efficacy of various agonists is reversed for different 
responses (Berg et al., 1998; Boddeke, 1991; Krumins & Barber，1997). Leff et al 
(1997) suggested that different agonists could either induce or stabilize different active 
receptor conformations that preferentially activate specific G-proteins, causing a 
distinct activation of different signaling pathways by different agonists. Previous 
studies have already been shown that agonist trafficking occurs in other GPCR families, 
e.g. cannabinoid and a2A-adrenergic receptors (Bonhaus et al., 1998; Kukkonen et al., 
2001). 
From Chapters 5 and 6，results suggest the IP-receptors possess coupling 
capacity towards Gs and Gq in mlP-CHO and NG108-15 cells. The presence of 
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prostacyclin analogues and non-prostanoid prostacyclin mimetics met the requirement 
that I would like to use various agonist and study the relative efficiency of agonist 
stimulated signal transduction pathway activation. In order to avoid confounding 
results that could occur when responses are measured under different conditions or in 
different cell populations, previous studies have measured the multiple signal 
transduction pathways activated by the same receptor in the same cell (Berg et al, 
1998). Therefore, I have also tried to use a variety of methods in order to study the 
simultaneous activation of AC and PLC by IP-receptor stimulation in the same cell. 
7.2 Method 
mlP-receptor cDNA was transfected into CHO cells using Lipofectamine and the 
[^H]-cAMP and [^H]-inositol phosphate production was assayed by metabolically 
labeling the cells with [^H]-adenine for 20 h or fH]-inositol for 42 h. After assaying the 
cell with IP-agonists, the pH]-cAMP or fH]-inositol phosphate produced was 
measured by column chromatography method. Measurement of AC activity using 
cAMP [1251] scintillation proximity assay (SPA) system was performed as described in 
section 4.3.2. Measurement of PLC activity using D-myo-inositol 1,4,5-trisphosphate 
(IP3) [^H] assay system was performed as described in section 4.4.2. 
7.3 Results and Discussion 
7.3.1 Simultaneous measurement of AC and PLC activation in 
metabolically-labelled mlP-CHO cells 
In order to measure both AC and PLC activation using column chromatography 
method, I need to load pH]-adenine and [^H]-inositol into CHO cells. In addition, I 
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need to use an assay buffer suitable for both AC and PLC assay condition. As a result, I 
need to confirm whether the presence of AC assay buffer components ( IBMX and 
INDO) affect IP-receptor mediated PLC activation in CHO cells. Also, I need to 
confirm whether the presence of PLC assay buffer components (LiCl and INDO) affect 
IP-receptor mediated AC activation in CHO cells. 
7.3.1.1 Effect of IBMX on PLC activation 
As mentioned in Chapter 4，section 4.3.1，IBMX (1 mM) works as phosphodiesterase 
inhibitor in the AC assay to prevent the breakdown of cAMR In order to 
simultaneously measure AC and PLC activation, I need to perform the AC and PLC 
assay in the same cell and this requires using assay buffer suitable both assays. As a 
result, it is necessary to see i f the presence of AC assay buffer components ( IBMX) wil l 
affect the PLC response and vice versa. The presence of IBMX used in my AC assay 
had no effect on PLC activity measurement in mlP-CHO cells (Fig. 34). According to 
results shown in Figure 34，the presence of 1 mM IBMX had no effect on basal or 
mlP-receptor stimulated PLC activity relative to the absence of IBMX in the PLC assay 
buffer (20 mM LiCl + 3 [ M INDO). 
7.3.1.2 Effect of Li+ ion on AC activation 
As mentioned in Chapter 4，section 4.4.1, LiCl (20 mM) works as an inositol 1-
phosphatase inhibitor in the PLC assay to prevent the recycling of inositol phosphate 
back into inositol phospholipids. As discussed above (Section 7.3.1.1)，I needed to 
check i f Li+ ion would affect the IP-receptor mediated AC response. According to 
results from Figure 35，I found that the presence of 20 mM LiCl had no effect on basal 
AC response but did seem to suppress the mlP-receptor mediated PLC activation, 
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although the result is not statistically significant. In contrast to the inhibitory effect of 
Li+ ion on iloprost-stimulated AC response, cicaprost-stimulated AC activation was not 
affected by the presence of 20 mM LiCl (Fig. 36). Further study is therefore necessary 
to confirm this inhibitory effect of LiCl on iloprost-stimulated AC activation. In 
addition, my results suggested that the presence of 20 mM LiCl significantly reduced 
the forskolin-stimulated [^H]-cAMP production (Fig. 36). It is unclear why Li+ ion 
should affect the interaction between forskolin and AC molecule. According to these 
results，I could not measure the AC and PLC pathways activation from the same cell 
using the same assay buffer. 
7.3.1.3 Separation of [^H]-adenine and [^HJ-inositol using column 
chromatography method 
Figure 37 shows the radioactivity extracted from mlP-CHO cells loaded with [^H]-
adenine (1 |LiCi/well) and ['H]-inositol (2 ^Ci/well) or ['H]-inositol alone, and then cell 
extracts run through the PLC assay column as mentioned in section 4.4.1.3. Result 
suggests the PLC assay column could not separate the [^H]-adenine from [^H]-inositol 
using conventional column method. Similarly, loading the [^H]-adenine (1 j^Ci/well) 
and [^H]-inositol (2 jiiCi/well) into the same cells also greatly enhance the radioactivity 
being measured from AC assay column (Fig. 38). Results suggest that I could not use 
conventional column chromatography method to separate the fH]-adenine and [^H]-
inositol from the same cell extract. Taken together, results from Figures 37 and 38 
suggest that I could not use conventional column chromatography method to separate 
the fH] -cAMP and pH]-inositol phosphate efficiently using either AC assay column or 
PLC assay column. Therefore, I could not use the radioactive method to detect the 
simultaneous activation of AC and PLC in the same cells. 
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7.3.2 Measurement of AC and PLC activation using different assay system 
7.3.2.1 cAMP '^^I-Scintillation Proximity Assay System 
In the first trial, the standard curve was similar as the protocol suggested. In order to 
validate the amount of cAMP detected from mlP-CHO cells, I used the serial dilution 
method. Theoretically, the total amount of cAMP should be the same either from neat, 
5-fold or 10-fold diluted sample after accounting for the differences in dilution. 
However, results suggested that more cAMP could be detected with greater dilution 
factor (Fig. 39(A) and (B)). This result suggests the presence of unknown factor, which 
affect the assay system for cAMP detection, could be eliminated with sample dilution. I 
think the protein content extracted from mlP-CHO cells would affect the assay system 
for cAMP detection. Dilution of samples also reduces the protein content and so 
removes the effect on assay system for cAMP detection. This idea is further supported 
as using lesser amount of cells produced a higher amount of cAMP production (Fig. 
39(A) and (B)). I think that when fewer cells are used, the effect of unknown factors is 
also reduced and so more cAMP could be measured from using the same assay kit. 
Unfortunately, I could not detect the amount of cAMP from mlP-CHO cells 
in the repeat experiment although the standard curve is comparable with the first trial 
experiment. The amount of cAMP from mlP-CHO was less than the amount of cAMP 
required fitting the reliable region within the standard curve. As a result, I could not use 
the repeat experiment to confirm or verify the results from the first trial. 
Actually, several possibilities may cause the error during the assay: 
1. Degradation of the immunoreagent may affect the binding of the antibody 
with the cAMP and so reduced the level of radioactivity and we could see this effect by 
comparing with protocol's data. 
2. The immunoreagent is not mixed well and so vary the amount of ⑵-I 
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cAMP mix with sample. 
3. The concentration of cAMP may be too dilute and therefore out of the 
standard curve detectable range (0.2 pmol - 12.8 pmol) but the sample is not enough to 
repeat experiment with concentrated sample. 
Altogether, results suggested that I could not measure cAMP production 
efficiently using cAMP '"I-Scintillation Proximity Assay System. Due to the presence 
of several possible errors with using this assay kit, and this assay kit is expensive; it is 
not worth to use this assay kit for further study. 
7.3.2.2 D-myo-Inositol 1,4,5-trisphosphate (IP3) [^H] assay system 
In the first trial, I could not construct the standard curve. I repeated the experiment and 
this time I could make a proper standard curve. However, most of the data could not fit 
into the standard curve and only a few data could be generated in this experiment (Fig. 
40). I used two different methods to extract the IP3 generated from mlP-CHO cells as 
mentioned in section 4.4.2.2. For diethyl ether extraction method, the amount of IP3 
was too low and so only the neat sample data could fit into the standard curve. However, 
perchloric acid extraction method gave too much IP3 from mlP-CHO cells and so all 
the data was out of the standard curve detectable range. I could not repeat the 
experiment using the same batch of sample as all samples was used up in the first trial. 
As a result, I could not detect IP3 production using the above mentioned assay kit. The 
extraction method for this assay kit is complicated and time-consuming, chemicals 
used for IP3 extraction are hazardous, e.g. diethyl ether, and this assay kit is expensive. 
According to these reasons, I could not incorporate these techniques into detecting 
inositol phosphate from the same cells used to assay cAMP production. 
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7.4 Conclusion 
As a result, our original aim to examine agonist trafficking has been diverted due to the 
problem to measure [^H]-cAMP and pH]-inositol phosphate production in the same 
cells using the same assay conditions or in the same cells using various assay systems 
Also, for the range of IP-agonists available for testing, the non-prostanoid prostacyclin 
mimetics turned out to be inhibitors of PLC activation, acting independently of IP-
receptors (Wise et al., 2001). It seems that only a limited amount of IP-agonists suitable 
for studying the agonist trafficking of IP-receptor, such as cicaprost, iloprost. 
Altogether, results suggested that I could not measure inositol phosphate production 
efficiently using this assay kit and I cannot use the conventional or new assay method 
to detect the AC and PLC activation simultaneously from the same cells. 
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Figure 34. Effect of phosphodiesterase inhibitor (IBMX) on PLC activity 
measurement in mlP-CHO cells. CHO cells were transfected with mlP-receptor 
cDNA (0.5 |ig/ml). Results represent mean 土 S.D. from 2 experiments, each 
performed in duplicate. 
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Figure 35. Effect of 20 mM Li+ ion on fH]-cAMP production in mlP-CHO cells. 
CHO cells were transfected with mlP-receptor cDNA (0.5 i^g/ml). Results represent 
mean 土 S.D. from 2 experiments, each performed in duplicate. 
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Figure 36. Effect of 20 mM Li+ ion on forskolin- and cicaprost-stimulated fH] -
cAMP production in CHO cells transfected with mlP-receptor cDNA (0.5 |ag/ml). 
Results represent mean 土 S.D. of 2 experiments, each performed in duplicate. Basal 
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Figure 37. Total radioactivity extracted from PLC assay column chromatography. 
mlP-CHO cells were loaded with [^H]-inositol (2 ^iCi/well) and [^H]-adenine (1 
^Ci/well) simultaneously and cell lysates were run through the PLC assay column. 
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Figure 38. Total radioactivity extracted from AC assay columns. mlP-CHO cells were 
loaded with ['H]-inositol (2 |aCi/well) and ['H]-adenine (1 ^Ci/well) simultaneously 
and cell lysates were run through the AC assay column. Results represent mean 土 S.D. 
of 2 experiments, each performed in duplicate. 
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Figure 39. Endogenous cAMP production from mlP-CHO cells in the first trial 
experiment. CHO cells were transfected with mlP-receptor cDNA (0.5 i^g/ml). 
Endogenous cAMP produced from mlP-CHO cells was detected using cAMP ['^^-I] 
Scintillation Proximity Assay System. Results represent mean 土 S.D. of 1 experiment, 
performed in duplicate. 
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Figure 40. Endogenous IP3 production from mlP-CHO cells. CHO cells were 
transfected with mlP-receptor cDNA (0.5 ^g/ml). IP3 was extracted using diethyl ether 
extraction method and detected using D-myo-inositol 1,4,5-trisphosphate assay system. 
Results represent mean 土 S.D. of 1 experiment, performed in duplicate. 
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CHAPTER 8 
Regulation of prostacyclin receptor coupling 
8.1 Introduction 
In general, the response of GPCRs tends to be tightly regulated by desensitization; a 
process which involves rapid receptor phosphorylation resulting in uncoupling of 
receptor G-protein interactions (Freedman & Lefkowitz, 1996) and subsequent 
receptor internalization. Usually, two classes of kinases may participate in GPCR 
phosphorylation: second messenger-dependent kinases, such as PKC and PKA, and 
the GPCR kinases (GRKs) (Freedman & Lefkowitz，1996). Nanimiya's group has 
identified the presence of PKA and PKC phosphorylation sites within the cytoplasmic 
face of the mlP-receptor (Namba et al., 1994). Smyth's study further identified one of 
the PKC phosphorylation sites, serine 328, as critical for homologous regulation of 
hlP-receptors (Smyth et al., 1996). This result indicated the fiinctional importance of 
PKC phosphorylation in UP-receptor desensitization. However, further study on hlP-
receptor internalization from the same group found that internalization and 
sequestration was PKC-independent (Smyth et al, 2000). A number of studies have 
now indicated that the hIP-receptor may undergo agonist-mediated receptor 
internalization and down-regulation in human platelets and other cell types, but that 
these steps are PKC-independent (Smyth et al, 2000). These pieces of evidence 
indicate that the whole regulatory process of GPCRs involves not only involves PKC, 
but also involve different kinases for specific steps in the whole process. 
However, we would like to know more about the IP-receptor regulation in 
non-transfected conditions including platelet as this result might provide significant 
improvement in the therapeutically efficacy of ？Gl, mimetics. Those cell lines e.g. 
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human fibroblasts, which endogenously express the hIP-receptor, provide suitable 
conditions to study the regulation of IP-receptors. Nilius et al. (2000) used human 
fibroblasts and results suggested a much slower kinetic of hlP-receptor 
desensitization in native tissue as compared with hIP-receptors overexpressed in 
HEK293 cells. This piece of information contrasts with transfection study indicated 
the involvement of PKC in hIP-receptor desensitization (Smyth et al., 1996). This 
indicated that the regulation of hlP-receptor signaling capacity is much more 
complicated in native tissue. 
As the IP-receptor possesses the multiple coupling capacity in our transfection 
system, I would like to know the regulation of IP-receptor by different signal 
transduction pathways. Smyth et al. (1996) suggested the tight regulation of IP-
receptor activity by second-messenger protein kinases. Disruption of PKC 
phosphorylation site also decreased the rate of agonist-mediated desensitization and 
enhances the IP-receptor mediated response (Smyth et al, 1998). This result implied 
the importance of PKC phosphorylation on IP-receptor regulation. On the other hand, 
the functional role of PKA on IP-receptor regulation is still unknown, although, 
except for hIP-receptor, all other cloned IP-receptors have one PKA phosphorylation 
site in the first cytoplasmic loop (Fig. 41). In vitro studies suggested that the agonist-
dependent phosphorylation of hlP-receptors was PKA-independent (Smyth et aL, 
1996). Also, PKA has been excluded from hIP-receptor internalization process in 
HEK 293 cells (Smyth et al, 2000). However, there is still not enough evidence to 
exclude the involvement of PKA on hlP-receptor regulation. Also, since other species 
of IP-receptor, e.g. mouse, rat and bovine have PKA and PKC phosphorylation site, I 
would like to know whether PKA and PKC would alter or switch the coupling 
specificity of the mlP-receptor. Another classical GPCR, the (3-adrenoceptor, can 
either couple to Gs pathway and increase pH]-cAMP level, or couple to Gi pathway 
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and enhance MAPK activity (Daaka et al, 1997) (see section 1.4.2). Phosphorylation 
of p-adrenoceptors by PKA can switch the coupling of the P-adrenoceptor from Gs to 
Gi. It is interesting to determine whether the IP-receptor wil l switch from Gs to Gq 
pathway upon PKA activation, and vice versa for PKC activation. In this chapter, I 
would like to indicate the potential role of PKA and PKC phosphorylation in 
regulating mlP-receptor activity and discuss the interaction between different signal 
transduction pathways. For comparison, I also tested SK-N-SH cells and unexpected 
results were obtained with respect to hlP-receptor regulation through PKA activation. 
8.2 Methods 
mlP-receptor cDNA (0.5 \xglm\) was transiently transfected into CHO cells using 
Lipofectamine as described in section 4.2. Measurement of [^H]-cAMP and [^H]-
inositol phosphate production from mlP-CHO and SK-N-SH cells was performed as 
described in section 4.3 and 4.4 unless otherwise stated. During the assay, mlP-CHO 
and SK-N-SH cells were pretreated with different protein kinase inhibitors including 
H-89 (10 ^iM), staurosporine (1 ^iM) or U-73122 (10 |iM) for 10 min. After the 
pretreatment, cells were stimulated with various concentration of cicaprost (1 pM - 1 
fiM)，or forskolin (10 |iM) in the presence of protein kinase inhibitors for 30 min in 
AC assay and 60 min in PLC assay. The [^H]-cAMP and [^H]-inositol phosphate 
production was measured by column chromatography method. 
For those experiments using enzyme activators in [^H]-cAMP measurement, 
mlP-CHO cells were pretreated with different enzyme activators including forskolin 
(10 [ i U l PMA (1 ixM) or Bt^cAMP (100 iiM) for 10 min. After the pretreatment, 
cells were stimulated with cicaprost (4 nM) in the presence of enzyme activators for 
30 min. For those experiments using enzyme activators in [^H]-inositol phosphate 
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measurement, mlP-CHO cells were pretreated with different enzyme activators 
including forskolin (10 jiM), PMA (1 |_iM) or Bt^cAMP (100 j iM) for 10 min. After 
the pretreatment, cells were stimulated with cicaprost (200 nM) in the presence of 
enzyme activators for 60 min. 
For those experiments using AC inhibitor in [^H]-cAMP measurement, mlP-
CHO cells were pretreated with SQ22536 (10 100 |iM) for 10 min. After the 
pretreatment, cells were stimulated with cicaprost (1 in the presence of SQ22536 
for 30 min. 
8.3 Results and Discussion 
8.3.1 Role of protein kinases on IP-receptor activity 
In studying the role of PKA phosphorylation of mlP-receptors, I used H-89 to block 
the PKA activity (Engh et al., 1996). As mlP-receptor possesses one PKA 
phosphorylation site within the first cytoplasmic loop, I would like to see i f the mlP-
receptor mediated [^H]-cAMP response is altered by the presence of H-89 in mlP-
CHO cells. In addition, I used staurosporine (1 )j.M) that is PKC inhibitor (Gescher， 
1998) and U-73122 (10 iiiM) that is PLCp inhibitor (Sanderson, 1995), to study the 
effect of these inhibitors on IP-receptor mediated AC or PLC activation. 
Firstly，I compared the basal value in either the control or treatment group. 
Results clearly showed that H-89 had no effect on basal [^H]-cAMP level in mlP-
CHO cells (Fig. 42(A)) but significantly enhanced the basal ['H]-inositol phosphate 
level in mlP-CHO cells (Fig. 42(B)). Ding et al (1997) studying cat iris sphincter 
smooth muscle cells suggest that PLC is phosphorylated by PKA activation. It is 
unclear whether the enhanced ['H]-inositol phosphate level in mlP-CHO cells is due 
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to the presence of H-89, which in turn blocks the inhibitory effect of PKA towards 
PLC activity. 
In both SK-N-SH cells and CHO cells transfected with mlP-receptor cDNA, 
the presence of H-89 enhanced the IP-receptor mediated pH]-cAMP production 
(Fig. 43 and 44). From Figure 43，the presence of H-89 enhanced the fH]-cAMP 
production relative to control condition but the effect is not statistical significant. I f 
results are expressed as “stimulated minus basal", I could observe a significant effect 
of H-89 on IP-receptor mediated [^H]-cAMP production relative to control condition 
(Fig. 44). The reason for assessing these different ways of expressing our results 
relates to the basal value that I used to calculate "fold basal" values. For example, the 
marked increase in basal pH]-inositol phosphate production caused by H-89 
complicates data analysis so dependent on basal values. The presence of H-89 seems 
to affect the total uptake of [^H]-inositol into CHO cells and this in turn affects the 
basal level of [^H]-inositol phosphate production. 
Possibly activation of PKA would produce negative feedback towards the 
mlP-receptor and suppress the mlP-receptor mediated [^H]-cAMP production. Using 
other PKA inhibitors such as Rp-cAMPS could help prove this possibility. In contrast, 
staurosporine had no effect on mlP-receptor mediated fH]-cAMP production in 
either cell type. This result suggested that PKC does not regulate the mlP-receptor 
mediated AC activation in either cell type. This result is unexpected as Smyth et al 
(1998) suggested the role of PKC in IP-receptor desensitization and effect of PKC 
activation on IP-receptor mediated AC response. This may be due to the balance 
between PKC and PKA regulation on IP-receptor activity. In the presence of 
staurosporine, the activity of PKC is inhibited. Because of the multiple coupling 
capacity of mlP-receptors，the receptor could still couple to AC pathway and cause 
PKA activation. Under this situation, any inhibitory effect from PKC was blocked but 
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activation of PKA could suppress the mlP-receptor activity simultaneously. This may 
be the reason for lack of effect of staurosporine on mlP-receptor mediated [^H]-
cAMP production. Initial study using U73122 suggested an inhibitory role of this 
drug on mlP-receptor mediated fH]-cAMP production in both CHO and SK-N-SH 
cells. However, further study on drug toxicity in both cell types indicated that the 
reduced [^H]-cAMP production relative to control group might relate to the toxicity 
ofU73122, as reported by Walker et al. (1998). As a result, I have eliminated this test 
group in our interpretation of results. 
Since the mlP-receptor has a recognition site for PKA (Fig. 41)，fH]-cAMP 
production and activation of PKA might regulate the mlP-receptor activity. As a 
result, the presence of H-89 might inhibit this regulatory mechanism and enhance the 
mlP-receptor mediated fH]-cAMP production. However, the result obtained from 
SK-N-SH cells was unexpected. According to sequence information, hIP-receptors do 
not possess a PKA phosphorylation site or consensus sequence (Fig. 41), and the 
presence of H-89 should not have any effect on hlP-receptor activity. As previous 
study has already excluded the role of PKA in hlP-receptor internalization process 
(Smyth et al, 2000)，we could exclude the possibility that the enhanced fH]-cAMP 
response is due to the disruption of internalization process in SK-N-SH cells although 
IP-receptor internalization processes are cell-specific. Another possibility might relate 
to a direct inhibitory effect of PKA towards AC. Recent studies suggested that certain 
AC isoforms could be regulated by PKA (Chen et al, 1997; Lai et al” 1999). AC6 
can be negatively regulated by PKA and this AC isoform is widely expressed in the 
central nervous system (Liu et al., 1998). As a result, it is possible to observe the 
inhibitory effect of PKA towards AC6 isoforms from neuroblastoma cell lines, i.e. 
SK-N-SH cells. However, results from forskolin-stimulated [^H]-cAMP responses 
suggested that H-89 had no direct effect towards AC activity in SK-N-SH cells. As 
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shown from Figure 45, the forskolin-stimulated [^H]-cAMP is not affected by H-89 
pretreatment in SK-N-SH cells. Moreover, Table 10 indicates the basal [^H]-cAMP 
response is not affected by H-89 pretreatment in SK-N-SH cells. Therefore, the 
regulatory role of PKA might not target directly on AC in SK-N-SH cells. 
Another possibility could be raised from the specificity of H-89, as some other 
substrate involved in hlP-receptor regulation, could also be regulated by H-89. Davies 
et al. (2000) recently highlighted the problem of using protein kinase inhibitors in 
dissecting the signal transduction pathway information in cell-based assays. 
According to Davies's study, H-89 wi l l not only inhibit PKA, but also inhibit four 
other kinases (PKC, mitogen- and stress-activated protein kinase 1，p70 ribosomal 
protein S6 kinase and Rho-dependent protein kinase) with potency similar to or 
greater than that for PKA. As a result, it is necessary to examine the reliability of 
using protein kinase inhibitors on cell-based assays. Using sequence-searching 
machine, I found that apart from PKC consensus sequences, hlP-receptors also 
possess casein kinase I I consensus sequence. It is necessary to consider the possible 
effect of H-89 on casein kinase I I that may be involved in hIP-receptor regulation. 
Apart from studying the AC response, I have also used protein kinase 
inhibitors and tested for PLC responses in both cell types. I found that it is possible to 
express our results in a way that could give opposite interpretation. I f I express our 
data as "fold basal", the presence of H-89 would suppress the mlP-receptor mediated 
[^H]-inositol phosphate production relative to control group in mlP-CHO cells 
although the result is not statistically significant (Fig. 46(A)). However, the presence 
of staurosporine had no effect on mlP-receptor mediated [^H]-inositol phosphate 
production relative to control group in mlP-CHO cells (Fig. 46(A)). On the other 
hand, i f I express my data as "stimulated minus basal", the presence of either H-89 or 
staurosporine significantly enhanced the mlP-receptor mediated [^H]-inositol 
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phosphate production relative to control group in mlP-CHO cells (Fig. 47). Under 
this situation, I could obtain opposite interpretation according to how I choose the 
method for data analysis. I f I express my data in terms of "fold basal", PKA and PKC 
seem have no effect towards mlP-receptor. On the other hand, results expressed in 
terms of "stimulated minus basal" suggests that PKA and PKC inhibit mlP-receptor 
activity. Inhibitory effect from PKA towards mlP-receptor mediated PLC activation 
indicates the cross talk between AC and PLC pathway under mlP-receptor activation, 
although the target for PKA is still unclear. Inhibitory effect from PKC suggests the 
negative feedback mechanism after PLC activation. 
In SK-N-SH cells, previous chapter has already shown the lack of PLC 
pathway activation with respect to IP agonists. None of these kinase inhibitors could 
enhance the [^H]-inositol phosphate production relative to control group (Fig. 46(B)). 
As a result, I could not study the interaction between AC and PLC pathways using 
SK-N-SH cells. Another neuroblastoma (NG108-15) cells wil l be used to further 
study the interaction between AC and PLC pathways. 
Apart from using protein kinase inhibitors and investigating the response from 
different signal transduction pathways, I also used different enzyme activators e.g. 
PMA (1 |iM) which is a PKC activator, BtacAMP (100 ^M) which is a cAMP 
mimetic, and forskolin (10 |iM) which is an AC activator. However, the effect of 
these activators on cicaprost-stimulated [^H]-cAMP and [^H]-inositol phosphate 
production was not significant (Fig. 48 and 49). It seems that I could not observe the 
cross talk between AC and PLC pathways using these enzyme activators. From 
Figure 48, the presence of forskolin enhanced the AC activity in mlP-CHO cells and 
so it complicates our data interpretation. As a result, I constructed the log 
concentration-response curve using various concentrations of forskolin (pECjo = 5.67) 
(Fig. 50). It is possible to reduce the effect of basal [^H]-cAMP in response to 
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forskolin stimulation and then measure the IP-receptor mediated AC activation. Also, 
further study wil l try to modify the experimental set-up, i.e. pretreat the cells with 
enzyme activators and stimulate the cells with IP agonist alone. Further study wil l 
carry on in order to investigate the effect of those enzyme activators on IP-receptor 
mediated AC and PLC activation. 
8.3.2 Effect of SQ22536 on IP-receptor activity 
Another means to study the interaction between AC and PLC pathway is to use 
enzyme inhibitors. In order to study the effect of AC pathway components on mlP-
receptor mediated PLC activation, various tools including enzyme inhibitors were 
used in our study. SQ22536 was suggested as useful AC inhibitor and so I would like 
to use this AC inhibitor in our system (Chen et al, 2000). Previous study has been 
suggested the role of SQ22536 in suppressing the [^H]-cAMP production in response 
to iloprost stimulation using male guinea-pig thoracic aorta (Turcato & Clapp，1999). 
As a result, I need to test the usefulness of SQ22536 in cell-based systems. 
To remove the activation of AC pathway components and investigate the mlP-
receptor mediated PLC activation in regulating the mlP-receptor activity from PLC 
pathway components I needed to use SQ22536. First, I needed to make sure that this 
enzyme inhibitor could completely remove AC pathway response in mlP-CHO and 
SK-N-SH cells. Therefore, I pretreated the cells with SQ22536 and then measured the 
IP agonist-mediated [^H]-cAMP production. Result expressed as %control cicaprost 
value suggested that the SQ22536 was ineffective in inhibiting AC (Fig. 51). The lack 
of effect of SQ22536 may be due to low cell permeability of this drug. Usually, the 
permeability of an enzyme inhibitor or activator is a critical factor determining the 
activity of the inhibitor or activator in cell-based assays. Another way to use this drug 
was using cell lysate to modulate the enzyme activity directly. However, this method 
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will disrupt the overall cell structure, so it may loss some protein-protein interaction 
in intact system. According to the results, it seems that I could not use SQ22536 to 
study the interaction between AC and PLC pathways in our cell systems. As other AC 
inhibitor i.e. MDL-12330 is usually used in cell lysate condition, it is difficult to find 
a suitable AC inhibitor at this moment. 
8.3.3 Role of PKA phosphorylation site in mlP-receptor activity 
Protein kinase inhibitors such as H-89 complicated results in studying the regulation 
of mlP-receptors. Therefore, an alternative way to study the role of PKA 
phosphorylation site in mlP-receptor regulation is to use mutant receptors, with the 
PKA phosphorylation site being mutated, and then measure the coupling efficiency 
compared with the wild type mlP-receptor. According to the amino acid sequence of 
mlP-receptors as described in Chapter 2, the mlP-receptor has one PKA 
phosphorylation site within the first cytoplasmic loop. Based on this information, it is 
practical to mutate the serine residue within the PKA phosphorylation site using site-
specific mutagenesis method (Ling & Robinson, 1997). An alternative way is to 
disrupt the consensus sequence of the phosphorylation site for PKA recognition using 
the same method. Dr. Cheng, H.K. (Biochemistry Dept, CUHK) has constructed two 
mlP-receptor PKA phosphorylation site mutants, S74A and mlP-PKA-KK. S74A 
mutant was constructed by mutating the serine residue at position 74 to alanine, thus 
eliminating the PKA phosphorylatable serine. mlP-PKA-KK mutant was constructed 
by mutation of two arginine at position 71 and 72 to lysine, to remove the consensus 
sequence for PKA phosphorylation i.e. RRRS. Preliminary results suggested that both 
S74A and mlP-PKA-KK mutant receptor cDNA could be expressed by CHO cells, 
and could still mediate the IP agonist response (Fig. 52). This indicated that neither 
mutation within the PKA phosphorylation site disrupted the overall structure of the 
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mlP-receptor nor so the receptors could be expressed on the membrane surface. 
Further study will carry on in order to estimate the expression level of these two 
mutant receptors compared with wild type mlP-receptors, and assay the mlP-receptor 
mediated [^H]-cAMP and [^H]-inositol phosphate response under PKA 
phosphorylation deficient condition. 
8.4 Conclusion 
In conclusion, I have examined the potential role of PKA and PKC in mlP-receptor 
activity. Results suggested the negative feedback ability towards the mlP-receptor 
through both PKA and PKC activation. This result suggests how the mlP-receptor 
limits the volume of signal transduction pathway activation after agonist stimulation. 
Also, I identified the cross talk mechanism exist between AC and PLC pathways 
through IP-receptor activation. Such cross talk might relate to the PKA inhibitory 
effect towards PLC or PLC pathway components. Further study using PKA 
phosphorylation-deficient mlP-receptors could provide more detailed information 
about the role of PKA phosphorylation site on mlP-receptor activity. From SK-N-SH 
cell study, I could observe an effect of H-89 on hlP-receptor regulation. This result 
not only suggested a specificity problem of using enzyme inhibitors, but also 
identifies other unknown components involved in hIP-receptor regulation. As the SK-
N-SH cells express the hIP-receptor, this raises the possibility that other mechanisms 
specific for human tissue are also important in hlP-receptor regulation. 
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Figure 41. Prostacyclin receptor first intracellular loop sequence alignment. Serine at 
position 74 indicates the PKA phosphorylation site. 
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Figure 42. Effect of different protein kinase inhibitors on basal AC and PLC activity 
in mlP-CHO cells. CHO cells were transfected with mlP-receptor cDNA (0.5 jag/ml). 
Results represent mean 土 S.E.M of 3 experiments, each performed in duplicate. 
Statistical levels of significant ( * * ;?< 0.01) were determined using one-way analysis 
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Figure 43. Effect of different protein kinase inhibitors on cicaprost-stimulated [^H]-
cAMP production in mlP-CHO and SK-N-SH cells. CHO cells were transfected with 
mlP-receptor cDNA (0.5 j^g/ml). Results are expressed as fold basal. Basal [^H]-
cAMP production: mlP-CHO control = 0.11 土 0.03; H-89 = 0.08 土 0.01; STAU = 
0.12 土 0.03; U-73122 = 0.19 土 0.01. SK-N-SH control = 0.08 土 0.01; H-89 = 0.11 土 
0.03; STAU = 0.09 土 0.02; U-73122 = 0.18 土 0.10 %conversion. Results represent 
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Figure 44. Effect of different protein kinase inhibitors on cicaprost-stimulated [^H]-
cAMP production from mlP-CHO and SK-N-SH cells CHO cells were transfected 
with mlP-receptor cDNA (0.5 |ig/ml). Results are expressed as stimulated minus 
basal activity. Basal [^H]-cAMP production: mlP-CHO control = 0.11 土 0.03; H-89 = 
0.08 土 0.01; STAU = 0.12 士 0.03. SK-N-SH control = 0.08 土 0.01; H-89 = 0.11 土 
0.03; STAU = 0.09 土 0.02 %conversion. Results represent mean 土 S.E.M. of 3 
experiments, each performed in duplicate. Statistical levels of significant (* p < 0.05) 
were determined using one-way analysis of variance followed by Bonferroni's 
Multiple Comparison Test. 
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Figure 45. Effect of different protein kinase inhibitors on forskolin-stimulated [^H]-
cAMP accumulation in SK-N-SH cells. SK-N-SH cells were stimulated with 10 |_iM 
forskolin. Basal fH]-cAMP accumulation: 0.08 土 0.01 %conversion. Results 
represent mean 土 S.E.M. of 3 experiments, each performed in duplicate. 
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Basal fH]-cAMP accumulation 
Treatment (%conversion) 
Control 0.08 ±0.01 
H-89(10| iM) 0.12 ±0.03 
STAU (1 |uM) 0.09 土 0.02 
Table 10. Basal AC activity in SK-N-SH cells. Al l results are expressed as 
%conversion data. Results represent mean 土 S.E.M. of 3 experiments, each 
performed in duplicate. 
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Figure 46. Effect of different protein kinase inhibitors on cicaprost-stimulated fH ] -
inositol phosphate production in mlP-CHO and SK-N-SH cells. CHO cells were 
transfected with mlP-receptor cDNA (0.5 |ig/ml). Results are expressed as fold basal. 
Basal [^H]-inositol phosphate production: mlP-CHO = 5.53 土 0.17 %conversion; SK-
N-SH =0.63 土 0.04 %conversion. For mlP-CHO, results represent mean 土 S.E.M. 
of 3 experiments, each performed in duplicate. For SK-N-SH, results represent mean 
土 S.D. of 1 experiment, performed in duplicate. 
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Figure 47. Effect of different protein kinase inhibitors on cicaprost-stimulated [^H]-
inositol phosphate production in mlP-CHO cells. CHO cells were transfected with 
mlP-receptor cDNA (0.5 |_ig/ml). Results are expressed as stimulated minus basal 
activity. Results represent mean 土 S.E.M. of 3 experiments, each performed in 
duplicate. Statistical levels of significant < 0.05) were determined using one-way 
analysis of variance followed by Bonferroni's Multiple Comparison Test. 
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Figure 48. Effect of several enzyme activators on cicaprost-stimulated [^H]-cAMP 
production in mlP-CHO cells. CHO cells were transfected with mlP-receptor cDNA 
(0.5 fig/ml). Results are expressed as either fold stimulation relative to treatment 
group basal or stimulated minus basal value. Basal [^H]-cAMP production: Control = 
0.09 土 0.09; Forskolin = 2.94 土 1.67; Bt^cAMP = 0.07 士 0.06; PMA = 0.11 土 0.07 
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Figure 49. Effect of several enzyme activators on cicaprost-stimulated [^H]-inositol 
phosphate production in mlP-CHO cells. CHO cells were transfected with mlP-
receptor cDNA (0.5 jig/ml). Results are expressed as either fold stimulation relative 
to treatment group basal or stimulated minus basal value. Basal [^H]-inositol 
phosphate production: Control = 4.80 土 0.69; Forskolin = 4.49 土 1.00; BtjcAMP = 
4.53 土 1.30; PMA = 5.30 土 1.25 %conversion. Results represent mean 土 S.D. of 2 
experiments, each performed in duplicate. • 
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Figure 50. Log concentration-response curve for forskolin-stimulated [^H]-cAMP 
production in mlP-CHO cells. CHO cells were transfected with mlP-receptor cDNA 
(0.5 ^g/ml). Results are expressed as fold basal. Basal [^H]-cAMP production: 0.04 土 
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Figure 51. Effect of SQ22536 on pH]-cAMP production in response to cicaprost (1 
jLiM) in mlP-CHO and SK-N-SH cells. CHO cells were transfected with mlP-receptor 
cDNA (0.5 |Lig/ml). Results are expressed as %control cicaprost response; that is, 
cicaprost-stimulated pH]-cAMP production relative to response from cells without 
SQ22536 treatment. Basal [^H]-cAMP production: mlP-CHO control = 0.05 土 0.03; 
10 [ M SQ22536 = 0.04 土 0.03; 100 |aM SQ22536 = 0.03 土 0.01. SK-N-SH control = 
0.10 土 0.03; 10 laM SQ22536 = 0.10 土 0.03; 100 i^M SQ22536 = 0.07 土 0.01 
o/oconversion. Results represent mean 土 S.D. of 2 experiments, each performed in 
duplicate. 
169 
3r c o 
ro 
3 -c - O - Basal 
P o 
§ w 2- Iloprost (lO^xM) 
CO g / 、 
I - y 
oL B ^ • • 
I 1 1 I 
0.0 0.5 1.0 1.5 
[mlP,卯/ml] 
3r C .2 "(3 
3 -e Basal 
i ' l 2- T Iloprost (10|iM) 
I - / 
oL ^ n 
I 1 1 , 
0.0 0.5 1.0 1.5 
[S74A, )ig/ml] 
3r c o ••g 
3 -e T - o - Basal 
i ' i 2- K "•"Iloprost(10^xM) 
u / 
I - 乂 
oL o 0 〇 
I 1 1 I 
0.0 0.5 1.0 1.5 
[mlP-PKA-KK,阅/ml] 
Figure 52. Iloprost-stimulated [^H]-cAMP production from CHO cells transfected 
with varying concentrations of mlP-receptor cDNA, S74A cDNA and mlP-PKA-KK 




Prostacyclin receptor isoprenylation 
9.1 Introduction 
In eukaryotic cells the process of isoprenylation results in the post-translational 
modification of proteins by either C-15 famesyl or C-20 geranylgeranyl isoprenoids 
(Brown & Goldstein，1993). The amino acid sequence C (cysteine) AA (aliphatic 
amino acid) X (any amino acid) is the signal structure determining whether these 
proteins become famesylated or geranylgeranylated by the corresponding transferases 
(Newman & Magee, 1993; Schafer & Rine, 1992). The isoprenoid group attaches to 
the cysteine residue and forms the isoprenylation motifs of proteins. Many members 
of low molecular weight GTPases such as Ras and Rho are targets for protein 
isoprenylation. This step is essential for correct intracellular localization, and 
consequently also for physiological function. It has also been proposed that the 
isoprenoid group may facilitate specific protein-protein interactions in vivo (Zhang & 
Casey, 1996). 
Before 1999，there was no literature supporting the role of isoprenylation in 
GPCRs. Hayes et al. (1999) suggested the presence of an isoprenylation consensus 
sequence within the mlP- and hlP-receptor C-terminal tail with the amino acid 
sequence CSLC. Further study indicated that the mlP- and hIP-receptor was 
isoprenylated and the functional significance of this modification was explored using 
the isoprenylation inhibitor lovastatin. Kinsella's group later used another fully 
synthetic pure enantiomer of lovastatin, cerivastatin to support the role of 
isoprenylation in mlP- and hlP-receptor (Lawler et al, 2001). The absence of 
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isoprenoid group did not alter the ligand binding property of the mlP- and hlP-
receptor, but impaired the coupling efficiency towards the second messenger system. 
Disruption of IP-receptor isoprenylation by site-specific mutagenesis significantly 
reduced agonist-induced cAMP level and mobilization in response to dose-
dependent stimulation by iloprost or cicaprost. As the presence of an isoprenoid group 
could provide membrane localization, it is suspected that the isoprenoid group might 
attach the C-terminal tail of the IP-receptor towards the inner membrane surface. 
Hayes et al (1999) therefore suggested the formation of a fourth intracellular loop for 
proper coupling between IP-receptors and second messenger systems. These studies 
indicate the possibility that statin therapy may interfere with IP-receptor signaling in 
vivo. During atherosclerosis, the inhibitory role of IP-receptor in platelet aggregation 
might therefore be affected by statin therapy. This potential effect remains to be 
determined. 
In this chapter, I would like to discuss the function of isoprenylation in IP-
receptor mediated signal transduction pathway either in mlP-receptor cDNA 
transfected CHO cells or SK-N-SH cells which endogenously express the hlP-
receptor. For comparison, I used mDP-receptor, which has no isoprenylation site 
within the C-terminal tail, to compare the effect of lovastatin on IP-receptor mediated 
function. 
9.2 Method 
Measurement of [^H]-cAMP production was performed as described in section 4.3 
unless otherwise stated. mlP-receptor cDNA (0.5 ^g/ml) was transiently transfected 
into CHO cells using Lipofectamine and [^H]-cAMP production was assayed by 
metabolically labeling the cells with [^H]-adenine for 20 h. For SK-N-SH cells, which 
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endogenously express the hlP-receptor, [^H]-cAMP production was assayed by 
metabolically labeling the cells with [^H]-ademne for 20 h. During the assay, 
transfected CHO cells or SK-N-SH cells were pretreated with lovastatin (10 |_LM)， 
which is an HMG-CoA reductase inhibitor or DMSO (0.1%) for 10 min. After the 
pretreatment, cells were stimulated with cicaprost (1 j iM), iloprost (10 ^iM) or 
forskolin (10 ^iM) in the presence of lovastatin (10 ^iM) or DMSO (0.1%) for 30 min 
and the [^H]-cAMP produced was measured by column chromatography method. For 
comparison, mDP-receptor cDNA (0.5 |ig/ml) was transiently transfected into CHO 
cells and [^H]-cAMP production was assayed in the same mamer as mlP-CHO cells. 
mDP-receptor transfected CHO cells were pretreated with lovastatin (10 jaM) or 
DMSO (0.1%) for 10 min. After the pretreatment, cells were stimulated with PGD2 (1 
fiM) or forskolin (10 \xM) in the presence of lovastatin (10 |j.M) or DMSO (0.1%) for 
30 min and the [^H]-cAMP produced was measured by column chromatography 
method. 
9.3 Results and Discussion 
For the first two experiments on CHO and SK-N-SH cells, the lovastatin was made up 
in DMSO, according to the manufacturer's instruction. In contrast to Hayes et al. 
1999，results showed that the coupling capacity of the mlP- and hIP-receptor did not 
alter with the lovastatin pretreatment (Fig. 53). Cytotoxicity test showed that the lack 
of effect from lovastatin pretreatment in both cell types was not related to any toxic 
effect of lovastatin or the concentration of DMSO that I used in the assay system. As a 
result, I could not conclude any consistent pattern of result from this section of study. 
In order to clarify this issue, we discussed with Dr. Kinsella and she stated that the 
problem might be correlated with the preparation of 'activated' lovastatin stock 
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solution. 
According to Kinsella's suggestion, the lovastatin should be activated as 
follows. First, 30 mg of lovastatin is dissolved in 0.6 ml of absolute ethanol. The 
solution is then heated at 50°C for at least 1 h. Next, 0.3 ml 0.6 M NaOH is added 
into the solution, and then 6 ml PBS solution is added. The mixture is incubated at 
room temperature for 30 min, and pH adjusted to 7.5 with 5 M HCl. Lastly, the 
solution is filter sterilized and aliquotted in 1 ml vials and stored at — 70。C until 
required. 
Although I had not used this procedure to prepare the original stock solution 
of lovastatin, I could use my last set of experimental data to compare with the 
previous two experiments. Fortunately, I had inadvertently heated my stock solution 
of lovastatin to 50°C for 20 mins. Results from the last experiment (Fig. 54) were 
completely different compared with the previous two experiments (Fig. 53). Figure 53 
showed that lovastatin did not alter the cicaprost- and iloprost-stimulated [^H]-cAMP 
production from CHO and SK-N-SH cells. However, I could easily observe an 
inhibitory effect of lovastatin on cicaprost- and iloprost-stimulated [^H]-cAMP 
production in CHO and SK-N-SH cells from the last experiment as shown in Figure 
54. The presence of lovastatin significantly suppressed the cicaprost- and iloprost-
stimulated [^H]-cAMP production from CHO and SK-N-SH cells. Also, there is no 
effect on PGD2-mediated [^H]-cAMP response in lovastatin pretreated group as 
compared with DMSO pretreated group. Al l these results match the expected effect 
from lovastatin's inhibitory effect on IP-receptor activity, the effect might relate to the 
presence of isoprenylation motif. On the other hand, mDP-receptor does not have 
isoprenylation motif and results suggested the lack of lovastatin effect on mDP-
receptor activity. However, there is some enhancement by lovastatin on forskolin-
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stimulated [^H]-cAMP production in mDP-CHO which is not understood. In general, 
results suggested that after the lovastatin was 'activated' through the heating process, 
'activated' lovastatin would inhibit the isoprenylation process and in turn impair the 
proper coupling between the IP-receptor and AC pathway. As a result, I could observe 
a similar effect of lovastatin in our study as compared with Kinsella's group (Hayes et 
al.’ 1999). 
Although I did not complete the activation procedure for lovastatin, it seems 
that heating at 50°C is an important step for lovastatin to be effective as an inhibitor 
of isoprenylation. It is worth to repeat this experiment with the lovastatin 
being 'activated' through the activation procedure. Unfortunately, I could not go 
further as according to a new patent restrictions, lovastatin is not allowed to invoice 
or ship from any US locations. As a result, I could not get any more lovastatin from 
Hong Kong supplier. 
9.4 Conclusion 
It is clearly important that complete descriptions of drug solution preparation should 
be mentioned to allow experiments to be replicated. Although I could not conclude 
anything from this result, the effect of lovastatin might be produced following the 
activation by heating. In future, it is worth to understand all information about the 
drugs being used before starting the experiment and make sure all related information 
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Figure 53. Effect of lovastatin (without heat treatment) pretreatment on agonist-
stimulated [3H]-CAMP production. CHO cells transfected with mlP-receptor cDNA 
(0.5 jj-g/ml), mDP-receptor cDNA (0.5 )ig/ml) or wild type SK-N-SH cells 
endogenously expressing the hlP-receptor. Results represent mean 士 S.D. of 2 
experiments, each performed in triplicate. Basal [^H]-cAMP production: mlP-CHO = 
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Figure 54. Effect of lovastatin (treated with heating process) pretreatment on agonist-
stimulated [^H]-cAMP production. CHO cells were transfected with mlP-receptor 
cDNA (0.5 |ig/ml), mDP-receptor cDNA (0.5 ^ig/ml) or wild type SK-N-SH 
endogenously expressed the hlP-receptor. Results represent mean 土 S.D. of 1 
experiment and performed in triplicate. Basal [^H]-cAMP production: mlP-CHO = 
0 . 0 4 士 0.01; mDP-CHO = 0.04 ± 0 . 0 1 ; SK-N-SH = 0.06 土 0.01%conversion. 
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CHAPTER 10 
IP/DP chimeric receptors 
10.1 Introduction 
Chimeric receptors have been used in order to identify a specific region of amino acids 
within a receptor responsible for agonist interaction. For example, chimeric receptors 
have been used to determine the regions responsible for selective agonist and 
antagonist binding in adrenergic receptors (Frielle et al, 1988; Kobilka et al, 1988). 
As a result, in order to understand the structural domains of IP-receptors conferring 
specificity for ligand binding, it is possible to identity the structural feature using the 
same strategy. 
Within the phylogenic tree of prostanoid receptor family, IP, DP, EPj and EP4 
have been grouped within the same category as relaxant receptors, mediating increases 
in cAMP and inducing smooth muscle relaxation (Ushikubi et al, 1995). The amino 
acid sequences of mDP and mlP show 58% identity to each other in the transmembrane 
domains. Whereas, mEPj and mlP show only 44% identity (Kobayashi et al, 2000). 
Based on the relatively high homology of amino acid sequences between DP and IP, as 
well as common signal transduction, Kobayashi constructed several IP/DP chimeric 
receptors (Kobayashi et al,, 1997). These chimeric receptors were constructed by 
successively replacing the regions from the carboxyl-terminal tail of mlP-receptor with 
the corresponding regions of the mDP-receptor. Results from ligand binding studies 
suggested that the ligand binding specificity of mlP-receptor is related to the amino 
acid sequence within the sixth and seventh transmembrane domains (Kobayashi et al., 
1997). Further study using site-specific mutagenesis method identified the serine 
residue within the first transmembrane domain of mlP-receptor as critical for broad 
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ligand recognition by mlP-receptors (Kobayashi et al., 2000). For those chimeric 
receptors being assayed, the IP^.vn/DPc ( IDl) chimeric receptor with mlP-receptor C-
terminal tail being replaced by corresponding region of mDP-receptor, showed 
constitutive activity compared with the wild type mlP-receptor, as measured by AC 
activation from CHO cells (Wise, 1999). We wondered which amino acid residues 
within the mlP-receptor seventh transmembrane domain are important for the 
constitutive activity. However, the IPnVDPvi-c (ID2) chimeric receptor, with mlP-
receptor from the sixth transmembrane domain to C-terminal tail being replaced by 
corresponding region in mDP-receptor, did not have constitutive activity compared 
with the wild type mlP-receptor, as measured by AC activation from CHO cells (Wise, 
1999). By comparing the mlP-receptor and ID l chimeric receptor amino acid 
sequences, Kobayashi identified two amino acid residues that showed variation 
between mlP- and mDP-receptor seventh transmembrane domain end region. As a 
result, Dr. Cheng, H.K. (Biochemistry Dept. CUHK) constructed three mlP-receptor 
mutants called M l (V320I), M2 (L323I) and M3 (V320I, L323I) (Fig. 55). Al l three 
mlP-receptor mutants have the same amino acid sequence as the wild type mlP-
receptor except those amino acid residues being mutated to the same amino acid as in 
mDP-receptor sequence. In addition, three ID l chimeric mutant receptors, called M4 
(I320V), M5 (I323L) and M6 (I320V, I323L) were constructed to identify which amino 
acid residues are important for the constitutive activity of the ID l chimeric receptor 
(Fig. 55). A l l three ID l chimeric mutant receptors have the same amino acid sequence 
as the ID l chimeric receptor except that amino acid is being mutated to the same amino 
acid as in the mlP-receptor sequence. 
10.2 Method 
Measurements of pH]-cAMP and pH]-inositol phosphate production were performed 
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as described in section 4.3 and 4.4 unless otherwise stated. cDNA for mlP-receptor 
mutants (M l , M2, M3) and chimeric IP/DP receptor mutants (M4，M5, M6) were 
constructed by Dr. Cheng, H.K. and Mr. Lai, Y.T. from Biochemistry Dept. CUHK. 
mlP-receptor mutants and chimeric IP/DP receptor mutants cDNA were transiently 
transfected into CHO cells using Lipofectamine and the pH]-cAMP and fH]-inositol 
phosphate production was assayed by metabolically labeling the cells with 阳]-
adenine for 20 h or fH]-inositol for 42 h. For M l , M2, M3, cells were stimulated with 
varying concentrations of cicaprost (10 pM — 1 [^H]-cAMP assay, 100 pM - 1 pM 
[^H]-inositol phosphate assay). For M4, M5, M6，cells were stimulated with varying 
concentration of cicaprost (10 pM - 1 jiM). Al l mutant receptor cDNAs were 
sequenced and target amino acids being mutated were checked before performing the 
functional assay. Part of the amino acid sequence has been listed in Figure 55. 
10.3 Results and Discussion 
10.3.1 Property of IP/DP chimeric receptors 
In terms of AC pathway responses, both ID l and ID2 give comparable stimulation of 
[^H]-cAMP accumulation as mlP-receptor (Fig. 56). This result indicated that the 
region from sixth transmembrane domain to C-terminal tail is not important for mlP-
receptor mediated AC activation. However, in terms of PLC pathway response, ID l 
give much smaller stimulation in PLC pathway compared with mlP-receptors (Fig. 56) 
([^H]-inositol phosphate production from mlP = 1.96 土 0.08 fold basal, ID l = 1.30 土 
0.04 fold basal). As in ID l , the region that replaced with mDP-receptor is the C-
terminal only; this indicated the importance of mlP-receptor C-terminal in PLC 
activation. Study from Kinsella's group suggests the presence of isoprenylation motif, 
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which is important for the proper coupling between the IP-receptor and PLC pathway 
component, at the C-terminal tail of IP-receptor (Hayes et al., 1999), Removal of 
mlP-receptor C-terminal tail in ID l chimeric receptor also removed the isoprenylation 
motif and it might impair the mlP-receptor mediated PLC activation. However, 
removal of mlP-receptor C-terminal in ID l chimeric receptor gave similar AC activity 
as wild type mlP-receptor. In contrast, Hayes et al. (1999) suggested the impaired 
coupling of IP-receptor with AC pathway after treating with isoprenylation inhibitor 
lovastatin. It is unclear why loss of isoprenylation motif in ID 1 chimeric receptor still 
gives similar AC activation as wild type mlP-receptor. Possibly the mDP-receptor C-
terminal is responsible for AC activation and this property is showed in ID 1 chimeric 
receptor. On the other hand, ID l give much smaller PLC activation compared with the 
wild type mlP-receptor. However, ID l still show a small increase in [^H]-inositol 
phosphate production relative to basal level (Fig. 56). As mDP-receptor has no PLC 
activation property as shown from Figure 56, this result suggests the involvement of 
other cytoplasmic region within the mlP-receptor for PLC activation. Another GPCR, 
thrombin receptor, showed the critical role of second cytoplasmic loop for PLC 
activation (Verrall et al., 1997). mlP-receptor might have the same property and 
explain the PLC activating property of ID l chimeric receptor. 
However, I could not observe any effect on [^H]-cAMP response from mlP-
receptor C-terminal as shown from Figure 56. The [^H]-cAMP response is comparable 
between the wild type mlP-receptor, ID 1 and ID2 chimeric receptor. It is because in 
ID l and ID2, the C-terminal of the IP-receptor has been swapped with the C-terminal 
of the DP-receptor. Since the DP-receptor readily couples to AC, the ID l and ID2 
receptor would also be expected to couple to the AC pathway. 
Then, we should also observe the same effect as in ID2, which replace the 
mlP-receptor sequence from the sixth transmembrane domain to the C-terminal with 
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mDP-receptor, to display the sole activation of AC pathway，but it clearly does not. ID2 
gave similar PLC activation compared with the wild type mlP-receptor (Fig. 56) 
([^H]-inositol phosphate production from mlP = 1.96 土 0.08 fold basal, ID2 = 1.98 土 
0.09 fold basal), this result confounds our previous interpretation about the ID l 
chimeric receptor. It is because ID2 receptor also loses the mlP-receptor region starting 
from sixth transmembrane domain. Also, previous study also indicated that the ID2 
chimeric receptor lack of constitutive activity (Wise, 1999). It seems that the ID2 
chimeric receptor behave similar as wild type mlP-receptor. Further study is necessary 
in order to study the role of mlP-receptor C-terminal in PLC activation response. One 
way to identify this is to test the chimeric receptor using mDP-receptor but replacing 
the sixth to seventh transmembrane domain with corresponding mlP-receptor amino 
acid, or sixth to C-terminal tail with corresponding mlP-receptor amino acid. However, 
these chimeric receptors failed to be expressed in COS-7 cells (Kobayashi, T.，personal 
communication) and therefore the hypothesis could not be tested further. Altogether, 
the results suggested that the C-terminal tail of the IP-receptor is not responsible for 
coupling of the IP-receptor to Gq. 
10.3.2 I D l chimeric receptor mutant receptors (M4, M5，M6) 
The ID l chimeric receptor, which shifts the coupling towards the AC pathway, 
indicates the presence of a specific receptor conformation for AC activation. It is 
interesting to examine any potential amino acid compared with the corresponding 
position in the mlP-receptor that might be important for the constitutive activity in ID l . 
As a result, Dr. Cheng, H.K. constructed three ID l chimeric receptor mutants and their 
AC pathway activation responses have been examined. I would like to test whether any 
chimeric receptor mutants wi l l show loss of constitutive activity compared with the 
ID 1 chimeric receptor. 
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The results indicated that two ID l chimeric receptor mutants, M5 and M6 
produced loss of potency for cicaprost-stimulated fH]-cAMP production (Fig. 57(B)) 
(IDl，pECjo = 9.60; M5, pEC,, = 8.61; M6, pEC，。= 8.89). Preliminary results 
indicated that amino acid isoleucine at position 323 is important for the enhanced 
potency of ID l chimeric receptor. As M6, which has both isoleucine 320 and 323 
mutated, also showed loss of potency comparable with the M5 mutant. However, M4 
behave similarly as the ID l chimeric receptor. This suggested that the isoleucine 323 is 
the critical amino acid for enhancing the potency of cicaprost-stimulated [^H]-cAMP 
production in the ID l chimeric receptor. As the cicaprost-stimulated maximum 
response also decreased in M5 transfected cells (Fig. 57(A)), it is necessary to examine 
the expression level of these mutant receptors in order to see whether the changed 
potency and efficacy are the result of different receptor densities (Samama et al., 1993). 
10.3.3 Mutant mlP-receptors ( M l , M2，M3) 
According to the sequence comparison between mlP- and mDP-receptors, within the 
cutting point at the end region of the seventh transmembrane domain in ID l chimeric 
receptors, there are two amino acid residues showing difference between these two 
receptor types (Fig. 55). As the ID l chimeric receptor showed constitutive activity, I 
think whether the constitutive activity was produced from the change of these amino 
acid residues within the seventh transmembrane domain. Dr. Cheng H.K. constructed 
several mlP-receptor mutants with changes of amino acid valine 320 and leucine 323 to 
isoleucine, which are amino acids in the same corresponding position in mDP-receptor. 
I tested these mlP-receptor mutants and log concentration-response curves for fH ] -
cAMP accumulation and [^H]-inositol phosphate accumulation were constructed and 
compared with the wild type mlP-receptor. 
Results from Figures 58 and 59 suggested that these amino acids (V320, 
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L323) were not responsible for the constitutive activity in the ID l chimeric receptor. 
A l l three mutant receptors behaved similarly as the wild type mlP-receptor in both AC 
and PLC activation (Fig. 58 and 59). Although the amino acid residues being mutated 
corresponded to the amino acid residues in the ID 1 chimeric receptor, results suggested 
that these amino acid residues could not produce the constitutive activity from wild 
type mlP-receptor. Further study wil l carry on in order to identify the expression level 
of these mutant receptors. 
10.3.4 Comparison between M5 and I D l receptor 
The M5 receptor lost the potency of cicaprost-stimulated [^H]-cAMP production 
compared to the IDl chimeric receptor, M5 gives similar EC，。value compared with 
wild type mlP-receptor (Fig. 60). This result suggested that isoleucine at residue 323 is 
important for the enhanced potency of ID l . However, the presence of isoleucine in 
mutant IP-receptor (M2) could not enhance the potency of cicaprost-stimulated fH ] -
cAMP production. I suspect whether the presence of mlP-receptor C-terminal tail still 
constraining the receptor conformation and so the M2 mutant could not form the 
constitutively activated conformation although the amino acid residue at position 323 
was mutated to isoleucine. As the C-terminal tail in ID l chimeric receptor is different 
compared with the mlP-receptor, it is necessary to pay attention when comparing the 
response between mlP-receptor and M5 mutant receptors. 
10.4 Conclusion 
In conclusion, I have demonstrated that mlP-receptor C-terminal tail does not appear to 
be responsible for coupling of the mlP-receptor to Gq. I suspect whether the state of 
mlP-receptor C-terminal tail (either loss of isoprenylation or complete removal of C-
terminal) could control the activation of mlP-receptor. Besides, preliminary studies 
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suggested that amino acid residue within the end region of the seventh transmembrane 
domain show a critical role in regulating the activity state of the mlP-receptor. It is 




mlP 303 D L L A F R F N A F N P I L D P W V F I L F R K A V F Q R L K F W L C C L C A R S V H G D L Q A P L S R P A S G R R D 361 
M l D L L A F R F N A F N P I L D P W I F I L F R K A V F Q R L K F W L C C L C A R S V H G D L Q A P L S R P A S G R R D 
M 2 D L L A F R F N A F N P I L D P W V F I I F R K A V F Q R L K F W L C C L C A R S V H G D L Q A P L S R P A S G R R D 
M 3 D L L A F R F N A F N P I L D P W I F I I F R K A V F Q R L K F W L C C L C A R S V H G D L Q A P L S R P A S G R R D 
IDl D L L A F R F N A F N P I L D P W I F I I F R T S V F R M L F H K V F T R P L I Y R N W S S H S Q Q S N V E S T L 
mDP-receptor 
M4 D L L A F R F N A F N P I L D P W V F I I F R T S V F R M L F H K V F T R P L I Y R N W S S H S Q Q S N V E S T L 
M5 D L L A F R F N A F N P I L D P W I F I L F R T S V F R M L F H K V F T R P L I Y R N W S S H S Q Q S N V E S T L 
M6 D L L A F R F N A F N P I L D P W V F I L F R T S V F R M L F H K V F T R P L I Y R丽 S S H S Q Q S N V E S T L 
Figure 55. Amino acid sequence for wild type mlP-receptor, mlP-receptor mutants 
(M l , M2, M3)，IP/DP chimeric receptor ( IDl ) and ID l chimeric mutants (M4, M5, 
M6). mlP-receptor was used as template for the construction of M l , M2 and M3 
mutants. In M l mutant, amino acid valine from mlP-receptor was changed to 
isoleucine (V320I). In M2 mutant, amino acid leucine from mlP-receptor was changed 
to isoleucine (L323I). In M3, amino acids valine and leucine from IP-receptor were 
changed to isoleucine (V320I, L323I). IP/DP chimeric receptor ( IDl ) was used as 
template for the construction of M4, M5, and M6 mutants. In M4 mutant, amino acid 
isoleucine from ID l was changed to valine (I320V). In M5 mutant, amino acid 
isoleucine from ID l was changed to leucine (I323L). In M6 mutant, two isoleucine 
amino acids from ID l were changed to valine and leucine (1320V, I323L). Wild type 
mlP-receptor (mlP) amino acid sequence is listed in black colour. Red colour letters 
indicate the position and type of amino acid after mutation. Blue colour letters indicate 
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Figure 56. [^H]-cAMP and [^H]-inositol phosphate accumulation by CHO cells 
transfected with mlP (0.5 ng/ml), ID l (1.33 ^g/ml), ID2 (0.4 ^g/ml) or mDP (0.5 
|ig/ml). Dotted line indicates no stimulation. Results represent mean ± S.E.M. of 3 
experiments, each performed in duplicate. 
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Receptor Basal [^H]-cAMP Basal [^H]-inositol n 
production phosphate production 
(%conversion) (%conversion) 
mlP 0.09 ±0.03 6.91 土 0.50 3 
ID l 0.11±0.04 6.45 ±0.88 3 
ID2 0.10 ±0.04 6.04 ±1.09 3 
mDP 0.05 ±0.01 6.78 ±1.16 3 
Table 11. Basal %conversion data of [^H]-cAMP and fH]-inositol phosphate 
production. CHO cells transfected with mlP (0.5 |ig/ml), ID l (1.33 ^g/ml), ID2 (0.4 
|ig/ml) and mDP (0.5 i^g/ml). Results represent mean 土 S.E.M. of 3 experiments, 
each performed in duplicate. 
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Figure 57. Log concentration-response curves for ID l , M4，M5 and M6 mediated 
[^H]-cAMP accumulation by CHO cells. CHO cells were transfected with IDl 
chimeric receptor cDNA or M4, M5, M6 mutant receptor cDNA at 1.33 \xg/ml 
Results represent means 士 S.D. from 1 experiment, performed in duplicate. Basal 
[^H]-cAMP production: IDl = 0.10 土 0.01; M4 = 0.08 ±0.01;M5 = 0.04 ±0.01; M6 
=0.05 土 0.002%conversion. 
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Figure 58. [^H]-cAMP production in CHO cells transfected with mlP-receptor cDNA 
or mlP-receptor mutant (M l , M2, M3) cDNA (0.5 jig/ml). Results represent mean 土 
S.D. from 2 experiments, each performed in duplicate. Basal [^H]-cAMP production: 
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Figure 59. [^H]-inositol phosphate production in CHO cells transfected with mlP-
receptor cDNA or mlP-receptor mutant (M l , M2, M3) cDNA (0.5 ^g/ml). Results 
represent mean 士 S.D. from 2 experiments, each performed in duplicate. Basal [^H]-
inositol phosphate production: mlP = 5.35 土 1.51; M l = 6.03 ± 0.17; M2 = 4.72 土 
0.01; M3 = 6.00 土 0.13%conversion. 
191 
120「 i_ 
100- 口 L 5 o mlP 
I § 口 ID1 
I I 一 A / I 去 • 
乏 】 -
IJ 40- y J 
-1 
I 1 1 1 1 I I I 
-12 -11 -10 -9 -8 -7 -6 -5 
log [Cicaprost, M] 
Figure 60. Comparison of [^H]-cAMP accumulation between various mlP-receptor 
mutant receptors and wild type mlP-receptor. CHO cells were transfected with ID l 
chimeric receptor cDNA (1.33 |ig/ml), M5 mutant receptor cDNA (1.33 jig/ml) or 
mlP-receptor cDNA (0.5 ^g/ml). Results represent mean 土 S.D. for ID l and M5 and 
performed in duplicate, from 2 experiments for mlP，each performed in duplicate. 




General Discussion and Conclusions 
11.1 Introduction 
The aim of this research project was to study the multiple coupling capacity of 
prostacyclin receptors (IP-receptor). Several studies have suggested that certain 
agonists can target activation of specific receptor signalling towards specific G-protein. 
This phenomenon, known as agonist trafficking, suggests the coupling capacity of 
GPCRs towards more than one G-protein (Kenakin, 1995). Previous study has already 
identified the coupling capacity of IP-receptor towards both Gs and Gq protein (Namba 
et al., 1994). However, it is often difficult to demonstrate if the activities of multiple 
signalling cascades are due to the interaction of IP agonists with IP-receptor subtypes, 
or the ability of a single IP-receptor to couple to multiple G-proteins. By 
co-transfecting cells with cDNAs of the IP-receptor and different subunits, we are 
able to elucidate the relationship of IP-receptor with different G-proteins and relate this 
information to responses from endogenously expressed IP-receptors. By expressing the 
IP-receptor in a cell environment of our choice, we aim to minimize problems 
associated with poor drug selectivity. By co-transfection of cells with cDNA for the 
IP-receptor and for different subunits, we hoped to replicate and verify the reports 
of multiple signalling by endogenous IP-receptors. 
11.2 Multiple coupling capacity of prostacyclin receptors 
We have determined the concentration-response relationships for cicaprost-stimulated 
[^H]-cAMP and [^H]-inositol phosphate production in our transfection system, and 
results confirmed the dual coupling of the IP-receptor to GaS and Gaq. All IP agonists 
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showed higher coupling efficiency (i.e. potency) towards the AC pathway compared 
with the PLC pathway. As a result, the presence of prostacyclin analogues and 
non-prostanoid prostacyclin mimetics met the requirement that we could use lots of 
agonists and study whether IP-receptors also showed the evidence of agonist 
trafficking. In order to achieve this goal, I tried to simultaneously measure AC and PLC 
activation in the same cells using conventional column separation methods. However, 
the column separation method failed to separate the [^H]-adenine and [^H]-inositol 
using either AC column or PLC column. Also, other assay systems e.g. cAMP 
'^^I-Scintillation Proximity Assay System and the D-myo-Inositol 1,4,5-trisphosphate 
(IPs) [^H]-assay system were found to be unsuitable. As a result, I was unable to 
achieve this particular objective. 
As the IP-receptor possesses the multiple coupling capacity, I would like to 
know the limiting factor within the signal transduction pathway controlling the level of 
stimulation by IP agonists. First, I studied the AC pathway by co-transfecting CHO 
cells with a fixed concentration of IP-receptor cDNA, plus increasing concentrations of 
GaS cDNA. GaS cDNA transfection had no effect on the potency of IP-receptor 
stimulated AC and PLC activity in mlP-CHO cells. It may be due to an existing high 
expression level of GaS protein in mlP-CHO cells. Therefore, further enhancing the 
expression level of GaS protein could not alter the coupling capacity of IP-receptor 
towards either AC or PLC pathways. In terms of maximal cicaprost stimulation, GaS 
cDNA transfection could not alter the maximal cicaprost-stimulated AC activation. It 
may relate to high expression level of GaS protein in mlP-CHO cells. However, it is 
unclear GaS cDNA transfection suppressed the cicaprost-stimulated PLC activation in 
mlP-CHO cells. Estimating the expression level of GaS protein using western blotting 
techniques after GaS cDNA transfection is necessary in order to understand the role of 
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GaS protein on IP-receptor-mediated AC and PLC activation. I think further 
transfection of GaS cDNA into mlP-CHO cells enhance the PKA activation and in turn 
enhance the inhibitory effect towards the PLC or PLC pathway components. Possibly 
the suppressed cicaprost-stimulated PLC activation is due to the cross talk mechanism 
between PKA and PLC pathway components in mlP-CHO cells. Mullaney et al. (1996) 
using NG108-15 cells, showed that the expression level of GaS protein is not a limiting 
factor in IP-receptor mediated AC activation. Further study using western blotting 
technique could clarify the expression level of GaS protein in CHO cells and the result 
could be used to compare with the expression level of the IP-receptor. 
Apart from studying the effect of GaS cDNA transfection on IP agonists 
stimulated AC and PLC response in mlP-CHO cells, CHO cells were also 
co-transfected with a fixed concentration of IP-receptor, plus increasing concentrations 
of Gaq cDNA. By doing this, I have observed an increased potency for 
cicaprost-stimulated PLC activity. On the other hand, I have observed a decreased 
potency for cicaprost-stimulated AC activity with Gaq cDNA transfection. Gaq cDNA 
transfection had no effect on maximal cicaprost-stimulated AC and PLC activity in 
mlP-CHO cells. These results suggest that the level of Gaq protein expression can 
affect the coupling capacity of IP-receptor towards both the AC and PLC pathways. 
This result suggests the Gaq pathway seems to limit the IP-receptor mediated PLC 
activation. In contrast to GaS cDNA and AC activation, the expression level of Gaq 
protein is critical for IP-receptor mediated PLC activation. The relationship between 
the transfection concentration of Gaq cDNA and Gaq limiting effect towards both the 
AC and PLC pathways is still unclear. Further study using western blotting techniques 
could determine the expression level of Gaq protein after Gaq cDNA transfection and 
in turn clarify the relationship mentioned before. 
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11.3 Factors influencing prostacyclin receptor coupling 
As I could observe the multiple coupling capacity of IP-receptor in the transfection 
system, it is important to confirm that endogenously expressed IP-receptors couple to 
more than one G-protein. A human neuroblastoma (SK-N-SH) cell line, which 
endogenously expresses the hIP-receptor, is a suitable model to test the coupling 
capacity of IP-receptors in more physiological conditions. I have observed 
cicaprost-stimulated [^H]-cAMP production, which indicates the coupling between 
IP-receptors and Gs proteins. PGE�，also gave a small [^H]-cAMP response and 
suggests the presence of EP2- or EP4-receptors. As there is no IP-receptor antagonist at 
this moment, it is difficult to confirm the PGE2-mediated AC activation is due to 
activation of IP- or EP-receptors. The pECso value for cicaprost-stimulated AC 
activation in SK-N-SH cells (pECso: 7.48 士 0.03) is quite different as in mlP-CHO 
cells (pECso = 8.36 土 0.01). As SK-N-SH cells express hIP-receptor but CHO cells 
express mlP-receptor, species-specific manner could account for such difference. On 
the other hand, no cicaprost-stimulated [^HJ-inositol phosphate production from 
SK-N-SH cells could be detected. Responses from two positive control agonists 
(bradykinin and carbachol) exclude any sensitivity problem of the assay system. The 
poor coupling of the IP-receptor towards PLC pathway may be due to a poor coupling 
of Gq protein towards IP-receptors in SK-N-SH cells. As a result, I tried to increase the 
expression level of Gq protein by transfecting varying concentrations of Gaq cDNA 
into SK-N-SH cells. As shown in Chapter 5, mlP-CHO cells transfected with Gaq 
cDNA enhanced the cicaprost-stimulated [^H]-inositol phosphate production at 
sub-maximal concentration of agonist. However, there is no enhancement of 
agonist-stimulated [^H]-inositoI phosphate production in SK-N-SH cells using 
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sub-maximally effective concentration of agonists. The reason may be that SK-N-SH 
cells are poor candidates for transfection (Ghosh et aL, 2000). Using a [3-galactosidase 
assay system, I found that the amount of cDNA taken up by SK-N-SH cells is much 
lower compared with the CHO cells. As a result, the absence of [^H]-inositol phosphate 
production enhancement may be due to the low transfection efficiency in SK-N-SH 
cells. On the other hand, Gaq cDNA transfection could significantly suppress the 
[3H]-inositol phosphate production in SK-N-SH cells using maximally effective 
concentration of agonists. At present, I still have no clear answer about this PLC 
inhibiting effect after Gaq cDNA transfection in SK-N-SH cells. 
In order to verify the result in SK-N-SH cells, I tried another neuroblastoma 
cell line (NG108-15 cells) and assayed the effect of Gaq cDNA transfection on 
IP-receptor mediated PLC activation. Before studying the effect of Gaq cDNA 
transfection on IP-receptor mediated PLC activation in NG108-15 cells, I need to 
characterize the property of IP-receptors expressed in NG108-15 cells. After 
performing the AC and PLC assay, results suggest that IP-receptor from NG108-15 cell 
also shows multiple coupling capacity towards AC and PLC pathways. In contrast to 
SK-N-SH cells, IP-receptors in NG108-15 cells can couple to PLC pathway with 
similar EC50 value as determined in mlP-CHO cells. Altogether, the property of 
IP-receptors in NG108-15 cells is similar to that in mlP-CHO cells in terms of AC and 
PLC activation. I further studied the influence of Gaq on the coupling capacity of 
IP-receptor towards the PLC pathway in NG108-15 cells. As similar as SK-N-SH cells 
study, transfection of Gaq cDNA into NG108-15 cells could not enhance the 
IP-receptor mediated [^H]-inositol phosphate production. The reason may be that 
NG108-15 cells are poor candidates for transfection. However, using a p-galactosidase 
assay system, I found that the amount of cDNA taken up by NG108-15 cells is 
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sufficient to observe the effect Gaq cDNA transfection on IP-receptor mediated 
[^H]-inositol phosphate production as similar as mlP-CHO cells transfected with Gaq 
cDNA. As a result, the result of absence of [^H]-inositol phosphate production 
enhancement in NG108-15 cells is unexpected. 
In order to clarify the structural features for IP-receptor activation, I used 
several mutant IP/DP chimeric receptors, and examined AC and PLC responses. 
According to the results, it seems that the IP-receptor C-terminal is not important for 
PLC activation. However, this result is in contrast to results of Hayes et al (1999) in 
which the IP-receptor C-terminal was shown to be crucial for activation of AC and 
PLC. I think whether the mlP-receptor C-terminal tail controls the activation of 
mlP-receptor itself. Based on the study using the IP/DP chimeric receptor, I tried to use 
several IP/DP chimeric mutant receptors (M4, M5 and M6) in order to study which 
amino acids are critical for the constitutive activity of this IP/DP chimeric receptor. 
Preliminary results suggest that amino acid isoleucine at position 323 is important for 
constitutive activity in the IP/DP chimeric receptor. This result indicates the possible 
role of amino acid residues within the end region of the seventh transmembrane domain 
in regulating the activity state of mlP-receptor in response to agonist stimulation. 
Further study on these mutant receptors expression level in CHO cells and re-examine 
the AC and PLC response with these mutant receptors have similar expression level. 
11.4 Prostacyclin receptor cross talk and regulation 
Although I could not use SK-N-SH cells to confirm the multiple coupling capacity of 
the IP-receptor in a non-transfection system, they are still useful for investigating the 
cross-talk activity and receptor regulation. As IP-receptor activation leads to 
[^H]-cAMP and [^H]-inositol phosphate production in mlP-CHO cells, these signal 
transduction pathways may interact with each other. Except for hIP-receptor, other 
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species of IP-receptor have both PKA and PKC phosphorylation site, and stimulation 
of the IP-receptor will lead to activation of both PKA and PKC. This activation might 
be crucial in regulating the activity of IP-receptor. Therefore, I think we could modify 
the signaling system through these pathways with the presence of different enzyme 
inhibitors or activators, e.g. PKA inhibitor (H-89). 
Results indicated that activation of the Gs pathway shows an auto-inhibitory 
effect towards both AC and PLC signaling through the activation of PKA. Also, results 
from PKC inhibitor treatment indicated that activation of the Gq pathway shows an 
auto-inhibitory effect towards mlP-receptor, but only for the PLC pathway. This result 
suggests the possible cross talk mechanism between AC and PLC pathways under 
IP-receptor activation. 
Also, the effect of H-89 in SK-N-SH cells raises the possibility that other 
protein kinases may be involved in IP-receptor regulation, as the hIP-receptor does not 
possess a PKA phosphorylation site yet H-89 appeared to increase [^H]-cAMP 
production in response to IP agonist. Therefore, this receptor should not be regulated 
by PKA activation. Experiments are underway in order to clarify the role of PKA or 
other protein kinases in IP-receptor regulation. Hopefully, the construction of PKA 
phosphorylation site deficient mutant IP-receptors will clarify the role of PKA in 
IP-receptor activation. 
In conclusion, I have obtained evidence of the multiple coupling capacity of 
the prostacyclin receptor in CHO and NG108-15 cells. However, there is no evidence 
to support this issue in SK-N-SH cells. Results also suggest a degree of cross talk 
between the two signal transduction pathways activated by the IP-receptor. Not only 
will this work increase our knowledge about the behaviour of IP-receptors in a variety 
of conditions, but it also has importance in increasing our understanding of the 
mechanism of agonists action in particular. 
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